Amedeo Smart

Free Medical Literature Service

 

Amedeo

COVID-19
  Free Subscription

Articles published in
J Med Virol
    May 2025
  1. CHO J, Park J, Son Y, Kim S, et al
    Post-Acute Sequelae of COVID-19 on Alopecia Areata in Individuals With Mental Illness in South Korea and Japan: A Binational Population-Based Cohort Study.
    J Med Virol. 2025;97:e70364.
    >> Share

  2. SENTIS C, Parraud D, Billaud G, Valette M, et al
    Performance of Subgenomic RT-PCR for Predicting SARS-CoV-2 Infectivity Compared to Genomic RT-PCR and Culture Isolation.
    J Med Virol. 2025;97:e70363.
    >> Share

    April 2025
  3. LARSEN TG, Ginty JR, Jessen R, Nielsen RB, et al
    Virus Monitoring in Denmark: A Community-Based Self-Sampling System to Surveil Respiratory Viruses and Associated Symptoms.
    J Med Virol. 2025;97:e70293.
    >> Share

  4. TACHIKAWA J, Aizawa Y, Watanabe K, Haino K, et al
    Sustained Maternal Antibodies Against Parechovirus-A3 During the Coronavirus Disease 2019 Pandemic.
    J Med Virol. 2025;97:e70313.
    >> Share

  5. LAI C, Lu S, Yang Y, You X, et al
    Myeloid-Driven Immune Suppression Subverts Neutralizing Antibodies and T Cell Immunity in Severe COVID-19.
    J Med Virol. 2025;97:e70335.
    >> Share

  6. KUMAR R, Verma A, Kamboj H, Bhattacharya TK, et al
    H3K27-me3 Inhibition Induces YTHDF2-Mediated Decay of m6A-Marked Severe Acute Respiratory Syndrome Coronavirus 2 Transcripts.
    J Med Virol. 2025;97:e70332.
    >> Share

  7. REUS P, Torbica E, Rothenburger T, Bechtel M, et al
    Papaverine Targets STAT Signaling: A Dual-Action Therapy Option Against SARS-CoV-2.
    J Med Virol. 2025;97:e70319.
    >> Share

  8. LIU J, Guo L, Zhong J, Wu Y, et al
    Proteomic Analysis of 442 Clinical Plasma Samples From Individuals With Symptom Records Revealed Subtypes of Convalescent Patients Who Had COVID-19.
    J Med Virol. 2025;97:e70203.
    >> Share

  9. ZHANG Y, Pu D, Liu Q, Li B, et al
    Epidemic Outbreak of Respiratory Syncytial Virus Infection After the end of the Zero-COVID-19 Policy in China: Molecular Characterization and Disease Severity Associated With a Novel RSV-B Clade.
    J Med Virol. 2025;97:e70343.
    >> Share

  10. GUSTANI-BUSS E, Buss CE, Biagi CAO, Oliveira IM, et al
    Unveiling the Dynamics of SARS-CoV-2 Gamma and Delta Waves in Parana, Brazil - Delta Displacing a Persistent Gamma Through Alternative Routes of Dispersal.
    J Med Virol. 2025;97:e70318.
    >> Share

  11. SUN P, Liu Q, Yuan S, Wang XT, et al
    SARS-CoV-2 Membrane Protein Induces MARCHF1/GPX4-Mediated Ferroptosis by Promoting Lipid Accumulation.
    J Med Virol. 2025;97:e70328.
    >> Share

  12. SULAIMAN X, Han Y, Liu S, Li K, et al
    Enrichment of G-to-U Substitution in SARS-CoV-2 Functional Regions and Its Compensation via Concurrent Mutations.
    J Med Virol. 2025;97:e70353.
    >> Share

  13. CHUANG CH, Wang YH, Yeh LT, Yeh CB, et al
    Long-Term Stroke and Mortality Risk Reduction Associated With Acute-Phase Paxlovid Use in Mild-to-Moderate COVID-19.
    J Med Virol. 2025;97:e70351.
    >> Share

  14. KIM TH, Son Y, Park J, Kim S, et al
    Post-Acute Sequelae of COVID-19 on Irritable Bowel Syndrome in Individuals With Mental Illness in South Korea: A Population-Based Cohort Study.
    J Med Virol. 2025;97:e70345.
    >> Share

    March 2025
  15. ZONG Y, Kamoi K, Zhang J, Yang M, et al
    The Silent Epidemic: Unveiling Herpetic Uveitis in the Elderly.
    J Med Virol. 2025;97:e70286.
    >> Share


  16. Correction to "Low Neutralization of SARS-CoV-2 Omicron BA5248, XBB15 and JN1 by Homologous Booster and Breakthrough Infection".
    J Med Virol. 2025;97:e70271.
    >> Share

  17. HANSEN KS, Jorgensen SE, Comert C, Schiottz-Christensen B, et al
    Genetic Landscape and Mitochondrial Metabolic Dysregulation in Patients Suffering From Severe Long COVID.
    J Med Virol. 2025;97:e70275.
    >> Share

  18. AZANZA JR, Gonzalez Del Castillo JM, Ferrando R, Molero JM, et al
    Cost-Effectiveness of Nirmatrelvir/Ritonavir in COVID-19 Patients at High-Risk for Progression in Spain.
    J Med Virol. 2025;97:e70288.
    >> Share

  19. LIU S, Liu P, Lu Q, Shen Y, et al
    The Compensatory Effect of S375F on S371F Is Vital for Maintaining the Infectivity of SARS-CoV-2 Omicron Variants.
    J Med Virol. 2025;97:e70242.
    >> Share

  20. GARCIA-VIDAL C, Teijon-Lumbreras C, Aiello TF, Chumbita M, et al
    COVID-19 Patients Benefitting From Remdesivir for Improved Survival: A Neural Network-Based Approach.
    J Med Virol. 2025;97:e70276.
    >> Share

  21. AMEGASHIE EA, Kwayisi-Darkwah CK, Adusei-Poku M, Sikeola RO, et al
    Lipid Peroxidation and Glutathione Levels Among People Living With HIV Co-infected With Human Coronaviruses in Ghana.
    J Med Virol. 2025;97:e70301.
    >> Share

  22. FOURGEAUD J, Turlure P, Dupont M, Veyrenche N, et al
    Remdesivir for the Treatment of Human Coronavirus OC43 Encephalitis.
    J Med Virol. 2025;97:e70314.
    >> Share

  23. VENTUROLI S, Bertoldi A, Manaresi E, Lazzarotto T, et al
    Epidemiology of Parvovirus B19 Infection In an Italian Metropolitan Area, 2012-2024: COVID-19 Pre-Pandemic, Pandemic and Post-Pandemic Trends.
    J Med Virol. 2025;97:e70296.
    >> Share

  24. BOTELLO-MARABOTTO M, Tarraso J, Mulet A, Presa-Fernandez L, et al
    Metabolomic Biomarkers of Pulmonary Fibrosis in COVID-19 Patients One Year After Hospital Discharge.
    J Med Virol. 2025;97:e70289.
    >> Share

    February 2025

  25. Correction to "Serum-Derived Bovine Immunoglobulin Treatment in COVID-19 Is Associated With Faster Resolution of Symptoms: A Randomized Pilot Clinical Trial".
    J Med Virol. 2025;97:e70202.
    >> Share

  26. LI J, Yan H, Li J, Ling F, et al
    Low Neutralization of SARS-CoV-2 Omicron BA5248, XBB15 and JN1 by Homologous Booster and Breakthrough Infection.
    J Med Virol. 2025;97:e70189.
    >> Share

  27. ZODDA E, Pons M, DeMoya-Valenzuela N, Calvo-Gonzalez C, et al
    Induction of the Inflammasome by the SARS-CoV-2 Accessory Protein ORF9b, Abrogated by Small-Molecule ORF9b Homodimerization Inhibitors.
    J Med Virol. 2025;97:e70145.
    >> Share

  28. CHANG S, Shin J, Park S, Park H, et al
    Continuous Tracking for Effective Tackling: Ad5/35 Platform-Based JN1 Lineage Vaccines Development in Response to Evolving SARS-CoV-2 Variants.
    J Med Virol. 2025;97:e70206.
    >> Share

  29. SUN J, Cheng J, Shi D, Xu X, et al
    Genetic Epidemiology of Porcine Epidemic Diarrhea Virus Circulating in China From 2010 to 2024: Characterization of Phylogenetic and Genetic Diversity of S1-Based Genes.
    J Med Virol. 2025;97:e70198.
    >> Share

  30. PENG Y, Zhang Y, Zeng S, Cai C, et al
    A Comprehensive Pan-Cancer Analysis of COVID-19 Booster Vaccination Efficacy and Safety.
    J Med Virol. 2025;97:e70211.
    >> Share

  31. HIKMAT H, Le Targa L, Boschi C, Py J, et al
    Five-Year (2017-2022) Evolutionary Dynamics of Human Coronavirus HKU1 in Southern France With Emergence of Viruses Harboring Spike H512R Substitution.
    J Med Virol. 2025;97:e70217.
    >> Share

  32. MAO T, Zhang P, Jiang S, Li D, et al
    Oral Ad5 Vector-Based SARS-CoV-2 Vaccine Effectively Induces Mucosal and Systemic Immune Responses in BALB/c Mice.
    J Med Virol. 2025;97:e70236.
    >> Share

  33. KALO E, Basyouni Z, Katz GM, Karkvandi V, et al
    Real-World Effectiveness of Sotrovimab in Patients Infected With SARS-CoV-2 Omicron Subvariant BA.2 in Western Sydney, Australia.
    J Med Virol. 2025;97:e70235.
    >> Share

  34. BERGNA A, Lai A, Sagradi F, Menzo S, et al
    Genomic Epidemiology of the Main SARS-CoV-2 Variants Circulating in Italy During the Omicron Era.
    J Med Virol. 2025;97:e70215.
    >> Share

  35. ZHAO M, Lei L, Jiang Y, Tian Y, et al
    Unveiling the Threat of Disease X: Preparing for the Next Global Pandemic.
    J Med Virol. 2025;97:e70227.
    >> Share

  36. YE J, Zhang R, Zhou J, Xu T, et al
    Systematic Reevaluation of Repurposed Drugs Against the Main Protease of SARS-CoV-2 via Combined Experiments.
    J Med Virol. 2025;97:e70229.
    >> Share

  37. MUKHOPADHYAY R, Lambisia AW, Hoang JP, Ravenhill BJ, et al
    Adenovirus-Specific T Cells in Adults Are Frequent, Cross-Reactive to Common Childhood Adenovirus Infections and Boosted by Adenovirus-Vectored Vaccines.
    J Med Virol. 2025;97:e70222.
    >> Share

  38. TORRES AR, Gaio V, Melo A, Lanca M, et al
    RSV-Bacterial Co-Infection Is Associated With Increased Illness Severity in Hospitalized Children - Results From a Prospective Sentinel Surveillance Study.
    J Med Virol. 2025;97:e70209.
    >> Share

  39. WANG S, Sun J, Hu Y, Zhang W, et al
    Clinical and Multiorgan Proteomics Characteristics of the Diverse Fatal Phase in Super Elderly Patients With SARS-CoV-2 Infection: A Descriptive Study.
    J Med Virol. 2025;97:e70207.
    >> Share

  40. ZHANG Y, Chen H, Li Y, Luo C, et al
    Animal Models for Long COVID: Current Advances, Limitations, and Future Directions.
    J Med Virol. 2025;97:e70237.
    >> Share

  41. LI Y, Lu J, He L, Jiang C, et al
    Repeated Omicron Infections Overcome T Cell Immune Imprinting to Original SARS-CoV-2.
    J Med Virol. 2025;97:e70264.
    >> Share

  42. FRAENKEL CJ, Thuresson S, Medstrand P, Alsved M, et al
    Comparison of Airborne SARS-CoV-2 Omicron and Pre-Delta Variants Around Infected Patients.
    J Med Virol. 2025;97:e70258.
    >> Share

  43. KIM J, Han E, Kim J, Kim YJ, et al
    Comparative Evaluation of the PowerChek Respiratory Virus Panel RT-PCR Assay Detecting 16 Respiratory Viruses Including SARS-CoV-2.
    J Med Virol. 2025;97:e70243.
    >> Share

  44. ZHAO Y, He C, Peng M, Li M, et al
    Large-Scale Screening of CD4(+) T-Cell Epitopes From SARS-CoV-2 Proteins and the Universal Detection of SARS-CoV-2 Specific T Cells for Northeast Asian Population.
    J Med Virol. 2025;97:e70241.
    >> Share

  45. HO SY, Zhou YT, Ho SY, Hu YL, et al
    Clinical Characteristics and Severity Predictors of Pediatric Adenovirus Infections.
    J Med Virol. 2025;97:e70248.
    >> Share

  46. HOTA M, Wondeu ALD, Abakar MF, Dezoumbe K, et al
    Integrated Seroprevalence and Genome-Based Study of SARS-CoV-2 Viral Strains in N'Djamena: Insights Into Chad's COVID-19 Epicenter.
    J Med Virol. 2025;97:e70234.
    >> Share

  47. DAMODAR T, Pattabiraman C, Singh B, Jose M, et al
    Microbiological Investigations for Chikungunya Virus in Children With Acute Encephalitis Syndrome in a Non-Outbreak Setting in Southern India.
    J Med Virol. 2025;97:e70233.
    >> Share

    January 2025
  48. LIU BM, Yao Q, Cruz-Cosme R, Yarbrough C, et al
    Genetic Conservation and Diversity of SARS-CoV-2 Envelope Gene Across Variants of Concern.
    J Med Virol. 2025;97:e70136.
    >> Share

  49. ZHAO X, Wei T, Hou Y, Wu Y, et al
    ATM/ATR-Mediated DNA Damage Response Facilitates SARS-CoV-2 Spike Protein-Induced Syncytium Formation.
    J Med Virol. 2025;97:e70137.
    >> Share

  50. CHEN J, Fan J, Malaviarachchi PA, Post SR, et al
    Alterations in Cellular Gene Expression Due to Co-Infection With Kaposi's Sarcoma-Associated Herpesvirus and SARS-CoV-2: Implications for Disease Severity.
    J Med Virol. 2025;97:e70149.
    >> Share

  51. ZHANG S, Kong X, Zhen Q, Wei Y, et al
    Dynamic Changes and Trends of SARS-CoV-2 Antibodies Induced by Infection and Vaccination Across Multiple Time Points.
    J Med Virol. 2025;97:e70161.
    >> Share

  52. KO C, Cheng CC, Mistretta D, Ambike S, et al
    SARS-CoV-2 Productively Infects Human Hepatocytes and Induces Cell Death.
    J Med Virol. 2025;97:e70156.
    >> Share

  53. SILVERIO BS, Guilardi MD, Martins JO, Duro RLS, et al
    Coronavirus Cryptic Landscape and Draft Genome of a Novel CoV Clade Related to MERS From Bats Circulating in Northeastern Brazil.
    J Med Virol. 2025;97:e70173.
    >> Share

  54. ALOSAIMI B, Awadalla M, Alturaiki W, Chen Z, et al
    A 10 Year Long-Lived Cellular and Humoral MERS-CoV Immunity Cross-Recognizing the Wild-Type and Variants of SARS-CoV-2: A Potential One-Way MERS-CoV Cross-Protection Toward a Pan-Coronavirus Vaccine.
    J Med Virol. 2025;97:e70071.
    >> Share

  55. ZHOU X, Liu H, Yang S, Dong X, et al
    Rapid Generation of Reverse Genetics Systems for Coronavirus Research and High-Throughput Antiviral Screening Using Gibson DNA Assembly.
    J Med Virol. 2025;97:e70171.
    >> Share

  56. CHUA HK, Singh A, Wang Y, Goh YS, et al
    Defining the Critical Requisites for Accurate Simulation of SARS-CoV-2 Viral Dynamics: Patient Characteristics and Data Collection Protocol.
    J Med Virol. 2025;97:e70174.
    >> Share

  57. AREVALO-HERRERA M, Rincon-Orozco B, Gonzalez-Escobar JM, Herrera-Arevalo SM, et al
    Longitudinal Follow-Up of the Specific Antibody Response to SARS-CoV-2 Vaccination in Colombia.
    J Med Virol. 2025;97:e70133.
    >> Share

  58. SANCHEZ-SIMARRO A, Cuevas-Ferrando E, Fernandez-Soto D, Grau B, et al
    Estimating SARS-CoV-2 Omicron XBB.1.5 Spike-Directed Functional Antibody Levels From an Anti-Receptor Binding Domain Wuhan-Hu-1-Based Commercial Immunoassay Results.
    J Med Virol. 2025;97:e70130.
    >> Share

  59. HUYGHE E, Abrams S, Andre E, Anseeuw K, et al
    Systematic Molecular Influenza A/B Screening Upon Hospital Admission in Belgium, January-April 2022: Positivity Ratios and Viral Loads According to Symptomatology, Age, and Vaccination Status.
    J Med Virol. 2025;97:e70167.
    >> Share

  60. BIRD PW, Zolana B, Oladejo S, Gurung S, et al
    Changing Patterns of Seasonal Respiratory Virus Incidence (2018-2023) Pre- and Post-COVID-19, Leicester, UK.
    J Med Virol. 2025;97:e70148.
    >> Share

  61. SOLAR P, Sery O, Vojtisek T, Krajsa J, et al
    The Blood-Cerebrospinal Fluid Barrier as a Potential Entry Site for the SARS-CoV-2 Virus.
    J Med Virol. 2025;97:e70184.
    >> Share

    December 2024
  62. WANG J, Ni S, Chen Q, Wang C, et al
    Discovery of a Novel Public Antibody Lineage Correlated With Inactivated SARS-CoV-2 Vaccine and the Resultant Neutralization Activity.
    J Med Virol. 2024;96:e70073.
    >> Share

  63. GRANINGER M, Endmayr V, Kuhner LM, Berger SM, et al
    Association Between NK Cell Genetic Variants and the Development of Long COVID Associated- and Prepandemic Small Fiber Neuropathy.
    J Med Virol. 2024;96:e70091.
    >> Share

  64. MAIMAITI M, Kong L, Yu Q, Wang Z, et al
    Analytical Performance of a Novel Nanopore Sequencing for SARS-CoV-2 Genomic Surveillance.
    J Med Virol. 2024;96:e70108.
    >> Share

  65. STICH M, Magalhaes VG, Burger F, Garbade SF, et al
    Elevated Soluble ACE2 Activity in Children and Adults After SARS-CoV-2 Exposure Irrespective of Laboratory-Confirmed Infection.
    J Med Virol. 2024;96:e70098.
    >> Share

  66. ZWYGART AC, Medaglia C, Zhu Y, Bart Tarbet E, et al
    Development of Broad-Spectrum beta-Cyclodextrins-Based Nanomaterials Against Influenza Viruses.
    J Med Virol. 2024;96:e70101.
    >> Share

  67. DALEXIS RD, Moshirian Farahi SMM, Dort J, Beogo I, et al
    Rates and Factors Related to COVID-19 Vaccine Uptake in Racialized and Indigenous Individuals in Canada: The Deleterious Effect of Experience of Racial Discrimination.
    J Med Virol. 2024;96:e70127.
    >> Share

  68. VLAMING-VAN EIJK LE, Ertugrul IA, Upasani V, Wold KI, et al
    Temporal Dynamics and (Para)Clinical Factors Associated With (Long) Viral RNA Shedding in COVID-19 Nonhospitalized Individuals - The COVID-HOME Study.
    J Med Virol. 2024;96:e70125.
    >> Share

  69. CHAN YJ, Chen CC, Tu YK, Hsu WH, et al
    The Effectiveness of COVID-19 Vaccination on Post-Acute Sequelae of SARS-CoV-2 Infection Among Geriatric Patients.
    J Med Virol. 2024;96:e70119.
    >> Share

  70. HUANG J, Li Y, Chen H, Liu H, et al
    Epidemiological, Clinical, and Genomic Traits of PIV in Hospitalized Children After the COVID-19 Pandemic in Wuhan, China.
    J Med Virol. 2024;96:e70117.
    >> Share

  71. MANRIQUE JM, Maffia-Bizzozero S, Delpino MV, Quarleri J, et al
    Multi-Organ Spread and Intra-Host Diversity of SARS-CoV-2 Support Viral Persistence, Adaptation, and a Mechanism That Increases Evolvability.
    J Med Virol. 2024;96:e70107.
    >> Share

  72. LAURE C, Hanae PR, Helene C, Melanie F, et al
    COVID-19 and Oncofertility: No SARS-CoV-2 in Semen but Inflammation Seems to Affect Sperm Parameters.
    J Med Virol. 2024;96:e70070.
    >> Share

  73. WANG C, Yang Y, Wu K, Wang C, et al
    An Outbreak of Human Adenovirus Infection Among Children Post COVID-19 Pandemic in Southern China.
    J Med Virol. 2024;96:e70139.
    >> Share

  74. LI K, Wu Y, Zhang H, Chen S, et al
    A Novel Circular Delta-XBB15 RBD Dimeric Protein Subunit Vaccine Mediated by Split Intein Elicits an Immune Response and Protection Against Multiple SARS-CoV-2 Variants in Mice.
    J Med Virol. 2024;96:e70134.
    >> Share

  75. GOSERT R, Koller R, Meyer J, Drager S, et al
    Multicenter Evaluation of the QIAstat-Dx and the BioFire Multiplex Panel Tests for the Detection of Respiratory Pathogens.
    J Med Virol. 2024;96:e70129.
    >> Share

    November 2024
  76. SONG K, Hasan A, Hao W, Wu Y, et al
    Stimulator of interferon genes (STING) inhibits coronavirus infection by disrupting viral replication organelles.
    J Med Virol. 2024;96:e70020.
    >> Share

  77. YILDIZ Y, Yasar E, Ozturk E, Karakan MS, et al
    Heterologous Versus Homologous COVID-19 Boosters: Immune Response Outcomes in Renal Transplant Recipients.
    J Med Virol. 2024;96:e70030.
    >> Share

  78. USTIUZHANINA MO, Boyko AA, Vavilova JD, Siniavin AE, et al
    The Antigen-Specific Response of NK Cells to SARS-CoV-2 Correlates With KIR2DS4 Expression.
    J Med Virol. 2024;96:e70057.
    >> Share

  79. ZHANG C, Wang M, Sun S, Yi M, et al
    Impact of COVID-19 on the Prevalence and Drug Resistance of Bacteria Isolated From Bacterial Meningitis Cerebrospinal Fluid in Shandong Province: A Multicenter Retrospective Study.
    J Med Virol. 2024;96:e70063.
    >> Share

  80. ESPI M, Charmetant X, Benotmane I, Lefsihane K, et al
    Memory B Cells Provide Long-Term Protection to Vaccinated Kidney Transplant Recipients Against SARS-CoV-2 Variants.
    J Med Virol. 2024;96:e70037.
    >> Share

  81. FACCO JV, Addas-Carvalho M, Duarte ADSS, Zangirolami AB, et al
    HLA-B*15 Is Associated With SARS-CoV-2 Infection in a Brazilian Population.
    J Med Virol. 2024;96:e70028.
    >> Share

  82. WANG N, Lin Q, Fan H, Wang Y, et al
    BIC/FTC/TAF Benefits People Living With HIV After Omicron Breakthrough Infection in Shortening Duration of Symptoms, Enhancing Specific Immune Response and Increasing Total CD4 Cells.
    J Med Virol. 2024;96:e70036.
    >> Share

  83. YE C, Tian Y, Huo D, Zhang T, et al
    Changes in Epidemics of Respiratory Viral Infections Resulted From the COVID-19 Pandemic in Shanghai.
    J Med Virol. 2024;96:e70034.
    >> Share

  84. DOS SANTOS ICM, Souza MS, Fogaca MMC, da Silva Brito RD, et al
    Elderly Individuals Exhibit Elevated Levels of Anti-Monkeypox Virus Antibodies Compared to Adults, Youth, and Children.
    J Med Virol. 2024;96:e70083.
    >> Share

  85. BAEK K, Kim D, Kang BM, Kim J, et al
    Parental Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Predominates Over Coinfected SARS-CoV-2 Delta, Producing Less Lethal Variants in a Long-Term Replication Mouse Model.
    J Med Virol. 2024;96:e70072.
    >> Share

  86. SUN H, Liu K, Yu B, Zhu M, et al
    Characterization of the Pathogenic Features of Multiple SARS-CoV-2 Pandemic Strains in Different Mouse Models.
    J Med Virol. 2024;96:e70049.
    >> Share


  87. Erratum to "Evaluation of the Effectiveness and Safety of Sequential Vaccination With Inactivated SARS-CoV-2 Vaccine and Ad5-nCoV Booster in Pediatric Liver Transplant Recipients".
    J Med Virol. 2024;96:e70053.
    >> Share

  88. TIAN W, Han Z, Shi D, Wang H, et al
    Indeterminate Result of Interferon-gamma Release Assay-A Risk Factor of Mortality for COVID-19 and Non-COVID-19 Respiratory Infections.
    J Med Virol. 2024;96:e70058.
    >> Share

  89. CHEN J, Zhang Y, Zhang B, Wang Z, et al
    In Vitro Characterization of Inhibition Function of Calcifediol to the Protease Activity of SARS-COV-2 PLpro.
    J Med Virol. 2024;96:e70085.
    >> Share

  90. USHIJIMA H, Pham NTK, Nishimura S, Kobayashi M, et al
    Human Astrovirus Infection and Outbreaks in Japanese Children Before and After the Emergence of COVID-19 Pandemic.
    J Med Virol. 2024;96:e70078.
    >> Share

  91. SIDDIQUE AI, Sarmah N, Bali NK, Nausch N, et al
    Differential Gene Expression and Transcriptomics Reveal High M-Gene Expression in JN.1 and KP.1/2 Omicron Sub-Variants of SARS-CoV-2: Implications for Developing More Sensitive Diagnostic Tests.
    J Med Virol. 2024;96:e70074.
    >> Share

    October 2024
  92. KUHN D, Heinen N, Sutter K, Herrmann ST, et al
    Divergent autoantibody and cytokine levels in COVID-19 sepsis patients influence survival.
    J Med Virol. 2024;96:e29935.
    >> Share

  93. DE ABREU GOES PEREIRA VM, Gularte JS, Demoliner M, da Silva MS, et al
    Influenza outbreak during the surge of SARS-CoV-2 omicron in a metropolitan area from southern Brazil: genomic surveillance.
    J Med Virol. 2024;96:e29944.
    >> Share

  94. XIAO P, Li C, Wu J, Dai J, et al
    Unravel the distinct effects of adiposity at different life stages on COVID-19 susceptibility and severity: A life-course Mendelian randomization study.
    J Med Virol. 2024;96:e29943.
    >> Share

  95. UTAY NS, Guerri-Fernandez R, Gharakhanian S, Asmuth DM, et al
    Serum-derived bovine immunoglobulin treatment in COVID-19 is associated with faster resolution of symptoms: A randomized pilot clinical trial.
    J Med Virol. 2024;96:e70005.
    >> Share

  96. SHANG C, Yu J, Zou S, Li H, et al
    Functional evaluation of TMEM176B and its predictive role for severe respiratory viral infection through integrated analysis of single-cell and bulk RNA-sequencing.
    J Med Virol. 2024;96:e29954.
    >> Share

  97. ZHOU H, Chen D, Ru X, Shao Q, et al
    Epidemiological and clinical characteristics of adenovirus-associated respiratory tract infection in children in Hangzhou, China, 2019-2024.
    J Med Virol. 2024;96:e29957.
    >> Share

  98. ZENG Z, Jia L, Zheng J, Nian X, et al
    Molecular epidemiology and vaccine compatibility analysis of seasonal influenza A viruses in the context of COVID-19 epidemic in Wuhan, China.
    J Med Virol. 2024;96:e29858.
    >> Share

  99. KOOPMAN G, Verhoeven T, Mooij P, Acar RF, et al
    Imaging the immune sequelae of infection with SARS-CoV-2 in nonhuman primates by using two nanobody PET-tracers.
    J Med Virol. 2024;96:e29956.
    >> Share

  100. XIE S, Song Z, Chen R, Zhang X, et al
    The SARS-unique domain (SUD) of SARS-CoV-2 nsp3 protein inhibits the antiviral immune responses through the NF-kappaB pathway.
    J Med Virol. 2024;96:e70007.
    >> Share

    September 2024
  101. LIU D, Leung KY, Zhang R, Lam HY, et al
    Efficacy of molnupiravir and interferon for the treatment of SARS-CoV-2 in golden Syrian hamster.
    J Med Virol. 2024;96:e29901.
    >> Share

  102. WANG M, Zhang D, Lei T, Zhou Y, et al
    Interferon-responsive neutrophils and macrophages extricate SARS-CoV-2 Omicron critical patients from the nasty fate of sepsis.
    J Med Virol. 2024;96:e29889.
    >> Share

  103. PLUMERS R, Dreier J, Knabbe C, Vollmer T, et al
    Unexpected high incidence of parvovirus B19 nucleic acid detection in German blood donors in the winter/spring season 2023/2024.
    J Med Virol. 2024;96:e29878.
    >> Share

  104. HUNG HC, Tan BF, Lin WS, Wu SC, et al
    Glycan masking of NTD loops with a chimeric RBD of the spike protein as a vaccine design strategy against emerging SARS-CoV-2 Omicron variants.
    J Med Virol. 2024;96:e29893.
    >> Share

  105. ZHOU Y, Feng W, Yang C, Wei X, et al
    E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting proteasome-dependent degradation of NSP5.
    J Med Virol. 2024;96:e29891.
    >> Share

  106. LO VT, Lim HA, Jang SS, Kim MC, et al
    N121T and N121S substitutions on the SARS-CoV-2 spike protein impact on serum neutralization.
    J Med Virol. 2024;96:e29871.
    >> Share

  107. LI K, Chen S, Li Z, Shen Y, et al
    Epidemiological characterization of hand, foot, and mouth disease among hospitalized children from 2014 to 2023 in a hospital in Henan Province: Longitudinal surveillance study.
    J Med Virol. 2024;96:e29916.
    >> Share

  108. NOH HE, Rha MS, Jeong Y, Kim D, et al
    Differential regulation of viral entry-associated genes modulated by inflammatory cytokines in the nasal epithelium.
    J Med Virol. 2024;96:e29913.
    >> Share

  109. KARACHALIOU M, Ranzani O, Espinosa A, Iraola-Guzman S, et al
    Antibody responses to common viruses according to COVID-19 severity and postacute sequelae of COVID-19.
    J Med Virol. 2024;96:e29862.
    >> Share

  110. GAY L, Desquiret-Dumas V, Nagot N, Rapenne C, et al
    Long-term persistence of mitochondrial dysfunctions after viral infections and antiviral therapies: A review of mechanisms involved.
    J Med Virol. 2024;96:e29886.
    >> Share

  111. ZHAO X, Chen L, Huo L, Wang M, et al
    Prevalence and risk factors of long COVID among maintenance hemodialysis patients post SARS-CoV-2 infection: A one-year follow-up study in China.
    J Med Virol. 2024;96:e29932.
    >> Share

  112. WANG X, Walker G, Kim KW, Stelzer-Braid S, et al
    The resurgence of influenza A/H3N2 virus in Australia after the relaxation of COVID-19 restrictions during the 2022 season.
    J Med Virol. 2024;96:e29922.
    >> Share

  113. LIN FL, Wei LC
    Evolving dynamics of COVID-19 vaccine hesitancy in China: Perspectives and suggestions from Taiwan.
    J Med Virol. 2024;96:e29930.
    >> Share

  114. SAHAY RR, Palav HC, Shete AM, Patil DY, et al
    Comparative immune profiling in survivors of the 2023 Nipah outbreak in Kerala state, India.
    J Med Virol. 2024;96:e29920.
    >> Share

  115. PARK U, Lee JH, Kim U, Jeon K, et al
    A humanized ACE2 mouse model recapitulating age- and sex-dependent immunopathogenesis of COVID-19.
    J Med Virol. 2024;96:e29915.
    >> Share

  116. ZHAO C, Cai G, Jiang S, Wang X, et al
    Broad-spectrum coronavirus neutralization induced by hetero RBD-Fc protein vaccine.
    J Med Virol. 2024;96:e29917.
    >> Share

  117. LOVELL JF, Miura K, Baik YO, Lee C, et al
    Interim safety and immunogenicity analysis of the EuCorVac-19 COVID-19 vaccine in a Phase 3 randomized, observer-blind, immunobridging trial in the Philippines.
    J Med Virol. 2024;96:e29927.
    >> Share

  118. LI H, Yang Y, Tao R, Shang S, et al
    Analyzing infections caused by 11 respiratory pathogens in children: Pre- and post-COVID-19 pandemic trends in China.
    J Med Virol. 2024;96:e29929.
    >> Share

  119. HORI M, Hayama-Terada M, Kitamura A, Hosozawa M, et al
    Risk factors for post-coronavirus disease condition in the Alpha-, Delta-, and Omicron-dominant waves among adults in Japan: A population-based matched case-control study.
    J Med Virol. 2024;96:e29928.
    >> Share

    August 2024
  120. OUOBA S, Sugiyama A, Ko K, Mirzaev UK, et al
    Development of a unit conversion tool for five quantitative anti-spike assays and agreement analysis of three qualitative anti-nucleocapsid assays for SARS-CoV-2.
    J Med Virol. 2024;96:e29826.
    >> Share

  121. NKINDA L, Barabona G, Ngare I, Nkuwi E, et al
    Evaluation of cross-neutralizing immunity following COVID-19 primary series vaccination during the Omicron surge in Tanzania.
    J Med Virol. 2024;96:e29822.
    >> Share

  122. JIANG X, Gao X, Ding J, Pang B, et al
    Fecal microbiota transplantation alleviates mild-moderate COVID-19 associated diarrhoea and depression symptoms: A prospective study of a randomized, double-blind clinical trial.
    J Med Virol. 2024;96:e29812.
    >> Share

  123. GUPTA A, Righi E, Konnova A, Sciammarella C, et al
    Interleukin-2-mediated CD4 T-cell activation correlates highly with effective serological and T-cell responses to SARS-CoV-2 vaccination in people living with HIV.
    J Med Virol. 2024;96:e29820.
    >> Share

  124. GALUCIO VCA, de Menezes DC, Chaves ECR, van den Berg AVS, et al
    Laboratory profiling of patients with long COVID in the Brazilian Amazon region: A cross-sectional study.
    J Med Virol. 2024;96:e29828.
    >> Share

  125. LI T, Li X, Lin F, Fu H, et al
    Epidemiology of the resurgence of respiratory syncytial virus infections among children post-COVID-19: A single-center retrospective observational study.
    J Med Virol. 2024;96:e29841.
    >> Share

  126. CHEN Y, Zhao X, Ye C, Zhou J, et al
    Epidemiology and viral loads of respiratory syncytial virus in hospitalized children prior to and during COVID-19 pandemic in Hangzhou, China.
    J Med Virol. 2024;96:e29855.
    >> Share

  127. TOMAR SS, Khairnar K
    Detection of lumpy skin disease virus reads in the human upper respiratory tract microbiome requires further investigation.
    J Med Virol. 2024;96:e29829.
    >> Share

  128. KOZAWA K, Higashimoto Y, Kawamura Y, Miura H, et al
    Temporal patterns of asymptomatic SARS-CoV-2 infection among pediatric population in Japan: A 3-year analysis.
    J Med Virol. 2024;96:e29847.
    >> Share

  129. SEEKIRCHER L, Astl M, Tschiderer L, Wachter GA, et al
    Anti-Spike IgG antibodies as correlates of protection against SARS-CoV-2 infection in the pre-Omicron and Omicron era.
    J Med Virol. 2024;96:e29839.
    >> Share

  130. KATONA M, Jeles K, Takacs P, Csoma E, et al
    DNA and seroprevalence study of MW and STL polyomaviruses.
    J Med Virol. 2024;96:e29860.
    >> Share

  131. SAKR AA, Mohamed AA, Ahmed AE, Abdelhaleem AA, et al
    Biochemical implication of acetylcholine, histamine, IL-18, and interferon-alpha as diagnostic biomarkers in hepatitis C virus, coronavirus disease 2019, and dual hepatitis C virus-coronavirus disease 2019 patients.
    J Med Virol. 2024;96:e29857.
    >> Share

  132. PIETROLUONGO E, Luciano A, Peddio A, Buonaiuto R, et al
    Exploring the interplay between Kaposi's sarcoma and SARS-CoV-2 infection: A case series and systematic review.
    J Med Virol. 2024;96:e29849.
    >> Share

  133. GARCIA-VEGA M, Llamas-Covarrubias MA, Loza M, Resendiz-Sandoval M, et al
    Single-cell transcriptomic analysis of B cells reveals new insights into atypical memory B cells in COVID-19.
    J Med Virol. 2024;96:e29851.
    >> Share

  134. BINAYKE A, Zaheer A, Vishwakarma S, Sharma P, et al
    Understanding the landscape of the SARS-CoV-2-specific T cells post-omicron surge.
    J Med Virol. 2024;96:e29877.
    >> Share

  135. PONTIROLI AE, Zanoni I, Tanzi E, Tagliabue E, et al
    Effect of influenza vaccination on SARS-CoV-2 infection: Relationship between SARS-CoV-2 infection rates and effects of influenza vaccination.
    J Med Virol. 2024;96:e29868.
    >> Share

  136. ZHAO XJ, Liu XL, Gu HJ, Liu T, et al
    SARS-CoV-2 reinfection broadens the antibody responses and promotes the phenotypic differentiation of virus-specific memory T cells in adolescents.
    J Med Virol. 2024;96:e29873.
    >> Share

  137. MAES M, Almulla AF, Tang X, Stoyanova K, et al
    From human herpes virus-6 reactivation to autoimmune reactivity against tight junctions and neuronal antigens, to inflammation, depression, and chronic fatigue syndrome due to Long COVID.
    J Med Virol. 2024;96:e29864.
    >> Share

  138. THIERRY AR, Salmon D
    Inflammation-, immunothrombosis,- and autoimmune-feedback loops may lead to persistent neutrophil self-stimulation in long COVID.
    J Med Virol. 2024;96:e29887.
    >> Share

  139. KITANO T, Kitagawa D, Murata M, Onishi M, et al
    Duration of PCR positivity by type of respiratory virus among children using a multiplex PCR test.
    J Med Virol. 2024;96:e29890.
    >> Share

    July 2024
  140. GALLEGO-GARCIA P, Estevez-Gomez N, De Chiara L, Alvarino P, et al
    Dispersal history of SARS-CoV-2 in Galicia, Spain.
    J Med Virol. 2024;96:e29773.
    >> Share

  141. VOLCIC M, Nchioua R, Pastorio C, Zech F, et al
    Attenuated replication and damaging effects of SARS-CoV-2 Omicron variants in an intestinal epithelial barrier model.
    J Med Virol. 2024;96:e29783.
    >> Share

  142. MEI HE, Schulz AR, Hirseland H, Diekmann LM, et al
    Prophylactic antibodies inhibit spike-specific T and B cell responses after COVID-19 vaccination.
    J Med Virol. 2024;96:e29778.
    >> Share

  143. KAO CL, Liu PH
    Comment on "A systematic review and meta-analysis of herpes zoster occurrence/recurrence after COVID-19 infection and vaccination".
    J Med Virol. 2024;96:e29785.
    >> Share

  144. LOPEZ-AYLLON BD, Marin S, Fernandez MF, Garcia-Garcia T, et al
    Metabolic and mitochondria alterations induced by SARS-CoV-2 accessory proteins ORF3a, ORF9b, ORF9c and ORF10.
    J Med Virol. 2024;96:e29752.
    >> Share

  145. CARRETERO D, Gimenez E, Albert E, Colomer E, et al
    SARS-CoV-2-Spike T-cell response after receiving one or two Wuhan-Hu-1-based mRNA COVID-19 vaccine booster doses in elderly nursing home residents.
    J Med Virol. 2024;96:e29790.
    >> Share

  146. LEE S, Lee K, Park J, Jeong YD, et al
    Global burden of vaccine-associated hepatobiliary and gastrointestinal adverse drug reactions, 1967-2023: A comprehensive analysis of the international pharmacovigilance database.
    J Med Virol. 2024;96:e29792.
    >> Share

  147. DECKER SRDR, Wolf JM, Pille A, Freese L, et al
    Temporal trends in respiratory pathogens following the COVID-19 pandemic and climate variables: A unicentric retrospective evaluation of 24 pathogens in a temperate subtropical region.
    J Med Virol. 2024;96:e29797.
    >> Share

  148. SPRINGER DN, Camp JV, Aberle SW, Deutsch J, et al
    Neutralization of SARS-CoV-2 Omicron XBB.1.5 and JN.1 variants after COVID-19 booster-vaccination and infection.
    J Med Virol. 2024;96:e29801.
    >> Share

  149. GAY L, Madariaga Zarza S, Abou Atmeh P, Rouviere MS, et al
    Protective role of macrophages from maternal-fetal interface in unvaccinated coronavirus disease 2019 pregnant women.
    J Med Virol. 2024;96:e29819.
    >> Share

  150. REINIG S, Kuo C, Wu CC, Huang SY, et al
    Specific long-term changes in anti-SARS-CoV-2 IgG modifications and antibody functions in mRNA, adenovector, and protein subunit vaccines.
    J Med Virol. 2024;96:e29793.
    >> Share

  151. SHEN Z, Li Q, Wu J, Zhu D, et al
    Dynamic evolution of COVID-19 vaccine hesitancy over 2021-2023 among Chinese population: Repeated nationwide cross-sectional study.
    J Med Virol. 2024;96:e29800.
    >> Share


  152. Correction to [A pilot study of the antiviral activity of anionic and cationic polyamidoamine dendrimers against the Middle East respiratory syndrome coronavirus].
    J Med Virol. 2024;96:e29803.
    >> Share

  153. LI S, Bu J, Pan X, Li Q, et al
    SARS-CoV-2 envelope protein-derived extracellular vesicles act as potential media for viral spillover.
    J Med Virol. 2024;96:e29782.
    >> Share

  154. CENAT JM, Moshirian Farahi SMM, Dalexis RD, Caulley L, et al
    COVID-19 vaccine mistrust, health literacy, conspiracy theories, and racial discrimination among a representative ethnically diverse sample in Canada: The vulnerability of Arab, Asian, Black, and Indigenous peoples.
    J Med Virol. 2024;96:e29795.
    >> Share

    June 2024
  155. JEONG YD, Lee K, Lee S, Park J, et al
    Global and regional burden of vaccine-associated facial paralysis, 1967-2023: Findings from the WHO international pharmacovigilance database.
    J Med Virol. 2024;96:e29682.
    >> Share

  156. CHEN IW, Yu TS, Lin CH, Hung KC, et al
    Effectiveness of nirmatrelvir-ritonavir on severe outcomes of COVID-19: A meta-regression analysis.
    J Med Virol. 2024;96:e29718.
    >> Share

  157. KOW CS, Ramachandram DS, Hasan SS, Thiruchelvam K, et al
    Antibiotics in COVID-19: Unveiling disturbing truths through critical scrutiny.
    J Med Virol. 2024;96:e29720.
    >> Share

  158. HAN Y, Ma Y, Wang Z, Feng F, et al
    TMPRSS13 promotes the cell entry of swine acute diarrhea syndrome coronavirus.
    J Med Virol. 2024;96:e29712.
    >> Share

  159. BORGOGNA C, Ferrante D, Rosso G, Guglielmetti G, et al
    A prospective humoral immune monitoring study of kidney transplant recipients receiving three doses of SARS-CoV-2 mRNA vaccine.
    J Med Virol. 2024;96:e29710.
    >> Share

  160. PAVIA G, Quirino A, Marascio N, Veneziano C, et al
    Persistence of SARS-CoV-2 infection and viral intra- and inter-host evolution in COVID-19 hospitalized patients.
    J Med Virol. 2024;96:e29708.
    >> Share

  161. SONG K, Ye RZ, Li YY, Gong C, et al
    A Statovirus-like virus from respiratory tracts of patients, China.
    J Med Virol. 2024;96:e29711.
    >> Share

  162. XIONG X, Zheng Z, Liu C, Wang X, et al
    Unveiling the metabolic and coagulation disruptions in SARS-CoV-2-associated acute macular neuroretinopathy: A case-control study.
    J Med Virol. 2024;96:e29714.
    >> Share

  163. JURKOWICZ M, Cohen H, Nemet I, Keller N, et al
    Epidemiological and clinical characteristics of hospitalized human metapneumovirus patients in Israel, 2015-2021: A retrospective cohort study.
    J Med Virol. 2024;96:e29709.
    >> Share

  164. SAADE A, Didier Q, Cha L, Garlantezec R, et al
    The prevalence, determinants, and consequences of post-COVID in healthcare workers: A cross-sectional survey.
    J Med Virol. 2024;96:e29725.
    >> Share

  165. KIM H, Kyung S, Park J, Lee H, et al
    Risks of cutaneous immune-related adverse events in long COVID: Multinational cohort studies in South Korea, Japan, and the UK.
    J Med Virol. 2024;96:e29740.
    >> Share

  166. AGUILAR R, Jimenez A, Santano R, Vidal M, et al
    Malaria and other infections induce polyreactive antibodies that impact SARS-CoV-2 seropositivity estimations in endemic settings.
    J Med Virol. 2024;96:e29713.
    >> Share

  167. SHI P, Wang R, Liu E, Deng Y, et al
    Timing patterns of initial respiratory syncytial virus infection and factors influencing disease severity in hospitalized infants with different health status.
    J Med Virol. 2024;96:e29719.
    >> Share

  168. LEE S, Jo H, Lee H, Lee H, et al
    Global estimates on the reports of vaccine-associated myocarditis and pericarditis from 1969 to 2023: Findings with critical reanalysis from the WHO pharmacovigilance database.
    J Med Virol. 2024;96:e29693.
    >> Share

  169. BLANGY-LETHEULE A, Vergnaud A, Dupas T, Habert D, et al
    Value of a secretomic approach for distinguishing patients with COVID-19 viral pneumonia among patients with respiratory distress admitted to intensive care unit.
    J Med Virol. 2024;96:e29756.
    >> Share

  170. ALMANZAR G, Koosha K, Vogt T, Stein A, et al
    Hybrid immunity by two COVID-19 mRNA vaccinations and one breakthrough infection provides a robust and balanced cellular immune response as basic immunity against severe acute respiratory syndrome coronavirus 2.
    J Med Virol. 2024;96:e29739.
    >> Share

  171. TANG Y, Zou X, Liu P, Dai Y, et al
    Human umbilical cord-derived mesenchymal stem cell transplantation improves the long COVID.
    J Med Virol. 2024;96:e29757.
    >> Share

  172. KARBIENER M, Kindle G, Meyts I, Seppanen MRJ, et al
    Clinical efficacy of SARS-CoV-2 Omicron-neutralizing antibodies in immunoglobulin preparations for the treatment of agammaglobulinemia in patients with primary antibody deficiency.
    J Med Virol. 2024;96:e29738.
    >> Share

  173. ZHU W, Gu L
    Resurgence of seasonal influenza driven by A/H3N2 and B/Victoria in succession during the 2023-2024 season in Beijing showing increased population susceptibility.
    J Med Virol. 2024;96:e29751.
    >> Share

  174. MALLICK A, Sukla S, De A, Biswas S, et al
    Evidences support that dengue virus can impart broad-spectrum immunity against betacoronaviruses in dengue endemic regions.
    J Med Virol. 2024;96:e29771.
    >> Share

  175. XIAO M, Banu A, Jia Y, Chang M, et al
    Circulation pattern and genetic variation of rhinovirus infection among hospitalized children on Hainan Island, before and after the dynamic zero-COVID policy, from 2021 to 2023.
    J Med Virol. 2024;96:e29755.
    >> Share

    May 2024
  176. HSU AY, Lin CJ, Hsia NY, Wang YH, et al
    Reply to comment on "The risk assessment of uveitis after COVID-19 diagnosis by Wu et al. 2024".
    J Med Virol. 2024;96:e29636.
    >> Share

  177. HEWEL C, Schmidt H, Runkel S, Kohnen W, et al
    Nanopore adaptive sampling of a metagenomic sample derived from a human monkeypox case.
    J Med Virol. 2024;96:e29610.
    >> Share

  178. ZHAO XJ, Liu XL, Liang YM, Zhang S, et al
    Epidemiological characteristics and antibody kinetics of elderly population with booster vaccination following both Omicron BA.5 and XBB waves in China.
    J Med Virol. 2024;96:e29640.
    >> Share

  179. TANG Z, Mao Y, Ruan P, Li J, et al
    Drugs targeting CMPK2 inhibit pyroptosis to alleviate severe pneumonia caused by multiple respiratory viruses.
    J Med Virol. 2024;96:e29643.
    >> Share

  180. MATUSALI G, Mazzotta V, Meschi S, Colavita F, et al
    JN.1 neutralizing antibody titers after XBB.1.5 monovalent vaccine boost in healthcare workers and people with HIV.
    J Med Virol. 2024;96:e29631.
    >> Share

  181. GAO R, Feng C, Sheng Z, Li F, et al
    Research progress in Fc-effector functions against SARS-CoV-2.
    J Med Virol. 2024;96:e29638.
    >> Share

  182. WANG F, Gao Y, Wagner AL, Lu Y, et al
    A systematic review and meta-analysis of herpes zoster occurrence/recurrence after COVID-19 infection and vaccination.
    J Med Virol. 2024;96:e29629.
    >> Share

  183. THOMAS S, Smatti MK, Alsulaiti H, Zedan HT, et al
    Antibody-dependent enhancement (ADE) of SARS-CoV-2 in patients exposed to MERS-CoV and SARS-CoV-2 antigens.
    J Med Virol. 2024;96:e29628.
    >> Share

  184. FENG Y, Zhao X, Chen Z, Wu Y, et al
    Prevalence and diversity of imported severe acute respiratory syndrome coronavirus 2 variants in China, 2021-2022.
    J Med Virol. 2024;96:e29664.
    >> Share

  185. ISHII T, Nawa N, Hosokawa S, Morio T, et al
    Exploring viral infections' role in Kawasaki disease onset: A study during the COVID-19 pandemic.
    J Med Virol. 2024;96:e29660.
    >> Share

  186. ASHOKKUMAR S, Lim JS, Kaushik NK, Han I, et al
    Human coronavirus 229E inactivation on porous and nonporous materials using dielectric barrier discharge (DBD) plasma.
    J Med Virol. 2024;96:e29655.
    >> Share

  187. WU JY, Chen CC, Liu MY, Hsu WH, et al
    Clinical effectiveness of nirmatrelvir plus ritonavir on the short- and long-term outcome in high-risk children with COVID-19.
    J Med Virol. 2024;96:e29662.
    >> Share

  188. CHENG P, Zhai K, Han W, Zeng J, et al
    Characterizing the antigenic evolution of pandemic influenza A (H1N1) pdm09 from 2009 to 2023.
    J Med Virol. 2024;96:e29657.
    >> Share

  189. CHEN SY, Hsieh TYJ, Hung YM, Oh JW, et al
    Prior COVID-19 vaccination and reduced risk of cerebrovascular diseases among COVID-19 survivors.
    J Med Virol. 2024;96:e29648.
    >> Share

  190. RZYMSKI P, Zarebska-Michaluk D, Parczewski M, Genowska A, et al
    The burden of infectious diseases throughout and after the COVID-19 pandemic (2020-2023) and Russo-Ukrainian war migration.
    J Med Virol. 2024;96:e29651.
    >> Share

  191. GRUBER CEM, Tucci FG, Giombini E, Mazzotta V, et al
    Molnupiravir increases SARS-CoV-2 genome diversity and complexity: A case-control cohort study.
    J Med Virol. 2024;96:e29642.
    >> Share

  192. KYUNG S, Son Y, Kim M, Kang J, et al
    Risks of alopecia areata in long COVID: Binational population-based cohort studies from South Korea and Japan.
    J Med Virol. 2024;96:e29668.
    >> Share

  193. FERNANDEZ-DE-LAS-PENAS C, Torres-Macho J, Ruiz-Ruigomez M, Arrieta-Ortubay E, et al
    Presence of SARS-CoV-2 RNA in COVID-19 survivors with post-COVID symptoms 2 years after hospitalization: The VIPER study.
    J Med Virol. 2024;96:e29676.
    >> Share

  194. QIAO H, Deng X, Qiu L, Qu Y, et al
    SARS-CoV-2 induces blood-brain barrier and choroid plexus barrier impairments and vascular inflammation in mice.
    J Med Virol. 2024;96:e29671.
    >> Share

  195. DAMODAR T, Dunai C, Prabhu N, Jose M, et al
    Diagnostic markers of acute encephalitis syndrome and COVID-associated multisystem inflammatory syndrome in children from Southern India.
    J Med Virol. 2024;96:e29666.
    >> Share

  196. HAQUE W, Talha M, Rahman S, Hasan M, et al
    Rotavirus trends and distribution of genotypes before and during COVID-19 pandemic era: Bangladesh, 2017-2021.
    J Med Virol. 2024;96:e29681.
    >> Share

  197. AMOROSO MG, Pucciarelli A, Serra F, Ianiro G, et al
    Ten different viral agents infecting and co-infecting children with acute gastroenteritis in Southern Italy: Role of known pathogens and emerging viruses during and after COVID-19 pandemic.
    J Med Virol. 2024;96:e29679.
    >> Share

  198. GONG S, Ma C, Ma R, Zhu T, et al
    Elevated pretreatment serum apolipoprotein E level associated with poor prognosis of patients with COVID-19 during the omicron BA.5 and BF.7 wave.
    J Med Virol. 2024;96:e29673.
    >> Share

  199. AKANCHISE T, Angelov B, Angelova A
    Nanomedicine-mediated recovery of antioxidant glutathione peroxidase activity after oxidative-stress cellular damage: Insights for neurological long COVID.
    J Med Virol. 2024;96:e29680.
    >> Share

    April 2024
  200. GUNGOR K, Bukavaz S, Ekuklu G
    Measles outbreak in the adult age group: Clinical, laboratory, and epidemiological features of the 11 patients admitted to the hospital.
    J Med Virol. 2024;96:e29583.
    >> Share

  201. HE S, Liu SQ, Teng XY, He JY, et al
    Comparative single-cell RNA sequencing analysis of immune response to inactivated vaccine and natural SARS-CoV-2 infection.
    J Med Virol. 2024;96:e29577.
    >> Share

  202. WOO HG, Kim HJ, Park J, Lee J, et al
    Global burden of vaccine-associated multiple sclerosis, 1967-2022: A comprehensive analysis of the international pharmacovigilance database.
    J Med Virol. 2024;96:e29591.
    >> Share

  203. GANDIKOTA C, Vaddadi K, Sivasami P, Huang C, et al
    The use of human iPSC-derived alveolar organoids to explore SARS-CoV-2 variant infections and host responses.
    J Med Virol. 2024;96:e29579.
    >> Share

  204. YANG H, Guan L, Yang T, Ma H, et al
    Two- and 3-year outcomes in convalescent individuals with COVID-19: A prospective cohort study.
    J Med Virol. 2024;96:e29566.
    >> Share

  205. MELE D, Ottolini S, Lombardi A, Conteianni D, et al
    Long-term dynamics of natural killer cells in response to SARS-CoV-2 vaccination: Persistently enhanced activity postvaccination.
    J Med Virol. 2024;96:e29585.
    >> Share

  206. FAN Y, Huang S, Wu D, Chu M, et al
    Immune features revealed by single-cell RNA and single-cell TCR/BCR sequencing in patients with rheumatoid arthritis receiving COVID-19 booster vaccination.
    J Med Virol. 2024;96:e29573.
    >> Share

  207. HUNG KC, Yu TS, Wang KF, Chen IW, et al
    Influenza vaccination on SARS-CoV-2 infection risk: A subgroup analysis on geographic factor.
    J Med Virol. 2024;96:e29576.
    >> Share

  208. ARUNAN B, Talukdar D, Swain S, Varadarajan A, et al
    Metagenomic insights into fungal community composition of the nasopharyngeal region of COVID-19 associated mucormycosis patients from India.
    J Med Virol. 2024;96:e29601.
    >> Share

  209. LI Y, Yu J, Wang Y, Yi J, et al
    Cocirculation and coinfection of multiple respiratory viruses during autumn and winter seasons of 2023 in Beijing, China: A retrospective study.
    J Med Virol. 2024;96:e29602.
    >> Share

  210. PARK D, Kim SM, Jang H, Kim K, et al
    Differential beta-coronavirus infection dynamics in human bronchial epithelial organoids.
    J Med Virol. 2024;96:e29600.
    >> Share

  211. SVIERCZ F, Jarmoluk P, Godoy Coto J, Cevallos C, et al
    The abortive SARS-CoV-2 infection of osteoclast precursors promotes their differentiation into osteoclasts.
    J Med Virol. 2024;96:e29597.
    >> Share

  212. RAI P, Marano JM, Kang L, Coutermarsh-Ott S, et al
    Obesity fosters severe disease outcomes in a mouse model of coronavirus infection associated with transcriptomic abnormalities.
    J Med Virol. 2024;96:e29587.
    >> Share

  213. KURYLOWICZ A, Babicki M, Wasowski M, Jankowski P, et al
    Triglicerydes/high-density lipoprotein ratio as a risk factor of post-Covid-19 sinus tachycardia: A retrospective study.
    J Med Virol. 2024;96:e29586.
    >> Share

  214. YE G, Tang Y, Yang Q, Zhang C, et al
    A peptide derived from SARS-CoV-2 nucleocapsid protein with broad-spectrum anti-coronavirus activity.
    J Med Virol. 2024;96:e29492.
    >> Share

  215. MENG H, Wang Y, Zhai Y, Luo W, et al
    Unveiling the micronutrient-immunity puzzle in inactivated COVID-19 vaccination: A comprehensive analysis of circulating micronutrient levels and humoral responses in healthy adults.
    J Med Virol. 2024;96:e29611.
    >> Share

  216. MAHLA RS, Dustin LB
    COVID-19 vaccination and autoimmunity: Do we need more evidence?
    J Med Virol. 2024;96:e29623.
    >> Share

  217. WEI M, Li S, Lu X, Hu K, et al
    Changing respiratory pathogens infection patterns after COVID-19 pandemic in Shanghai, China.
    J Med Virol. 2024;96:e29616.
    >> Share

  218. OKITSU S, Khamrin P, Hikita T, Onda Y, et al
    Remarkable increase in the detection and molecular characterization of adenovirus F41 in children with acute gastroenteritis in Japan, 2017-2023.
    J Med Virol. 2024;96:e29615.
    >> Share

  219. MATUSALI G, Vergori A, Cimini E, Mariotti D, et al
    Poor durability of the neutralizing response against XBB sublineages after a bivalent mRNA COVID-19 booster dose in persons with HIV.
    J Med Virol. 2024;96:e29598.
    >> Share

  220. CHEN IW, Weng HL, Lai YC, Hung KC, et al
    Incidence of fatigue 2 years after SARS-CoV-2 infection: An updated meta-analysis and subgroup analysis.
    J Med Virol. 2024;96:e29619.
    >> Share

  221. DESTREMAU M, Chaussade H, Hemar V, Beguet M, et al
    Convalescent plasma transfusion for immunocompromised viremic patients with COVID-19: A retrospective multicenter study.
    J Med Virol. 2024;96:e29603.
    >> Share

  222. SUN Q, Gao J, An R, Wang M, et al
    Probing molecular pathways: Illuminating the connection between COVID-19 and Alzheimer's disease through the endocannabinoid system dynamics.
    J Med Virol. 2024;96:e29590.
    >> Share

  223. SONG G, Li R, Cheng MQ
    Safety, immunogenicity, and protective effective of inhaled COVID-19 vaccines: A systematic review and meta-analysis.
    J Med Virol. 2024;96:e29625.
    >> Share

    March 2024
  224. ZHANG N, Ye Z, Li C, Zhou J, et al
    A subunit-based influenza/SARS-CoV-2 Omicron combined vaccine induced potent protective immunity in BALB/c mice.
    J Med Virol. 2024;96:e29479.
    >> Share

  225. XIAO J, Luo Y, Li Y, Yao X, et al
    The characteristics of BCR-CDR3 repertoire in COVID-19 patients and SARS-CoV-2 vaccinated volunteers.
    J Med Virol. 2024;96:e29488.
    >> Share

  226. WU P, Yii CY, Yong SB
    Comment on "The risk assessment of uveitis after COVID-19 diagnosis".
    J Med Virol. 2024;96:e29494.
    >> Share

  227. CHEN IW, Lin HJ, Lin YT, Hung KC, et al
    Comment on "The association of sickle cell disorder with adverse outcomes in COVID-19 patients: A meta-analysis".
    J Med Virol. 2024;96:e29495.
    >> Share

  228. LIU Y, Li M, Cui T, Chen Z, et al
    A superior heterologous prime-boost vaccination strategy against COVID-19: A bivalent vaccine based on yeast-derived RBD proteins followed by a heterologous vaccine.
    J Med Virol. 2024;96:e29454.
    >> Share

  229. KIM JW, Lee JH, Kim HJ, Heo K, et al
    Empowering SARS-CoV-2 variant neutralization with a bifunctional antibody engineered with tandem heptad repeat 2 peptides.
    J Med Virol. 2024;96:e29506.
    >> Share

  230. ZHANG R, Yan H, Zhou J, Yan G, et al
    Improved fluorescence-based assay for rapid screening and evaluation of SARS-CoV-2 main protease inhibitors.
    J Med Virol. 2024;96:e29498.
    >> Share

  231. XIONG N, Sun Q
    Identifying COVID-19 subtypes by single-sample gene set enrichemnt analysis and providing guidance for sensitive drug selection.
    J Med Virol. 2024;96:e29497.
    >> Share

  232. WU N, Chen Z, Zha G, Deng Z, et al
    Clinical and immunological features of COVID-19 in patients with anti-MDA5 dermatomyositis during the omicron wave in Chongqing, China.
    J Med Virol. 2024;96:e29493.
    >> Share


  233. Retraction: "Safety and immunogenicity of a recombinant receptor-binding domain-based protein subunit vaccine (Noora vaccine) against COVID-19 in adults: A randomized, double-blind, placebo-controlled, Phase 1 trial".
    J Med Virol. 2024;96:e29509.
    >> Share


  234. Correction to "Exploring the impact of ursodeoxycholic acid therapy on COVID-19 in a real-word setting".
    J Med Virol. 2024;96:e29518.
    >> Share

  235. ZHENG Y, Feng J, Song Y, Yu Y, et al
    Design and synthesis of APN and 3CLpro dual-target inhibitors based on STSBPT with anticoronavirus activity.
    J Med Virol. 2024;96:e29512.
    >> Share

  236. ROJO-ALBA S, Martinez ZP, Gonzalez-Alba JM, Boga JA, et al
    Respiratory syncytial virus incidence and typing in the last six seasons in the north of Spain (Asturias). Genetic characterization during the SARS-CoV-2 pandemic.
    J Med Virol. 2024;96:e29499.
    >> Share

  237. YEH LT, Chan CH, Wang YH, Lee CY, et al
    Exploring the incidence of peripheral arterial occlusive disease following COVID-19 infection: A retrospective cohort study.
    J Med Virol. 2024;96:e29519.
    >> Share

  238. TAI CG, Haviland MJ, Kissler SM, Lucia RM, et al
    Low antibody levels associated with significantly increased rate of SARS-CoV-2 infection in a highly vaccinated population from the US National Basketball Association.
    J Med Virol. 2024;96:e29505.
    >> Share

  239. LEE C, Greenwood DC, Master H, Balasundaram K, et al
    Prevalence of orthostatic intolerance in long covid clinic patients and healthy volunteers: A multicenter study.
    J Med Virol. 2024;96:e29486.
    >> Share

  240. ROBERTS SC, Jolley SE, Beaty LE, Aggarwal NR, et al
    Association between monoclonal antibody therapy, vaccination, and longer-term symptom resolution after acute COVID-19.
    J Med Virol. 2024;96:e29541.
    >> Share

  241. DE AGUIRRE PM, Carlos S, Pina-Sanchez M, Mbikayi S, et al
    High pre-Delta and early-Omicron SARS-CoV-2 seroprevalence detected in dried blood samples from Kinshasa (D.R. Congo).
    J Med Virol. 2024;96:e29529.
    >> Share

  242. TRANTER E, Frentsch M, Hutter-Kronke ML, Vuong GL, et al
    Comparable CD8(+) T-cell responses to SARS-CoV-2 vaccination in single-cell transcriptomics of recently allogeneic transplanted patients and healthy individuals.
    J Med Virol. 2024;96:e29539.
    >> Share

  243. ZHOU J, Zhou Y, Wei XF, Fan L, et al
    TRIM6 facilitates SARS-CoV-2 proliferation by catalyzing the K29-typed ubiquitination of NP to enhance the ability to bind viral genomes.
    J Med Virol. 2024;96:e29531.
    >> Share

  244. JITOBAOM K, Peerapen P, Boonyuen U, Meewan I, et al
    Identification of inositol monophosphatase as a broad-spectrum antiviral target of ivermectin.
    J Med Virol. 2024;96:e29552.
    >> Share

  245. HUANG M, Cui T, Liu S, Su X, et al
    Blended BA.5 infection within 8 days after a boosted bivalent mRNA vaccination strengthens and lengthens the host immunity.
    J Med Virol. 2024;96:e29544.
    >> Share

  246. ZHANG H, Guo H
    Optimization of a DNA-launched SARS-CoV-2 replicon with RNA splicing inhibitor Isoginkgetin.
    J Med Virol. 2024;96:e29547.
    >> Share

  247. ZHA G, Chen Z, Wu N, Huang T, et al
    Clinical characteristics and immunogenicity after Omicron breakthrough infection in patients with chronic hepatitis B infection: A longitudinal observational study.
    J Med Virol. 2024;96:e29548.
    >> Share

  248. KUO YM, Kang CM, Lai ZY, Huang TY, et al
    Temporal changes in biomarkers of neutrophil extracellular traps and NET-promoting autoantibodies following adenovirus-vectored, mRNA, and recombinant protein COVID-19 vaccination.
    J Med Virol. 2024;96:e29556.
    >> Share

  249. ZEDAN HT, Smatti MK, Al-Sadeq DW, Al Khatib HA, et al
    SARS-CoV-2 infection triggers more potent antibody-dependent cellular cytotoxicity (ADCC) responses than mRNA-, vector-, and inactivated virus-based COVID-19 vaccines.
    J Med Virol. 2024;96:e29527.
    >> Share

  250. FU X, Wang Z, Chen B, Sun H, et al
    Detection of SARS-CoV-2 virus in middle ear effusions and its association with otitis media with effusion.
    J Med Virol. 2024;96:e29545.
    >> Share

  251. FROHLICH GC, Gregianini TS, Pinheiro FG, Nascimento R, et al
    Resurgence of human respiratory syncytial virus during COVID-19 pandemic in Southern Brazil.
    J Med Virol. 2024;96:e29551.
    >> Share

  252. HUNG KC, Lin HJ, Chen IW
    New-onset neurodegenerative diseases following SARS-CoV-2 infection: An analysis of prediction interval.
    J Med Virol. 2024;96:e29563.
    >> Share

  253. WANG A
    Integrating Frechet distance and AI reveals the evolutionary trajectory and origin of SARS-CoV-2.
    J Med Virol. 2024;96:e29557.
    >> Share

  254. HUANG J, Qiu Y, Luo L, Wu J, et al
    Long-term immunogenicity and safety of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants who had received two or three doses of inactivated vaccine.
    J Med Virol. 2024;96:e29542.
    >> Share

  255. BROGNA C, Montano L, Zanolin ME, Bisaccia DR, et al
    A retrospective cohort study on early antibiotic use in vaccinated and unvaccinated COVID-19 patients.
    J Med Virol. 2024;96:e29507.
    >> Share

  256. ZHENG L, Wang H, Liu X, Xu C, et al
    A panel of multivalent nanobodies broadly neutralizing Omicron subvariants and recombinant.
    J Med Virol. 2024;96:e29528.
    >> Share

  257. OGUNJINMI OD, Abdullahi T, Somji RA, Bevan CL, et al
    The antiviral potential of the antiandrogen enzalutamide and the viral-androgen signaling interplay in seasonal coronaviruses.
    J Med Virol. 2024;96:e29540.
    >> Share

  258. ZHENG Z, Wu H, Sun X, Lu Y, et al
    Evaluation of the effectiveness and safety of sequential vaccination with inactivated SARS-CoV-2 vaccine and Ad5-nCoV booster in pediatric liver transplant recipients.
    J Med Virol. 2024;96:e29543.
    >> Share

  259. FARAONE JN, Wang X, Qu P, Zheng YM, et al
    Neutralizing antibody response to SARS-CoV-2 bivalent mRNA vaccine in SIV-infected rhesus macaques: Enhanced immunity to XBB subvariants by two-dose vaccination.
    J Med Virol. 2024;96:e29520.
    >> Share

    February 2024
  260. LIU P, Xing Z, Peng X, Zhang M, et al
    Machine learning versus multivariate logistic regression for predicting severe COVID-19 in hospitalized children with Omicron variant infection.
    J Med Virol. 2024;96:e29447.
    >> Share

  261. ANGUINZE RS, Toure A, Cisse F, Grayo S, et al
    Viral etiology of measles-like rash in Guinean children during the COVID epidemic in 2022.
    J Med Virol. 2024;96:e29437.
    >> Share

  262. CHEN Y, Liu X, Zhaohui T
    Reply to: Inspiratory muscle training for COVID-19: Benefits appear promising but findings remain uncertain.
    J Med Virol. 2024;96:e29441.
    >> Share

  263. CAMPS-VILARO A, Pinsach-Abuin ML, Degano IR, Ramos R, et al
    Genetic characteristics involved in COVID-19 severity. The CARGENCORS case-control study and meta-analysis.
    J Med Virol. 2024;96:e29404.
    >> Share

  264. VIRTANEN J, Korhonen EM, Salonen S, Vapalahti O, et al
    SARS-CoV-2 infections among pregnant women, 2020, Finland-Cross-testing of neutralization assays.
    J Med Virol. 2024;96:e29415.
    >> Share

  265. SOUZA MS, Farias JP, Andreata-Santos R, Silva MP, et al
    Neutralizing antibody response after immunization with a COVID-19 bivalent vaccine: Insights to the future.
    J Med Virol. 2024;96:e29416.
    >> Share

  266. HE M, Cao L, Liu L, Jin X, et al
    Reconstitution of RNA cap methylation reveals different features of SARS-CoV-2 and SARS-CoV methyltransferases.
    J Med Virol. 2024;96:e29411.
    >> Share

  267. SELVAVINAYAGAM ST, Suvaithenamudhan S, Yong YK, Hemashree K, et al
    Genomic surveillance of omicron B.1.1.529 SARS-CoV-2 and its variants between December 2021 and March 2023 in Tamil Nadu, India-A state-wide prospective longitudinal study.
    J Med Virol. 2024;96:e29456.
    >> Share

  268. CHANG LC, Chen IW, Hung KC
    Additional analyses support superior efficacy of nirmatrelvir/ritonavir over molnupiravir for COVID-19.
    J Med Virol. 2024;96:e29464.
    >> Share

  269. PASSOS V, Henkel LM, Wang J, Zapatero-Belinchon FJ, et al
    Innate immune response to SARS-CoV-2 infection contributes to neuronal damage in human iPSC-derived peripheral neurons.
    J Med Virol. 2024;96:e29455.
    >> Share

  270. NEDELCU I, Florian P, Ion D, Militaru E, et al
    Dynamics of serum cross-neutralization capacity against SARS-CoV-2 Delta variant in convalescent COVID-19 patients.
    J Med Virol. 2024;96:e29448.
    >> Share

  271. GAN M, Cao J, Zhang Y, Fu H, et al
    Landscape of T cell epitopes displays hot mutations of SARS-CoV-2 variant spikes evading cellular immunity.
    J Med Virol. 2024;96:e29452.
    >> Share

  272. COLSON P, Delerce J, Pontarotti P, Devaux C, et al
    Resistance-associated mutations to the anti-SARS-CoV-2 agent nirmatrelvir: Selection not induction.
    J Med Virol. 2024;96:e29462.
    >> Share

  273. SADAT LARIJANI M, Javadi A, Eskandari SE, Doroud D, et al
    The impact of ABO blood types on humoral immunity responses and antibody persistency after different COVID-19 vaccine regimens.
    J Med Virol. 2024;96:e29438.
    >> Share

  274. CENAT JM, Farahi SMMM, Dalexis RD, Yaya S, et al
    COVID-19 vaccine uptake, conspiracy theories, and health literacy among Black individuals in Canada: Racial discrimination, confidence in health, and COVID-19 stress as mediators.
    J Med Virol. 2024;96:e29467.
    >> Share

  275. KWOK KO, Wei WI, Mcneil EB, Tang A, et al
    Comparative analysis of symptom profile and risk of death associated with infection by SARS-CoV-2 and its variants in Hong Kong.
    J Med Virol. 2024;96:e29326.
    >> Share

  276. KIM D, Kim M, Kim J, Baek K, et al
    A mouse xenograft long-term replication yields a SARS-CoV-2 Delta mutant with increased lethality.
    J Med Virol. 2024;96:e29459.
    >> Share

  277. ZHAN H, Xie Y, Liu Y, Cheng L, et al
    Omicron BA.4/5 neutralization and cell-mediated immune responses in relation to baseline immune status and breakthrough infection among PLWH: A follow-up cohort study.
    J Med Virol. 2024;96:e29446.
    >> Share

  278. GAN J, Zhang H, Wu J, Liu Y, et al
    Effect of inactivated vaccine boosters against severe and critical COVID-19 during the Omicron BA.5 wave: A retrospective analysis of hospitalized patients in China.
    J Med Virol. 2024;96:e29402.
    >> Share

  279. CHIRUMBOLO S, Tirelli U
    On coming back, the scaring COVID-19 concern. Addressing indoor microclimates with innovative and straightforward solutions to prevent SARS-CoV2 spreading.
    J Med Virol. 2024;96:e29490.
    >> Share

  280. OMBELET S, Castanares-Zapatero D, Desimpel F, Hulstaert F, et al
    Effectiveness of nirmatrelvir-ritonavir on severe outcomes of COVID-19 in the era of vaccination and Omicron: An updated meta-analysis.
    J Med Virol. 2024;96:e29434.
    >> Share

  281. YANG D, Chan JF, Yoon C, Luk TY, et al
    Type-II IFN inhibits SARS-CoV-2 replication in human lung epithelial cells and ex vivo human lung tissues through indoleamine 2,3-dioxygenase-mediated pathways.
    J Med Virol. 2024;96:e29472.
    >> Share

    January 2024
  282. PALOMINO-CABRERA R, Tejerina F, Molero-Salinas A, Veintimilla C, et al
    No emergence of resistance mutations in COVID-19 patients receiving nirmatrelvir/ritonavir.
    J Med Virol. 2024;96:e29337.
    >> Share

  283. ALESSANDRI F, d'Ettorre G, Ciccozzi M, Migliara G, et al
    Early recognition of a superinfection: This is the problem in the critically ill COVID-19 patients.
    J Med Virol. 2024;96:e29345.
    >> Share

  284. QI F, Cao Y, Shen Y, Wang H, et al
    Nasopharyngeal neutrophilic-retention signatures could predict disease progression in early SARS-CoV-2 infection.
    J Med Virol. 2024;96:e29328.
    >> Share

  285. LI C, Ye G, Jiang Y, Wang Z, et al
    Artificial Intelligence in battling infectious diseases: A transformative role.
    J Med Virol. 2024;96:e29355.
    >> Share

  286. KIM MJ, Park PG, Hwang SJ, Bang SJ, et al
    Saliva-based Proteinase K method: A rapid and reliable diagnostic tool for the detection of SARS-COV-2 in children.
    J Med Virol. 2024;96:e29361.
    >> Share

  287. DURSTENFELD MS, Peluso MJ, Lin F, Peyser ND, et al
    Association of nirmatrelvir for acute SARS-CoV-2 infection with subsequent Long COVID symptoms in an observational cohort study.
    J Med Virol. 2024;96:e29333.
    >> Share

  288. CICCOZZI A, Fiori PL, Casu M, Sanna D, et al
    The mutation point of view of the SARS-CoV-2 HV.1 lineage.
    J Med Virol. 2024;96:e29359.
    >> Share

  289. PONTIROLI AE, Scovenna F, Carlini V, Tagliabue E, et al
    Vaccination against influenza viruses reduces infection, not hospitalization or death, from respiratory COVID-19: A systematic review and meta-analysis.
    J Med Virol. 2024;96:e29343.
    >> Share

  290. LIANG Z, Tong J, Sun Z, Liu S, et al
    Rational prediction of immunogenicity clustering through cross-reactivity analysis of thirteen SARS-CoV-2 variants.
    J Med Virol. 2024;96:e29314.
    >> Share

  291. HU L, Yang Y, Lin J, Yan Q, et al
    Epidemiological characteristics of respiratory syncytial virus infection in pediatric patients before, during the COVID-19 pandemic and after easing of COVID-19 restrictive measures in China.
    J Med Virol. 2024;96:e29374.
    >> Share

  292. ZHANG Y, Ma Y, Sun W, Zhou X, et al
    Exploring gut-lung axis crosstalk in SARS-CoV-2 infection: Insights from a hACE2 mouse model.
    J Med Virol. 2024;96:e29336.
    >> Share

  293. FAVRESSE J, Gillot C, Closset M, Cabo J, et al
    Durability of humoral and cellular immunity six months after the BNT162b2 bivalent booster.
    J Med Virol. 2024;96:e29365.
    >> Share

  294. CHOI CY, Gadhave K, Villano J, Pekosz A, et al
    Generation and characterization of a humanized ACE2 mouse model to study long-term impacts of SARS-CoV-2 infection.
    J Med Virol. 2024;96:e29349.
    >> Share

  295. LEE HM, Shih PC, Wei JC
    Comment on Shao et al.'s "Risk factors associated with COVID-19 pneumonia in Chinese patients with pre-existing interstitial lung disease during the SARS-CoV-2 pandemic".
    J Med Virol. 2024;96:e29383.
    >> Share

  296. LI J, Zhang K, Lin G, Li J, et al
    CRISPR-Cas system: A promising tool for rapid detection of SARS-CoV-2 variants.
    J Med Virol. 2024;96:e29356.
    >> Share

  297. CAPELLI N, Domitien Payet L, Alcocer Cordellat C, Pisoni A, et al
    SARS-CoV-2 nucleocapsid antigen in plasma of children hospitalized for COVID-19 or with incidental detection of SARS-CoV-2 infection.
    J Med Virol. 2024;96:e29358.
    >> Share

  298. CORPECHOT C, Verdoux M, Frank-Soltysiak M, Duclos-Vallee JC, et al
    Exploring the impact of ursodeoxycholic acid therapy on COVID-19 in a real-word setting.
    J Med Virol. 2024;96:e29418.
    >> Share


  299. Corrigendum to "A pilot study of the antiviral activity of anionic and cationic polyamidoamine dendrimers against the Middle East respiratory syndrome coronavirus".
    J Med Virol. 2024;96:e29421.
    >> Share

  300. ROMERO-OLMEDO AJ, Schulz AR, Das Gupta D, Staudenraus D, et al
    Unusual T(SCM) -like cells with poly-chemokine-receptor expression in a B-cell-depleted survivor of severe COVID-19.
    J Med Virol. 2024;96:e29367.
    >> Share

  301. HUANG J, Liu Y, Wang J, Xu D, et al
    Pregnancy outcomes after frozen-thawed embryo transfer in women with COVID-19 history: A prospective cohort study.
    J Med Virol. 2024;96:e29377.
    >> Share

  302. LIN WC, Wu MC, Wang YH, Lin CH, et al
    The prevalence of obstructive sleep apnea syndrome after COVID-19 infection.
    J Med Virol. 2024;96:e29392.
    >> Share

  303. SHARMA S, Thiriard A, Olislagers V, Lechien JR, et al
    Mucosal antibody response and SARS-CoV-2 shedding in patients with COVID-19 related olfactory dysfunction.
    J Med Virol. 2024;96:e29398.
    >> Share

  304. VASBINDER A, Padalia K, Pizzo I, Machado K, et al
    SuPAR, biomarkers of inflammation, and severe outcomes in patients hospitalized for COVID-19: The International Study of Inflammation in COVID-19.
    J Med Virol. 2024;96:e29389.
    >> Share

  305. HUANG Y, Dong Q, Liu G, Wang T, et al
    A novel three-plasmid packaging system for chimeric SFV/SIN VRPs derived from Semliki Forest virus and Sindbis virus as a candidate gene delivery vector.
    J Med Virol. 2024;96:e29376.
    >> Share

  306. YANG L, Zeng XT, Luo RH, Ren SX, et al
    SARS-CoV-2 NSP12 utilizes various host splicing factors for replication and splicing regulation.
    J Med Virol. 2024;96:e29396.
    >> Share

  307. WANG WT, Chen IW, Hung KC
    Inspiratory muscle training for COVID-19: Benefits appear promising but findings remain uncertain.
    J Med Virol. 2024;96:e29387.
    >> Share

  308. GUO F, Adekanmbi V, Hsu CD, Polychronopoulou E, et al
    One dose versus two doses of COVID-19 vaccine for the prevention of breakthrough infections among people previously infected with SARS-Cov-2.
    J Med Virol. 2024;96:e29391.
    >> Share

  309. ATZLER F, Dahms F, Paul G, Perisic S, et al
    The swab site of the upper airways influences the diagnostic sensitivity for the omicron variant of SARS-CoV-2.
    J Med Virol. 2024;96:e29390.
    >> Share

  310. WANG Y, Lan X, Qiao Y, Huo Y, et al
    Safety and immunogenicity of homologous prime-boost CoronaVac vaccine in people living with HIV in China: A multicenter prospective cohort study.
    J Med Virol. 2024;96:e29395.
    >> Share

  311. WANG E, Yang QJ, Xu XX, Zou QC, et al
    Differential pathogenic and molecular features in neurological infection of SARS-CoV-2 Omicron BA.5.2 and BA.2.75 and Delta.
    J Med Virol. 2024;96:e29357.
    >> Share


  312. Correction to "Evaluation of the relationship between pentraxin 3 (PTX3) rs2305619 (281A/G) and rs1840680 (1449A/G) polymorphisms and the clinical course of COVID-19".
    J Med Virol. 2024;96:e29378.
    >> Share

  313. YANG X, Wang Y, Liang Z, Cui T, et al
    Immune escape of BA.2.86 is comparable to XBB subvariants from the plasma of BA.5- and BA.5-XBB-convalescent subpopulations.
    J Med Virol. 2024;96:e29417.
    >> Share

  314. ZHANG T, Magazine N, McGee MC, Carossino M, et al
    Th2 and Th17-associated immunopathology following SARS-CoV-2 breakthrough infection in Spike-vaccinated ACE2-humanized mice.
    J Med Virol. 2024;96:e29408.
    >> Share

  315. JIA J, Garbarino E, Wang Y, Li J, et al
    Generation of SARS-CoV-2 spike receptor binding domain mutants and functional screening for immune evaders using a novel lentivirus-based system.
    J Med Virol. 2024;96:e29425.
    >> Share

  316. SUN Y, Zhou J, Nie W, Tian D, et al
    Study on the epidemiological characteristics of enterovirus among pediatric patients in Hangzhou, China: A comparison between the pre-COVID-19, COVID-19 pandemic, and post-COVID-19 periods.
    J Med Virol. 2024;96:e29412.
    >> Share

    December 2023
  317. HUANG PY, Lai CC, Hsu CK
    Assessing risk factors for COVID-19 pneumonia in Chinese patients with pre-existing interstitial lung disease.
    J Med Virol. 2023;95:e29281.
    >> Share

  318. LI J, Liu Y, Wei X, Liu Z, et al
    Antibody responses to SARS-CoV-2 Omicron infection in patients with hematological malignancies: A multicenter, prospective cohort study.
    J Med Virol. 2023;95:e29300.
    >> Share

  319. SONG R, Chen X, Li B, Ni J, et al
    Nasal spray of an IgM-like ACE2 fusion protein HH-120 prevents SARS-CoV-2 infection: Two investigator-initiated postexposure prophylaxis trials.
    J Med Virol. 2023;95:e29275.
    >> Share

  320. HORA S, Pahwa P, Siddiqui H, Saxena A, et al
    Metabolic alterations unravel the maternofetal immune responses with disease severity in pregnant women infected with SARS-CoV-2.
    J Med Virol. 2023;95:e29257.
    >> Share

  321. YANG J, Kim HJ, Kim JW, Baek JY, et al
    Evolution of neutralizing antibodies through vaccination and breakthrough infections in the era of COVID-19 endemicity.
    J Med Virol. 2023;95:e29285.
    >> Share

  322. GE P, Luo Y, Liu J, Liu J, et al
    Eliminating COVID-19 as the immediate culprit for igniting pancreatitis.
    J Med Virol. 2023;95:e29272.
    >> Share

  323. BAY P, Rodriguez C, Caruso S, Demontant V, et al
    Omicron induced distinct immune respiratory transcriptomics signatures compared to pre-existing variants in critically ill COVID-19 patients.
    J Med Virol. 2023;95:e29268.
    >> Share

  324. YU H, Yang L, Han Z, Zhou X, et al
    SARS-CoV-2 nucleocapsid protein enhances the level of mitochondrial reactive oxygen species.
    J Med Virol. 2023;95:e29270.
    >> Share

  325. TSOI JYH, Cai J, Situ J, Lam WJ, et al
    Autoantibodies against angiotensin-converting enzyme 2 (ACE2) after COVID-19 infection or vaccination.
    J Med Virol. 2023;95:e29313.
    >> Share

  326. MEISTER TL, Kirchhoff L, Bruggemann Y, Todt D, et al
    Stability of pathogens on banknotes and coins: A narrative review.
    J Med Virol. 2023;95:e29312.
    >> Share

  327. CHEN Q, Qin S, Zhou HY, Deng YQ, et al
    Competitive fitness and homologous recombination of SARS-CoV-2 variants of concern.
    J Med Virol. 2023;95:e29278.
    >> Share

  328. YIN ZJ, Xiao H, McDonald S, Brusic V, et al
    Dynamically adjustable SVEIR(MH) model of multiwave epidemics: Estimating the effects of public health measures against COVID-19.
    J Med Virol. 2023;95:e29301.
    >> Share

  329. LI J, Mao H, Song W, Chen Y, et al
    Low neutralization of SARS-CoV-2 Omicron BA.5.2.48, BF.7.14, XBB.1 subvariants by homologous or heterologous booster.
    J Med Virol. 2023;95:e29306.
    >> Share

  330. BENNING L, Bartenschlager M, Kim H, Kalble F, et al
    Live-virus serum neutralization after bivalent SARS-CoV-2 mRNA vaccination in hemodialysis patients.
    J Med Virol. 2023;95:e29303.
    >> Share

  331. FUKUDA Y, Togashi A, Hirakawa S, Yamamoto M, et al
    Resurgence of human metapneumovirus infection and influenza after three seasons of inactivity in the post-COVID-19 era in Hokkaido, Japan, 2022-2023.
    J Med Virol. 2023;95:e29299.
    >> Share

  332. WANG R, Guo J, Lu J, Du P, et al
    A potential broad-spectrum neutralizing antibody against Betacoronavirus.
    J Med Virol. 2023;95:e29252.
    >> Share

  333. XIAO Y, Chang L, Ji H, Sun H, et al
    Posttranslational modifications of ACE2 protein: Implications for SARS-CoV-2 infection and beyond.
    J Med Virol. 2023;95:e29304.
    >> Share

  334. LIU W, Gong F, Zheng X, Pei L, et al
    Factors associated with prolonged viral shedding of SARS-CoV-2 Omicron variant infection in Shanghai: A multicenter, retrospective, observational study.
    J Med Virol. 2023;95:e29342.
    >> Share

  335. LEE DH, Han E, Ryu S, Choi HJ, et al
    Clinical performance of the STANDARD M10 SARS-CoV-2 rapid RT-PCR assay in patients visiting an emergency department.
    J Med Virol. 2023;95:e29330.
    >> Share

  336. KAPUSTA J, Babicki M, Pieniawska-Smiech K, Kaluzinska-Kolat Z, et al
    Clinical and electrocardiographic correlates of myocardial dysfunction after COVID-19 in nonhospitalised patients in long-term follow-up. Data from the polish long-covid cardiovascular study.
    J Med Virol. 2023;95:e29331.
    >> Share

  337. ZHOU Y, Liu Y, Jiang L, Zhang R, et al
    Azvudine and nirmatrelvir-ritonavir in hospitalized patients with moderate-to-severe COVID-19: Emulation of a randomized target trial.
    J Med Virol. 2023;95:e29318.
    >> Share

  338. SULLIVAN DJ, Focosi D, Hanley DF, Cruciani M, et al
    Outpatient randomized controlled trials to reduce COVID-19 hospitalization: Systematic review and meta-analysis.
    J Med Virol. 2023;95:e29310.
    >> Share

  339. LI Y, Yamamoto S, Horii K, Mizoue T, et al
    Long COVID during the Omicron predominant waves among Japanese healthcare workers.
    J Med Virol. 2023;95:e29322.
    >> Share

  340. FEGHOUL L, Caillault A, Peyrony O, Salmona M, et al
    Respiratory torque teno virus load at emergency department visit predicts intensive care unit admission of SARS-CoV-2 infected patients.
    J Med Virol. 2023;95:e29319.
    >> Share

  341. LEE B, Ko JH, Kim YC, Baek JY, et al
    Clinical utility of quantitative immunoassays and surrogate virus neutralization tests for predicting neutralizing activity against the SARS-CoV-2 Omicron BA.1 and BA.5 variants.
    J Med Virol. 2023;95:e29329.
    >> Share

  342. LI J, Nie L, Guo C, Deng Y, et al
    Immunogenicity and safety of inactivated SARS-CoV-2 vaccines in people living with HIV: A longitudinal cohort study.
    J Med Virol. 2023;95:e29334.
    >> Share

    November 2023
  343. LI S, Li X, Liang H, Yu K, et al
    SARS-CoV-2 ORF7a blocked autophagy flux by intervening in the fusion between autophagosome and lysosome to promote viral infection and pathogenesis.
    J Med Virol. 2023;95:e29200.
    >> Share

  344. MAHLA RS
    Interstitial lung diseases and COVID-19 pneumonia.
    J Med Virol. 2023;95:e29207.
    >> Share

  345. KIM IS, Kang CK, Lee SJ, Lee CH, et al
    Tracking antigen-specific TCR clonotypes in SARS-CoV-2 infection reveals distinct severity trajectories.
    J Med Virol. 2023;95:e29199.
    >> Share

  346. ZHANG YN, Zhu GH, Liu W, Chen XX, et al
    Discovery of the covalent SARS-CoV-2 M(pro) inhibitors from antiviral herbs via integrating target-based high-throughput screening and chemoproteomic approaches.
    J Med Virol. 2023;95:e29208.
    >> Share

  347. NGIAM JN, Ng OT, Toh MPHS, Gao Q, et al
    Predictors of disease severity in SARS-CoV-2 omicron variant XBB sublineages and variants of interest.
    J Med Virol. 2023;95:e29204.
    >> Share

  348. COLSON P, Bader W, Fantini J, Dudouet P, et al
    From viral democratic genomes to viral wild bunch of quasispecies.
    J Med Virol. 2023;95:e29209.
    >> Share

  349. WANG Y, Wu L, Yu X, Wang G, et al
    Development of a rapid, sensitive detection method for SARS-CoV-2 and influenza virus based on recombinase polymerase amplification combined with CRISPR-Cas12a assay.
    J Med Virol. 2023;95:e29215.
    >> Share

  350. BERGNA A, Lai A, Ventura CD, Bruzzone B, et al
    Genomic epidemiology of the main SARS-CoV-2 variants in Italy between summer 2020 and winter 2021.
    J Med Virol. 2023;95:e29193.
    >> Share

  351. WANG B, Yang W, Tong Y, Sun M, et al
    Integrative proteomics and metabolomics study reveal enhanced immune responses by COVID-19 vaccine booster shot against Omicron SARS-CoV-2 infection.
    J Med Virol. 2023;95:e29219.
    >> Share

  352. SPRINGER DN, Reuberger E, Borsodi C, Puchhammer-Stockl E, et al
    Comparison of anti-nucleocapsid antibody assays for the detection of SARS-CoV-2 Omicron vaccine breakthroughs after various intervals since the infection.
    J Med Virol. 2023;95:e29229.
    >> Share

  353. KIM Y, Kim Y, Lim HJ, Kim DK, et al
    Integrative single-cell transcriptome analysis provides new insights into post-COVID-19 pulmonary fibrosis and potential therapeutic targets.
    J Med Virol. 2023;95:e29201.
    >> Share

  354. LIU D, Wang Z, Mao M, Zhang Z, et al
    Application of whole-genome tiling array at Shanghai port, China: An alternative method for SARS-CoV-2 surveillance.
    J Med Virol. 2023;95:e29222.
    >> Share

  355. BUCK AM, Deitchman AN, Takahashi S, Lu S, et al
    The breadth of the neutralizing antibody response to original SARS-CoV-2 infection is linked to the presence of Long COVID symptoms.
    J Med Virol. 2023;95:e29216.
    >> Share

  356. LOW K, Moller R, Stegmann C, Becker M, et al
    Luminescent reporter cells enable the identification of broad-spectrum antivirals against emerging viruses.
    J Med Virol. 2023;95:e29211.
    >> Share

  357. ABDOLAHI T, Maamouri G, Behmadi M, Mirzaeian S, et al
    Investigating the impact of Sinopharm COVID-19 vaccination on antibody response in pregnant women and their newborns.
    J Med Virol. 2023;95:e29231.
    >> Share

  358. RIVAS G, Labiod N, Luczkowiak J, Lasala F, et al
    Superior neutralizing response after first versus second SARS-CoV-2 infection in fully vaccinated individuals.
    J Med Virol. 2023;95:e29225.
    >> Share

  359. WU JY, Liu MY, Hung KC, Hsu WH, et al
    Nutritional deficiency anemia and post-acute sequelae in patients with severe acute respiratory syndrome coronavirus 2 infection: A six-month retrospective cohort analysis of 30 892 patients.
    J Med Virol. 2023;95:e29246.
    >> Share

  360. KANG SW, Kim JW, Kim JY, Lim SY, et al
    Virological characteristics and the rapid antigen test as deisolation criteria in immunocompromised patients with COVID-19: A prospective cohort study.
    J Med Virol. 2023;95:e29228.
    >> Share

  361. LI Z, Xiong Y, Long J, Li T, et al
    Resurgence of influenza during COVID-19 in Chongqing, China: A retrospective analysis.
    J Med Virol. 2023;95:e29249.
    >> Share

  362. CHENANE HR, Lingas G, Menidjel R, Laouenan C, et al
    High sera levels of SARS-CoV-2 N antigen are associated with death in hospitalized COVID-19 patients.
    J Med Virol. 2023;95:e29247.
    >> Share

  363. WANG Z, Zhao C, Li C, Liu S, et al
    Molecular PET/CT mapping of rhACE2 distribution and quantification in organs to aid in SARS-CoV-2 targeted therapy.
    J Med Virol. 2023;95:e29221.
    >> Share

  364. HU GM, Tai YC, Chen CM
    Unraveling the evolutionary patterns and phylogenomics of coronaviruses: A consensus network approach.
    J Med Virol. 2023;95:e29233.
    >> Share

  365. MAO R, Fan Z, He M, Li J, et al
    Acne and COVID-19 susceptibility, hospitalization, and severity: A genetic correlation study.
    J Med Virol. 2023;95:e29265.
    >> Share

  366. KONDO Y, Kawamura Y, Hattori F, Nakai H, et al
    Serological analysis of severe acute respiratory syndrome coronavirus 2 infection in children with Kawasaki disease.
    J Med Virol. 2023;95:e29274.
    >> Share

  367. ZENG G, Zhang Z, Wang L, Li J, et al
    Risk factors of long COVID 6-12 months after infection with the Omicron variant among nonhospitalized patients.
    J Med Virol. 2023;95:e29235.
    >> Share

    October 2023
  368. SHIH HL, Lee YT, Sun CK, Chang R, et al
    Considerations regarding the long-term risk of herpes zoster following COVID-19.
    J Med Virol. 2023;95:e29130.
    >> Share

  369. FAPPANI C, Gori M, Bianchi S, Terraneo M, et al
    Differential diagnosis of fever and rash cases negative for measles and rubella to complement surveillance activities.
    J Med Virol. 2023;95:e29141.
    >> Share

  370. XU W, Wen X, Cong X, Jiang W, et al
    COVID-19 mRNA vaccine, but not a viral vector-based vaccine, promotes neutralizing anti-type I interferon autoantibody production in a small group of healthy individuals.
    J Med Virol. 2023;95:e29137.
    >> Share

  371. HOLLSTEIN MM, Dierks S, Schon MP, Bergmann A, et al
    Humoral and cellular immune responses in fully vaccinated individuals with or without SARS-CoV-2 breakthrough infection: Results from the CoV-ADAPT cohort.
    J Med Virol. 2023;95:e29122.
    >> Share

  372. WIEDEL NA, Sayles H, Larson J, Wardian JL, et al
    Associations between COVID-19 therapies and inpatient gastrointestinal bleeding: A multisite retrospective study.
    J Med Virol. 2023;95:e29100.
    >> Share

  373. HU M, Wang X, Li B, Wang B, et al
    Fitness evaluation of SARS-CoV-2 variants: A retrospective study.
    J Med Virol. 2023;95:e29123.
    >> Share

  374. RECTOR A, Bloemen M, Van Ranst M, Wollants E, et al
    Used paper tissues for pathogen identification in acute respiratory infection.
    J Med Virol. 2023;95:e29127.
    >> Share

  375. LI X, Zhang Y, Wang J, Han J, et al
    Long-term dynamic shifts in genomic base content and evolutionary trajectories of SARS-CoV-2 variants.
    J Med Virol. 2023;95:e29128.
    >> Share

  376. LIANG T, Guo K, Ni P, Duan G, et al
    The association of sickle cell disorder with adverse outcomes in COVID-19 patients: A meta-analysis.
    J Med Virol. 2023;95:e29120.
    >> Share

  377. SHI T, Xu L, Li X, Huang L, et al
    The CD19(+) B cell as a marker for the febrile children infected with influenza A and Omicron variant.
    J Med Virol. 2023;95:e29097.
    >> Share

  378. FENG S, Fan Z, Zhou K, Ma S, et al
    Subunit vaccine raised against the SARS-CoV-2 spike of Delta and Omicron variants.
    J Med Virol. 2023;95:e29160.
    >> Share

  379. LIU J, Zhang H, Kong J, Liu S, et al
    Alleviated symptoms of SARS-CoV-2 Omicron variant infection in chronic hepatitis B patients with immune control.
    J Med Virol. 2023;95:e29173.
    >> Share

  380. BREZNIK JA, Rahim A, Bhakta H, Clare R, et al
    Early humoral and cellular responses after bivalent SARS-CoV-2 mRNA-1273.214 vaccination in long-term care and retirement home residents in Ontario, Canada: An observational cohort study.
    J Med Virol. 2023;95:e29170.
    >> Share

  381. GAO Y, Zhang Y, Mou K, Liu Y, et al
    Assessment of alterations in the retina and vitreous in pre- and post-COVID-19 patients using swept-source optical coherence tomography and angiography: A comparative study.
    J Med Virol. 2023;95:e29168.
    >> Share

  382. YI J, Li X, Zhang R, Kong L, et al
    The impact of the COVID-19 pandemic on the prevalence and genotype distribution of HPV infection in Beijing, China.
    J Med Virol. 2023;95:e29155.
    >> Share

  383. BA Z, Yang A, Zhu S, Li Y, et al
    Comprehensive evaluation of the effect of inactivated SARS-CoV-2 vaccination on female fertility: A retrospective cohort study.
    J Med Virol. 2023;95:e29161.
    >> Share

  384. HU Z, Jin Z, Zhou M, Zhang C, et al
    CoronaVac and BBIBP-CorV vaccines against SARS-CoV-2 during predominant circulation of Omicron BA.5.2 and BF.7 in China, a retrospective cohort study.
    J Med Virol. 2023;95:e29143.
    >> Share

  385. ABBASI HQ
    Comments on: Bacterial and fungal superinfections are detected at higher frequency in critically ill patients affected by SARS CoV-2 infection than negative patients and are associated to a worse outcome.
    J Med Virol. 2023;95:e29167.
    >> Share

  386. MATIC S, Milovanovic D, Mijailovic Z, Djurdjevic P, et al
    Its all about IFN-lambda4: Protective role of IFNL4 polymorphism against COVID-19-related pneumonia in females.
    J Med Virol. 2023;95:e29152.
    >> Share

  387. COLSON P, La Scola B, Beye M, Delerce J, et al
    Emergence of a second SARS-CoV-2 variant with a tremendous genetic leap from its ancestors.
    J Med Virol. 2023;95:e29124.
    >> Share

  388. WEI D, Yu X, Li Y, Chen Y, et al
    Sequential reinfection with Omicron variants elicits broader neutralizing antibody profiles in booster vaccinees and reduces the duration of viral shedding.
    J Med Virol. 2023;95:e29151.
    >> Share

  389. CHEN D, Li X, Hao X, Qiu Y, et al
    Reduced neutralization and Fc effector function to Omicron subvariants in sera from SARS-CoV-1 survivors after two doses of CoronaVac plus one dose subunit vaccine.
    J Med Virol. 2023;95:e29136.
    >> Share

  390. JIAO F, Andrianov AM, Wang L, Furs KV, et al
    Repurposing Navitoclax to block SARS-CoV-2 fusion and entry by targeting heptapeptide repeat sequence 1 in S2 protein.
    J Med Virol. 2023;95:e29145.
    >> Share

  391. YANG X, Hu C, Yang X, Yang X, et al
    Evaluation and comparison of immune responses induced by two Mpox mRNA vaccine candidates in mice.
    J Med Virol. 2023;95:e29140.
    >> Share

  392. LIU S, Wang P, Shi X, Weng T, et al
    Maternal antibody transfer rate of vaccination against SARS-CoV-2 before or during early pregnancy and its protective effectiveness on offspring.
    J Med Virol. 2023;95:e29125.
    >> Share

  393. COLSON P, Delerce J, Fantini J, Pontarotti P, et al
    The return of the "Mistigri" (virus adaptative gain by gene loss) through the SARS-CoV-2 XBB.1.5 chimera that predominated in 2023.
    J Med Virol. 2023;95:e29146.
    >> Share

  394. DE FRANCESCO MA, Piva S, Pellizzeri S, Signorini L, et al
    Response to the Letter to the Editor on "Bacterial and fungal superinfections are detected at higher frequency in critically ill patients affected by SARS-CoV-2 infection than negative patients and are associated to a worse outcome".
    J Med Virol. 2023;95:e29192.
    >> Share

  395. WANG Q, Jia M, Jiang M, Cao Y, et al
    Increased population susceptibility to seasonal influenza during the COVID-19 pandemic in China and the United States.
    J Med Virol. 2023;95:e29186.
    >> Share

  396. MOHAMMADI-PILEHDARBONI H, Shenagari M
    Regarding the article Causal effect of COVID-19 on Alzheimer's disease: A Mendelian randomization study by Baranova et al.
    J Med Virol. 2023;95:e29176.
    >> Share

  397. CACCURI F, Messali S, Scarpa F, Giovanetti M, et al
    First detection of SARS-CoV-2 BA.2.86.1 in Italy.
    J Med Virol. 2023;95:e29175.
    >> Share

  398. LI T, Chen N, Wang X, Chen N, et al
    Epidemiology of influenza A outbreak among children after COVID-19: A single-center retrospective observational study.
    J Med Virol. 2023;95:e29174.
    >> Share

  399. AHN H, Calderon BM, Fan X, Gao Y, et al
    Structural basis of the American mink ACE2 binding by Y453F trimeric spike glycoproteins of SARS-CoV-2.
    J Med Virol. 2023;95:e29163.
    >> Share

  400. MEYERS E, Park J, Coen A, Raman L, et al
    Evaluation of a smartphone-operated point-of-care device using loop-mediated isothermal amplification technology for rapid and remote detection of SARS-CoV-2.
    J Med Virol. 2023;95:e29158.
    >> Share

  401. BASTOS V, Pacheco V, Rodrigues EDL, Moraes CNS, et al
    Neuroimmunology of rabies: New insights into an ancient disease.
    J Med Virol. 2023;95:e29042.
    >> Share

  402. HSIA NY, Hsu AY, Wang YH, Li JX, et al
    The risk assessment of uveitis after COVID-19 diagnosis: A multicenter population-based study.
    J Med Virol. 2023;95:e29188.
    >> Share

  403. QI Z, Yuan S, Wei J, Xia S, et al
    Clinical and pathological features of omicron variant of SARS-CoV-2-associated kidney injury.
    J Med Virol. 2023;95:e29196.
    >> Share

  404. ARONS E, Henry K, Haas C, Gould M, et al
    Characterization of B-cell receptor clonality and immunoglobulin gene usage at multiple time points during active SARS-CoV-2 infection.
    J Med Virol. 2023;95:e29179.
    >> Share

    September 2023

  405. Correction to "Safety and immunogenicity of COVID-19 vaccination in patients with hepatocellular carcinoma (CHESS-NMCID 2101): A multicenter prospective study".
    J Med Virol. 2023;95:e29063.
    >> Share

  406. SENGUPTA S, Shaw SK, Chatterjee S, Bhattacharya G, et al
    Perturbations in spike-specific peripheral T follicular helper cells in SARS-CoV2 breakthrough convalescent individuals immunized by BBV152 vaccine.
    J Med Virol. 2023;95:e29053.
    >> Share

  407. ZHOU H, Xie P, Qiu M, Dong S, et al
    Arbidol increases the survival rate by mitigating inflammation in suckling mice infected with human coronavirus OC43 virus.
    J Med Virol. 2023;95:e29052.
    >> Share

  408. DAS S, Kumar S
    Exploring the mechanisms of long COVID: Insights from computational analysis of SARS-CoV-2 gene expression and symptom associations.
    J Med Virol. 2023;95:e29077.
    >> Share

  409. AHLUWALIA P, Vashisht A, Singh H, Sahajpal NS, et al
    Ethno-demographic disparities in humoral responses to the COVID-19 vaccine among healthcare workers.
    J Med Virol. 2023;95:e29067.
    >> Share

  410. MA J, Qiu S
    Infection with critically ill COVID-19 increases the risk of cardioembolic stroke.
    J Med Virol. 2023;95:e29066.
    >> Share

  411. MOLINA IS, Jimenez-Vasquez V, Lizarraga W, Sevilla N, et al
    Sub-lineage B.1.6 of hMPXV in a global context: Phylogeny and epidemiology.
    J Med Virol. 2023;95:e29056.
    >> Share

  412. CASO JM, Fernandez-Ruiz M, Lopez-Medrano F, Caro-Teller JM, et al
    Nirmatrelvir/ritonavir for the treatment of immunocompromised adult patients with early-stage symptomatic COVID-19: A real-life experience.
    J Med Virol. 2023;95:e29082.
    >> Share

  413. HAO S, Ning K, Kuz CA, Xiong M, et al
    SARS-CoV-2 infection of polarized human airway epithelium induces necroptosis that causes airway epithelial barrier dysfunction.
    J Med Virol. 2023;95:e29076.
    >> Share

  414. SCARPA F, Ciccozzi M
    On the SARS-CoV-2 BA.2.86 lineage: a mutation point of view.
    J Med Virol. 2023;95:e29079.
    >> Share

  415. SCARPA F, Pascarella S, Ciccozzi A, Giovanetti M, et al
    Genetic and structural analyses reveal the low potential of the SARS-CoV-2 EG.5 variant.
    J Med Virol. 2023;95:e29075.
    >> Share

  416. SHAO C, Shi Y, Chen R, Liu X, et al
    Risk factors associated with COVID-19 pneumonia in Chinese patients with pre-existing interstitial lung disease during the SARS-CoV-2 pandemic.
    J Med Virol. 2023;95:e29098.
    >> Share

  417. HOSSAIN MS, Kerkvliet JG, Hoppe AD
    Whole genome CRISPR screening strategy to identify genes contributing to SARS-CoV-2 spike and VSV-G mediated entry.
    J Med Virol. 2023;95:e29087.
    >> Share

  418. ZHANG B, Tsai YW, Wu JY, Liu TH, et al
    Risk of cytomegalovirus diseases among coronavirus disease survivors: A retrospective cohort study.
    J Med Virol. 2023;95:e29096.
    >> Share

  419. TSO WW, Kwan MY, Ip P, Chan JF, et al
    Response to the Letter to the Editor on "Clinical characteristics of unvaccinated or incompletely vaccinated children with neurological manifestations due to SARS-CoV-2 Omicron infection".
    J Med Virol. 2023;95:e29095.
    >> Share

  420. HUANG SW, Yeh WB, Chen HY, Yong SB, et al
    Long-term risk of herpes zoster following COVID-19: A retrospective cohort study of 2 442 686 patients.
    J Med Virol. 2023;95:e29101.
    >> Share

  421. HANSEN KS, Jorgensen SE, Skouboe MK, Agergaard J, et al
    Examination of autoantibodies to type I interferon in patients suffering from long COVID.
    J Med Virol. 2023;95:e29089.
    >> Share

  422. ZUO T, Liang G, Huang Z, Cao Z, et al
    Baseline gut microbiome features prior to SARS-CoV-2 infection are associated with host symptoms in and post COVID-19.
    J Med Virol. 2023;95:e29083.
    >> Share

  423. CAKIR C, Kuspinar G, Kurt G, Berber M, et al
    Comparison of semen parameters in the same patients before and after diagnosis of COVID-19.
    J Med Virol. 2023;95:e29094.
    >> Share

  424. CHU WM, Hsieh TH, Wei JC
    Comment on Tsai et al.'s "clinical effectiveness of oral antiviral agents in older patients with COVID-19 based on real-world data".
    J Med Virol. 2023;95:e29086.
    >> Share

  425. JIANG T, Liu R, Shen J
    CRISPR dual enzyme cleavage triggers DNA and RNA substrate cleavage for SARS-CoV-2 dual gene detection.
    J Med Virol. 2023;95:e29090.
    >> Share

  426. RAFATI A, Jameie M, Amanollahi M, Jameie M, et al
    Association of seizure with COVID-19 vaccines in persons with epilepsy: A systematic review and meta-analysis.
    J Med Virol. 2023;95:e29118.
    >> Share

  427. YULUG B, Ayyildiz B, Ayyildiz S, Sayman D, et al
    Infection with COVID-19 is no longer a public emergency: But what about degenerative dementia?
    J Med Virol. 2023;95:e29072.
    >> Share

  428. DE SOUSA LAF, Ferreira LSS, Lobato LFL, Ferreira HLDS, et al
    Molecular epidemiology of SARS-CoV-2 variants in circulation in the state of Maranhao, Brazil.
    J Med Virol. 2023;95:e29092.
    >> Share

  429. XIANG Y, Mou C, Shi K, Chen X, et al
    SADS-CoV nsp1 inhibits the IFN-beta production by preventing TBK1 phosphorylation and inducing CBP degradation.
    J Med Virol. 2023;95:e29104.
    >> Share

  430. TSAI YW, Wu JY, Liu TH, Chuang MH, et al
    Clinical effectiveness of oral antiviral agents in older patients with COVID-19 based on real-world data.
    J Med Virol. 2023;95:e29085.
    >> Share

  431. BRUZZESI E, Gabrieli A, Bernasconi D, Marchetti G, et al
    HIV-DNA decrease during treatment in primary HIV-1 infection with three different drug regimens: Italian Network of Acute HIV Infection (INACTION) clinical trial.
    J Med Virol. 2023;95:e29114.
    >> Share

  432. ZHAN Y, Ye L, Ouyang Q, Yin J, et al
    The binding profile of SARS-CoV-2 with human leukocyte antigen polymorphisms reveals critical alleles involved in immune evasion.
    J Med Virol. 2023;95:e29113.
    >> Share

  433. LI B, Zhang J, Huang Y, Li X, et al
    A conserved N protein nano-vaccine of COVID-19 exerts potent and cross-reactive humoral and cellular immune responses in mice.
    J Med Virol. 2023;95:e29115.
    >> Share

  434. COELHO GM, Cataneo AHD, Raboni SM, Nogueira MB, et al
    Development of an anti-SARS-CoV-2 monoclonal antibody panel and its applicability as a reagent in high-throughput fluorescence reduction neutralization and immunohistochemistry assays.
    J Med Virol. 2023;95:e29111.
    >> Share

    August 2023
  435. ROY A, Saade C, Josset L, Clement B, et al
    Determinants of protection against SARS-CoV-2 Omicron BA.1 and Delta infections in fully vaccinated outpatients.
    J Med Virol. 2023;95:e28984.
    >> Share

  436. CHEN Y, Liu X, Tong Z
    Can inspiratory muscle training benefit patients with COVID-19? A systematic review and meta-analysis.
    J Med Virol. 2023;95:e28956.
    >> Share

  437. ZENG G, Li J, Wang L, Zhang Z, et al
    Impact of corticosteroids use on midterm sequelae in survivors of COVID-19 admitted to hospital.
    J Med Virol. 2023;95:e28988.
    >> Share

  438. YU W, Guo Y, Hu T, Liu Y, et al
    Incidence and severity of SARS-CoV-2 reinfection, a multicenter cohort study in Shanghai, China.
    J Med Virol. 2023;95:e28997.
    >> Share

  439. LI X, Chen N, Wang X, Li T, et al
    Epidemiology of respiratory syncytial virus outbreak among children after the COVID-19 pandemic.
    J Med Virol. 2023;95:e29017.
    >> Share

  440. HIRATA Y, Katano H, Iida S, Mine S, et al
    Genomic analysis of SARS-CoV-2 in forensic autopsy cases of COVID-19.
    J Med Virol. 2023;95:e28990.
    >> Share

  441. VELAZQUEZ-SALINAS L
    Deciphering the evolutionary mechanisms of SARS-CoV-2: Absence of ORF8 protein and its potential advantage in the emergence of viral lineages.
    J Med Virol. 2023;95:e29002.
    >> Share

  442. ZUIN M, Mazzitelli M, Cattelan A
    Long-COVID: Is it time to revise the definition?
    J Med Virol. 2023;95:e29011.
    >> Share

  443. LIU TH, Chuang MH, Wu JY, Huang PY, et al
    Effectiveness of oral antiviral agents on long-term cardiovascular risk in nonhospitalized patients with COVID-19: A multicenter matched cohort study.
    J Med Virol. 2023;95:e28992.
    >> Share

  444. SHANG S, Fu B, Geng Y, Zhang J, et al
    Azvudine therapy of common COVID-19 in hemodialysis patients.
    J Med Virol. 2023;95:e29007.
    >> Share

  445. WANG Y, Zhao D, Xiao W, Shi J, et al
    Paxlovid reduces the risk of Long COVID in patients six months after hospital discharge.
    J Med Virol. 2023;95:e29014.
    >> Share

  446. ZHIYANOV A, Shkurnikov M, Nersisyan A, Hui C, et al
    The signature of SARS-CoV-2 evolution reflects selective pressures within human guts.
    J Med Virol. 2023;95:e28996.
    >> Share

  447. ABBASI HQ
    Comments on: Clinical characteristics of unvaccinated or incompletely vaccinated children with neurological manifestations due to SARS-CoV-2 Omicron infection.
    J Med Virol. 2023;95:e29008.
    >> Share

  448. MOHAMMADI B, Dua K, Saghafi M, Singh SK, et al
    COVID-19-induced autoimmune thyroiditis: Exploring molecular mechanisms.
    J Med Virol. 2023;95:e29001.
    >> Share

  449. WASSERMAN EB, Sills AK, Martins D, Casolaro A, et al
    Factors associated with antibody titer levels among an occupational cohort of fully vaccinated individuals and subsequent risk of COVID-19 infection: A cohort study.
    J Med Virol. 2023;95:e28999.
    >> Share

  450. THURLAPATI A, McGann M, Davis JA, Granger K, et al
    Role of tixagevimab-cilgavimab in preventing SARS-CoV-2 in hematopoietic stem cell transplant and chimeric antigen receptor T-cell therapy recipients.
    J Med Virol. 2023;95:e29027.
    >> Share

  451. BAI Y, Shen L, Sun M, Yang Z, et al
    The short and long-term impact of nonpharmaceutical interventions on the prevalence of varicella in Xi'an during the COVID-19 pandemic.
    J Med Virol. 2023;95:e29020.
    >> Share

  452. LIU M, Zhang J, Li L, Tian J, et al
    Inactivated vaccine fueled adaptive immune responses to Omicron in 2-year COVID-19 convalescents.
    J Med Virol. 2023;95:e28998.
    >> Share

  453. GIOVANETTI M, Branda F, Cella E, Scarpa F, et al
    Epidemic history and evolution of an emerging threat of international concern, the severe acute respiratory syndrome coronavirus 2.
    J Med Virol. 2023;95:e29012.
    >> Share

  454. HOQUE SA, Pham NTK, Onda-Shimizu Y, Nishimura S, et al
    Sapovirus infections in Japan before and after the emergence of the COVID-19 pandemic: An alarming update.
    J Med Virol. 2023;95:e29023.
    >> Share

  455. ISHISAKA Y, Aikawa T, Malik A, Kampaktsis PN, et al
    Association of Remdesivir use with bradycardia: A systematic review and meta-analysis.
    J Med Virol. 2023;95:e29018.
    >> Share

  456. SUN Z, Wang S, Sun X, Shi Y, et al
    COVID-19 has causal effects on cancer risk? Something we might ignore.
    J Med Virol. 2023;95:e29034.
    >> Share

  457. BAUER C, Mack E, Hefter V, Fischer A, et al
    Impaired systemic nucleocapsid antigen clearance in severe COVID-19.
    J Med Virol. 2023;95:e29032.
    >> Share

  458. MAK WA, Visser W, van der Vliet M, Markus HY, et al
    Ancestral SARS-CoV-2 and Omicron BA.5-specific neutralizing antibody and T-cell responses after Omicron bivalent booster vaccination in previously infected and infection-naive individuals.
    J Med Virol. 2023;95:e28989.
    >> Share

  459. DAS A, Meng W, Liu Z, Hasib MM, et al
    Molecular and immune signatures, and pathological trajectories of fatal COVID-19 lungs defined by in situ spatial single-cell transcriptome analysis.
    J Med Virol. 2023;95:e29009.
    >> Share

  460. LU S, Luo S, Bai B, Fan Z, et al
    Omicron breakthrough infections in wild-type SARS-CoV-2 vaccinees elicit high levels of neutralizing antibodies against pangolin coronavirus GX_P2V.
    J Med Virol. 2023;95:e29031.
    >> Share

  461. FANG C, Yan W, Chen Y, Dou Z, et al
    Long-term SARS-CoV-2 neutralizing antibody level prediction using multimodal deep learning: A prospective cohort study on longitudinal data in Wuhan, China.
    J Med Virol. 2023;95:e29036.
    >> Share

  462. FOURIE E, Bording ES, Euser SM, Badoux P, et al
    Nasal discharge: A unique enhanced alternative for the detection of respiratory pathogens in adults.
    J Med Virol. 2023;95:e29047.
    >> Share

  463. ZHAO Y, Zhao Y, Zhu J, Lei L, et al
    Association of inactivated COVID-19 vaccination with maternal coagulation function in early pregnancy.
    J Med Virol. 2023;95:e29051.
    >> Share

  464. GUO H, Yin M, Liu Y, Wang B, et al
    COVID-19 infection after oocyte retrieval did not have detrimental effects on embryo implantation for frozen embryo transfer.
    J Med Virol. 2023;95:e29054.
    >> Share

  465. BASTO-ABREU A, Carnalla M, Torres-Ibarra L, Sanchez-Pajaro A, et al
    SARS-CoV-2 seroprevalence and vaccine coverage from August to November 2021: A nationally representative survey in Mexico.
    J Med Virol. 2023;95:e29038.
    >> Share

  466. ZHAO Y, Zhang H, Zhao Z, Liu F, et al
    Efficacy and safety of Oral LL-37 against the Omicron BA.5.1.3 variant of SARS-COV-2: A randomized trial.
    J Med Virol. 2023;95:e29035.
    >> Share

  467. GONDIM RNDG, de Arruda EAG, Neto RDJP, Medeiros MS, et al
    Cytokines, chemokines, and cells growth factors in patients with mild to moderate SARS-CoV-2 infection: A case-control study.
    J Med Virol. 2023;95:e29044.
    >> Share

  468. NGUYEN NN, Houhamdi L, Meddeb L, Colson P, et al
    Reinfection with SARS-CoV-2 Omicron BA.4 and BA.5 variants.
    J Med Virol. 2023;95:e29033.
    >> Share

  469. SILVA MFS, de Oliveira FCE, Pinto ACMD, Luciano MCDS, et al
    Antibody response following the fourth SARS-CoV-2 vaccine dose during the Omicron wave in Brazil.
    J Med Virol. 2023;95:e29055.
    >> Share

  470. GUTERRES A
    Viral load: We need a new look at an old problem?
    J Med Virol. 2023;95:e29061.
    >> Share

  471. YANG H, Wang Z, Zhang Y, Xu M, et al
    Clinical characteristics and factors for serious outcomes among outpatients infected with the Omicron subvariant BF.7.
    J Med Virol. 2023;95:e28977.
    >> Share

  472. LIAO HC, Huang MS, Chiu FF, Chai KM, et al
    Co-delivery of a trimeric spike DNA and protein vaccine with aluminum hydroxide enhanced Th1-dominant humoral and cellular immunity against SARS-CoV-2.
    J Med Virol. 2023;95:e29040.
    >> Share

    July 2023
  473. SOLIS M, Benotmane I, Gallais F, Caillard S, et al
    Torque teno virus viral load predicts SARS-CoV-2 vaccine response in kidney transplant recipients.
    J Med Virol. 2023;95:e28936.
    >> Share

  474. ZHAO Q, Wang X, Zhang Z, Liu X, et al
    Serum neutralization of SARS-CoV-2 Omicron BA.2, BA.2.75, BA.2.76, BA.5, BF.7, BQ.1.1 and XBB.1.5 in individuals receiving Evusheld.
    J Med Virol. 2023;95:e28932.
    >> Share

  475. KHAN M, Khan K, Motwani J
    Comment on "Long-term risk of herpes zoster following COVID-19: A retrospective cohort study of 2 442 686 patients".
    J Med Virol. 2023;95:e28938.
    >> Share

  476. TSO WW, Kwan MY, Kwok JS, Tsang JO, et al
    Clinical characteristics of unvaccinated or incompletely vaccinated children with neurological manifestations due to SARS-CoV-2 Omicron infection.
    J Med Virol. 2023;95:e28895.
    >> Share

  477. GATES S, Andreani J, Dewar R, Smith DB, et al
    Postpandemic rebound of adeno-associated virus type 2 (AAV2) infections temporally associated with an outbreak of unexplained severe acute hepatitis in children in the United Kingdom.
    J Med Virol. 2023;95:e28921.
    >> Share

  478. ALBERT E, Fernandez-Soto D, Gimenez E, Casanovas JM, et al
    Antibody-dependent NK-cell and neutralizing antibody responses against the Spike protein of Wuhan-Hu-1 and Omicron BA.1 SARS-CoV-2 variants in vaccinated experienced and vaccinated naive individuals.
    J Med Virol. 2023;95:e28900.
    >> Share

  479. HUANG PY, Liu TH, Wu JY, Tsai YW, et al
    Response to the letter to the editor on "Clinical efficacy and safety of molnupiravir for nonhospitalized and hospitalized patients with COVID-19: A systematic review and meta-analysis of randomized control trials".
    J Med Virol. 2023;95:e28918.
    >> Share

  480. YI S, Zhang SS, Wang XR, Zhou Y, et al
    Dynamics of parainfluenza virus among hospitalized children with acute respiratory tract infection under two-child policy and COVID-19 pandemic in Hubei Province, China, 2014-2022.
    J Med Virol. 2023;95:e28899.
    >> Share

  481. ZHANG H, Lu Z, Yang F, Chen H, et al
    Symptom profiles and vaccination status for COVID-19 after the adjustment of the dynamic zero-COVID policy in China: An observational study.
    J Med Virol. 2023;95:e28893.
    >> Share

  482. RAMUNNO M, Savitz R
    COVID-19 vaccination and decreased death rates: A county-level study in Pennsylvania.
    J Med Virol. 2023;95:e28883.
    >> Share

  483. DE FRANCESCO MA, Signorini L, Piva S, Pellizzeri S, et al
    Bacterial and fungal superinfections are detected at higher frequency in critically ill patients affected by SARS CoV-2 infection than negative patients and are associated to a worse outcome.
    J Med Virol. 2023;95:e28892.
    >> Share

  484. RAHMATI M, Yon DK, Lee SW, Soysal P, et al
    New-onset neurodegenerative diseases as long-term sequelae of SARS-CoV-2 infection: A systematic review and meta-analysis.
    J Med Virol. 2023;95:e28909.
    >> Share

  485. MIELKE A, Denwood M, Christiansen LE
    Estimating true prevalence through questionnaire data.
    J Med Virol. 2023;95:e28908.
    >> Share

  486. CHUNG HY, Jian MJ, Chang CK, Lin JC, et al
    Accelerating pandemic response with the emergency Omicron RT-PCR test: A comprehensive solution for COVID-19 diagnosis and tracking.
    J Med Virol. 2023;95:e28914.
    >> Share

  487. GUO Z, Jin Q, Li P, Xing G, et al
    Potential cross-species transmission risks of emerging swine enteric coronavirus to human beings.
    J Med Virol. 2023;95:e28919.
    >> Share

  488. SENDI P, Widmer N, Branca M, Thierstein M, et al
    Do quantitative levels of antispike-IgG antibodies aid in predicting protection from SARS-CoV-2 infection? Results from a longitudinal study in a police cohort.
    J Med Virol. 2023;95:e28904.
    >> Share

  489. KANG SY, Yoo JR, Park Y, Kim SH, et al
    Fatal outcome of severe fever with thrombocytopenia syndrome (SFTS) and severe and critical COVID-19 is associated with the hyperproduction of IL-10 and IL-6 and the low production of TGF-beta.
    J Med Virol. 2023;95:e28894.
    >> Share

  490. LIN WC, Wei JC
    Long-term risk of herpes zoster following COVID-19: A retrospective cohort study of 2 442 686 patients.
    J Med Virol. 2023;95:e28903.
    >> Share

  491. LIU TH, Wu JY, Huang PY, Tsai YW, et al
    The effect of nirmatrelvir-ritonavir on the long-term risk of neuropsychiatric sequelae following COVID-19.
    J Med Virol. 2023;95:e28951.
    >> Share

  492. AN Y, Zhao G, Duan H, Zhang N, et al
    Robust and protective immune responses induced by heterologous prime-boost vaccination with DNA-protein dimeric RBD vaccines for COVID-19.
    J Med Virol. 2023;95:e28948.
    >> Share

  493. MA Q, Xu G
    New-onset and relapsed thrombotic microangiopathy post-COVID-19 vaccination.
    J Med Virol. 2023;95:e28946.
    >> Share

  494. GHAZIZADEH ESSLAMI G, Mamishi S, Pourakbari B, Mahmoudi S, et al
    Systematic review and meta-analysis on the serological, immunological, and cardiac parameters of the multisystem inflammatory syndrome (MIS-C) associated with SARS-CoV-2 infection.
    J Med Virol. 2023;95:e28927.
    >> Share

  495. CHEN YC, Ho CH, Liu TH, Wu JY, et al
    Response to the letter to the editor on "Long-term risk of herpes zoster following COVID-19: A retrospective cohort study of 2 442 686 patients".
    J Med Virol. 2023;95:e28945.
    >> Share

  496. HUANG Y, Zhu X, Guo X, Zhou Y, et al
    Advances in mRNA vaccines for viral diseases.
    J Med Virol. 2023;95:e28924.
    >> Share

  497. HUANG C
    Comment on Huang PS et al. Clinical efficacy and safety of molnupiravir for nonhospitalized and hospitalized patients with COVID-19: A systematic review and meta-analysis of randomized control trials. Med Virol. 2023; 95: e28621.
    J Med Virol. 2023;95:e28907.
    >> Share

  498. CHEN H, Ye B, Su W, Song Y, et al
    The causal role of gut microbiota in susceptibility and severity of COVID-19: A bidirectional Mendelian randomization study.
    J Med Virol. 2023;95:e28880.
    >> Share

  499. KOZAWA K, Kawamura Y, Hattori F, Miura H, et al
    Changes in trends of pediatric beta- and gamma-herpesvirus infections during the COVID-19 pandemic: A single-center observational study.
    J Med Virol. 2023;95:e28925.
    >> Share

  500. KIRSCH JA, Slutske WS, McCarthy DE, Smith SS, et al
    Factors associated with 60-day readmission among inpatients with COVID-19 at 21 United States health systems.
    J Med Virol. 2023;95:e28972.
    >> Share

  501. YANG H, Wang Z, Jiang C, Zhang Y, et al
    Oral azvudine for mild-to-moderate COVID-19 in high risk, nonhospitalized adults: Results of a real-world study.
    J Med Virol. 2023;95:e28947.
    >> Share

  502. PONIEDZIALEK B, Rzymski P, Zarebska-Michaluk D, Rogalska M, et al
    Short-term exposure to ambient air pollution and COVID-19 severity during SARS-CoV-2 Delta and Omicron waves: A multicenter study.
    J Med Virol. 2023;95:e28962.
    >> Share

  503. KIM Y, Kim S, Kim HJ, Kwon R, et al
    National trends in body mass index, overweight, and obesity among adults before and during the COVID-19 pandemic in 2009-2021: A representative longitudinal serial study in South Korea.
    J Med Virol. 2023;95:e28958.
    >> Share

  504. FANG Q, He X, Zheng X, Fu Y, et al
    Verifying AXL and putative proteins as SARS-CoV-2 receptors by DnaE intein-based rapid cell-cell fusion assay.
    J Med Virol. 2023;95:e28953.
    >> Share


  505. Retraction: Zhang, N, Qi, X, Chang, H, et al. Combined effects of inflammation and coronavirus disease 2019 (COVID-19) on the risks of anxiety and depression: a cross-sectional study based on UK Biobank. J Med Virol. 2023; 95:e28726. doi:10.1002/jmv.2
    J Med Virol. 2023;95:e28937.
    >> Share

  506. HE J, Mei Q, Peng Y, Xie J, et al
    Are the original SARS-CoV-2 novel mutants from in vitro culture able to escape the immune response?
    J Med Virol. 2023;95:e28931.
    >> Share


  507. Correction to "Long-Term Risk of Herpes Zoster Following Covid-19: A Retrospective Cohort Study of 2 442 686 Patients".
    J Med Virol. 2023;95:e28944.
    >> Share

  508. QU Y, Wang W, Xiao MZX, Zheng Y, et al
    The interplay between lipid droplets and virus infection.
    J Med Virol. 2023;95:e28967.
    >> Share


  509. Correction to "Clinical efficacy and safety of molnupiravir for nonhospitalized and hospitalized patients with COVID-19: a systematic review and meta-analysis of randomized control trials".
    J Med Virol. 2023;95:e28916.
    >> Share


  510. Correction to "SARS-CoV-2 RNA load in nasopharyngeal specimens from outpatients with breakthrough COVID-19 due to Omicron BA.1 and BA.2".
    J Med Virol. 2023;95:e28935.
    >> Share

  511. AUGUSTINE G, Sisila V, Indhu M, Gupta D, et al
    Redirecting the JAK-STAT signal blocks the SARS-CoV-2 replication.
    J Med Virol. 2023;95:e28965.
    >> Share

  512. VISOS-VARELA I, Zapata-Cachafeiro M, Pintos-Rodriguez S, Bugarin-Gonzalez R, et al
    Outpatient atorvastatin use and severe COVID-19 outcomes: A population-based study.
    J Med Virol. 2023;95:e28971.
    >> Share

  513. SHARIQ M, Malik AA, Sheikh JA, Hasnain SE, et al
    Regulation of autophagy by SARS-CoV-2: The multifunctional contributions of ORF3a.
    J Med Virol. 2023;95:e28959.
    >> Share

  514. WATANABE A, Malik A, Aikawa T, Briasoulis A, et al
    Extracorporeal membrane oxygenation for COVID-19-associated acute respiratory distress syndrome: A nationwide analysis.
    J Med Virol. 2023;95:e28961.
    >> Share

    June 2023
  515. LIN YY, Yao R, Zhuang J, Wang B, et al
    PACT inhibits the replication of SARS-CoV-2 through the blockage of GSK-3beta-N-nsp3 cascade.
    J Med Virol. 2023;95:e28832.
    >> Share

  516. RAHMATI M, Yon DK, Lee SW, Udeh R, et al
    New-onset type 1 diabetes in children and adolescents as postacute sequelae of SARS-CoV-2 infection: A systematic review and meta-analysis of cohort studies.
    J Med Virol. 2023;95:e28833.
    >> Share

  517. QIAN X, Wu B, Chen X, Peng H, et al
    Multi-omic and comparative analyses revealed monocyte-derived alpha-defensin-1 correlated with COVID-19 severity and inhibited SARS-CoV-2 infection.
    J Med Virol. 2023;95:e28845.
    >> Share

  518. REN Y, Wang G, Han D
    Statins in hospitalized COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials.
    J Med Virol. 2023;95:e28823.
    >> Share

  519. GUO M, Zhu J, Hu Z, Wang Q, et al
    Histone mRNA polyadenylation-mediated inflammation underlies various virus infections and cancers.
    J Med Virol. 2023;95:e28826.
    >> Share

  520. ZENG G, Wang L, Li J, Zhang Z, et al
    Real-world effectiveness of Azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19.
    J Med Virol. 2023;95:e28836.
    >> Share

  521. BOSKOVIC B, Bilic I, Soda J, Kero I, et al
    Transcranial magnetic stimulation in assessment of vocal cord paralysis due to post-viral (COVID-19) vagal neuropathy.
    J Med Virol. 2023;95:e28838.
    >> Share

  522. MONDI A, Mastrorosa I, Piselli P, Cimaglia C, et al
    Evolution of SARS-CoV-2 variants of concern over a period of Delta and Omicron cocirculation, among patients hospitalized for COVID-19 in an Italian reference hospital: Impact on clinical outcomes.
    J Med Virol. 2023;95:e28831.
    >> Share

  523. GAULT N, Bachelet D, Laouenan C, Borie R, et al
    Impact of corticosteroids use on midterm sequelae in survivors of COVID-19 admitted to hospital: A prospective cohort study.
    J Med Virol. 2023;95:e28819.
    >> Share

  524. MESSALI S, Rondina A, Giovanetti M, Bonfanti C, et al
    Traceability of SARS-CoV-2 transmission through quasispecies analysis.
    J Med Virol. 2023;95:e28848.
    >> Share

  525. RAHMATI M, Udeh R, Yon DK, Lee SW, et al
    A systematic review and meta-analysis of long-term sequelae of COVID-19 2-year after SARS-CoV-2 infection: A call to action for neurological, physical, and psychological sciences.
    J Med Virol. 2023;95:e28852.
    >> Share

  526. RANARD BL, Chow CC, Megjhani M, Asgari S, et al
    A mathematical model of SARS-CoV-2 immunity predicts paxlovid rebound.
    J Med Virol. 2023;95:e28854.
    >> Share

  527. REDLBERGER-FRITZ M, Springer DN, Aberle SW, Camp JV, et al
    Respiratory syncytial virus surge in 2022 caused by lineages already present before the COVID-19 pandemic.
    J Med Virol. 2023;95:e28830.
    >> Share

  528. YU W, Wang J, Yang Y, Tang C, et al
    SARS-CoV-2 Omicron (B.1.1.529) infection in rhesus macaques, hamsters, and BALB/c mice with severe lung histopathological damage.
    J Med Virol. 2023;95:e28846.
    >> Share

  529. OH T, Kim G, Baek SH, Woo Y, et al
    Comparative spatial transcriptomic profiling of severe acute respiratory syndrome coronavirus 2 Delta and Omicron variants infections in the lungs of cynomolgus macaques.
    J Med Virol. 2023;95:e28847.
    >> Share

  530. LI J, Wang B, He X, Li Z, et al
    Epidemiological characteristics of norovirus infection in pediatric patients during the COVID-19 pandemic.
    J Med Virol. 2023;95:e28874.
    >> Share

  531. TSAI YW, Wu JY, Liu TH, Chuang MH, et al
    Clinical effectiveness of oral antiviral agents in older patients with COVID-19 based on real-world data.
    J Med Virol. 2023;95:e28869.
    >> Share

  532. WU JY, Liu MY, Liu TH, Chuang MH, et al
    Clinical efficacy of nirmatrelvir and ritonavir combination for treating diabetic patients with COVID-19.
    J Med Virol. 2023;95:e28866.
    >> Share

  533. FENG K, Zhang HJ, Min YQ, Zhou M, et al
    SARS-CoV-2 NSP13 interacts with host IRF3, blocking antiviral immune responses.
    J Med Virol. 2023;95:e28881.
    >> Share

  534. PEREZ-CATALAN I, Gomez-Alfaro I, Garcia-Munoz S, Roig-Marti C, et al
    Antiviral treatment or mAbs for persistent SARS-COV-2 infection in patients with hematologic malignancies: A case series.
    J Med Virol. 2023;95:e28865.
    >> Share

  535. LI F, Xu K, Pan Y, Liu P, et al
    Stability of SARS-CoV-2 and persistence of viral nucleic acids on common foods and widely used packaging material surfaces.
    J Med Virol. 2023;95:e28871.
    >> Share

  536. YE RZ, Gong C, Cui XM, Liu JY, et al
    Continuous evolution and emerging lineage of seasonal human coronaviruses: A multicenter surveillance study.
    J Med Virol. 2023;95:e28861.
    >> Share

  537. DOBROWOLSKA K, Zarebska-Michaluk D, Poniedzialek B, Jaroszewicz J, et al
    Overview of autoantibodies in COVID-19 convalescents.
    J Med Virol. 2023;95:e28864.
    >> Share

  538. KO M, Lee JY, Shin YS, Jeon S, et al
    Novel SARS-CoV-2 entry inhibitors, 2-anilinoquinazolin-4(3H)-one derivatives, show potency as SARS-CoV-2 antivirals in a human ACE2 transgenic mouse model.
    J Med Virol. 2023;95:e28863.
    >> Share

  539. CROOKS CJ, West J, Gazis T, Simmonds M, et al
    Maximal temperature varies by sex and ethnic group in hospital in-patients with Covid-19 infection.
    J Med Virol. 2023;95:e28837.
    >> Share

  540. VASCONCELOS MW, de Barros FRO, Pilonetto JC, Rosa SGB, et al
    Relationship between SARS-CoV-2 vaccination and cases, program breakthrough cases, and deaths in Dois Vizinhos, Parana, Brazil.
    J Med Virol. 2023;95:e28882.
    >> Share

  541. WATANABE Y, Yamamoto H, Matsuba I, Watanabe K, et al
    Time-series transcriptome analysis of peripheral blood mononuclear cells obtained from individuals who received the SARS-CoV-2 mRNA vaccine.
    J Med Virol. 2023;95:e28884.
    >> Share

  542. AHMADI AS, Zadheidar S, Sadeghi K, Nejati A, et al
    SARS-CoV-2 intrahost evolution in immunocompromised patients in comparison with immunocompetent populations after treatment.
    J Med Virol. 2023;95:e28877.
    >> Share

  543. RAMJATTUN K, Ma X, Gao SJ, Singh H, et al
    COVID-19db linkage maps of cell surface proteins and transcription factors in immune cells.
    J Med Virol. 2023;95:e28887.
    >> Share

  544. CAO G, Guo Z, Liu J, Liu M, et al
    Change from low to out-of-season epidemics of influenza in China during the COVID-19 pandemic: A time series study.
    J Med Virol. 2023;95:e28888.
    >> Share

  545. XIE Y, Yang M, Zhou P, Fan J, et al
    New-onset pemphigus foliaceus after COVID-19 infection.
    J Med Virol. 2023;95:e28867.
    >> Share

  546. TRAGNI V, Mercurio I, Paoletti DP, Onofrio A, et al
    Deconstructing SARS-CoV-2 neutralization: A modular molecular framework for computational design and comparison of antibodies and nanobodies targeting the spike RBD.
    J Med Virol. 2023;95:e28875.
    >> Share

  547. LUO J, Zhang J, Tang HT, Wong HK, et al
    Prevalence and risk factors of long COVID 6-12 months after infection with the Omicron variant among nonhospitalized patients in Hong Kong.
    J Med Virol. 2023;95:e28862.
    >> Share

  548. YETMAR ZA, Yao JD, Razonable RR
    SARS-CoV-2 spike codon mutations and risk of hospitalization after antispike monoclonal antibody therapy in solid organ transplant recipients.
    J Med Virol. 2023;95:e28885.
    >> Share

  549. ZHENG L, Wang L, Lu F
    Looking back on the outbreak of acute severe hepatitis with unknown etiology in children in 2022: What do we know now and where do we go from here?
    J Med Virol. 2023;95:e28890.
    >> Share

  550. AMANI B, Akbarzadeh A, Amani B, Shabestan R, et al
    Comparative efficacy and safety of nirmatrelvir/ritonavir and molnupiravir for COVID-19: A systematic review and meta-analysis.
    J Med Virol. 2023;95:e28889.
    >> Share

    May 2023
  551. MUHAMMED OA, Tawfeeq HM, Al-Jaf SMA, Niranji SS, et al
    Comments on "Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers".
    J Med Virol. 2023;95:e28822.
    >> Share

  552. SONG R, Chen X, Li B, Zhang H, et al
    Nasal spray of an IgM-like ACE2 fusion protein HH-120 accelerates SARS-CoV-2 clearance: A single-center propensity score-matched cohort study.
    J Med Virol. 2023;95:e28805.
    >> Share

  553. ALI AM, Tofiq AM, Rostam HM, Ali KM, et al
    Response to comments to the editor on "Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers".
    J Med Virol. 2023;95:e28820.
    >> Share

  554. ALI AM, Tofiq AM, Rostam HM, Ali KM, et al
    Corrigendum on "Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers".
    J Med Virol. 2023;95:e28824.
    >> Share

  555. VARGHESE R, Pai S, Kumar D, Sharma R, et al
    SARS-CoV-2 XBB.1.16 variant: India in focus?
    J Med Virol. 2023;95:e28829.
    >> Share

  556. PARCZEWSKI M, Kufel J, Aksak-Was B, Piwnik J, et al
    Artificial neural network based prediction of the lung tissue involvement as an independent in-hospital mortality and mechanical ventilation risk factor in COVID-19.
    J Med Virol. 2023;95:e28787.
    >> Share

  557. ZHANG Y, Liu J, Li H, Yuan F, et al
    Comparison of the immunogenicity of nasal-spray rVSV vector, adenovirus vector, and inactivated COVID-19-based vaccines in rodent models.
    J Med Virol. 2023;95:e28806.
    >> Share

  558. SONG J, Wu Y, Yin X, Ma H, et al
    The causal links between gut microbiota and COVID-19: A Mendelian randomization study.
    J Med Virol. 2023;95:e28784.
    >> Share

  559. ZENG G, He F, Zhang X, Li G, et al
    Antibody response to the third dose of inactivated COVID-19 vaccine in people living with HIV (PLWH): A longitudinal cohort.
    J Med Virol. 2023;95:e28797.
    >> Share

  560. BEGUM F, Srivastava AK, Tripathi PP, Ray U, et al
    A substrate for a cell free in vitro assay system to screen drugs targeting trypsin like protease-based cleavage of SARS-CoV-2 spike glycoprotein and viral entry.
    J Med Virol. 2023;95:e28796.
    >> Share

  561. LIU TH, Huang PY, Wu JY, Chuang MH, et al
    Clinical effectiveness of nirmatrelvir plus ritonavir in patients with COVID-19 and substance use disorders based on real-world data.
    J Med Virol. 2023;95:e28801.
    >> Share

  562. YIN Y, Lin J, Yuan S, Tong S, et al
    Vaccination status for mild and asymptomatic infections with SARS-CoV-2 Omicron BA.2 variant in Shanghai.
    J Med Virol. 2023;95:e28767.
    >> Share

  563. HUESPE IA, Ferraris A, Lalueza A, Valdez PR, et al
    COVID-19 vaccines reduce mortality in hospitalized patients with oxygen requirements: Differences between vaccine subtypes. A multicontinental cohort study.
    J Med Virol. 2023;95:e28786.
    >> Share

  564. SEVGI DY, Demirbas ND, Genc Yaman I, Derin O, et al
    Evaluation of the late presentation and associated factors of people living with HIV in Turkey.
    J Med Virol. 2023;95:e28781.
    >> Share

  565. CHEN L, Zhang Q, Li H, Ma K, et al
    Clinical considerations for a gastric Dieulafoy's disease patient: Cardiac arrhythmias caused by SARS-CoV-2 or terlipressin?
    J Med Virol. 2023;95:e28792.
    >> Share

  566. OGUNBAYO AE, Mogotsi MT, Sondlane H, Sabiu S, et al
    Metagenomics characterization of respiratory viral RNA pathogens in children under five years with severe acute respiratory infection in the Free State, South Africa.
    J Med Virol. 2023;95:e28753.
    >> Share

  567. FONG SW, Goh YS, Torres-Ruesta A, Chang ZW, et al
    Prolonged inflammation in patients hospitalized for coronavirus disease 2019 (COVID-19) resolves 2 years after infection.
    J Med Virol. 2023;95:e28774.
    >> Share

  568. WANLAPAKORN N, Kanokudom S, Phowatthanasathian H, Chansaenroj J, et al
    Comparison of the reactogenicity and immunogenicity between two-dose mRNA COVID-19 vaccine and inactivated COVID-19 vaccine followed by an mRNA vaccine in children aged 5-11 years.
    J Med Virol. 2023;95:e28758.
    >> Share

  569. RIAD A, Schulz-Weidner N, Dziedzic A, Howaldt HP, et al
    Oral side effects of COVID-19 vaccines in 32 European countries: Analysis of EudraVigilance reports.
    J Med Virol. 2023;95:e28771.
    >> Share

  570. TIRELLI U, Franzini M, Chirumbolo S
    Post-COVID syndrome, the real matter of debate.
    J Med Virol. 2023;95:e28785.
    >> Share

  571. QIU S, Zheng K, Hu Y, Liu G, et al
    Genetic correlation, causal relationship, and shared loci between vitamin D and COVID-19: A genome-wide cross-trait analysis.
    J Med Virol. 2023;95:e28780.
    >> Share

  572. FORTHAL DN
    Comment on the immunogenicity of the Noora vaccine against SARS-CoV-2.
    J Med Virol. 2023;95:e28731.
    >> Share

  573. SAKAI-TAGAWA Y, Yamayoshi S, Halfmann PJ, Wilson N, et al
    Sensitivity of rapid antigen tests for Omicron subvariants of SARS-CoV-2.
    J Med Virol. 2023;95:e28788.
    >> Share

  574. SCHUURMANS STEKHOVEN SJ, Winkel KGT, Souverein D, Sondermeijer BM, et al
    Clinical validation of novel dried blood spot based collecting device using serum separation for measuring SARS-CoV-2 antibodies.
    J Med Virol. 2023;95:e28765.
    >> Share

  575. ZHANG Y, Clarke SP, Wu H, Li W, et al
    A comprehensive overview on the transmission, pathogenesis, diagnosis, treatment, and prevention of SARS-CoV-2.
    J Med Virol. 2023;95:e28776.
    >> Share

  576. NASCIMENTO JHFD, Andrade AB, Gusmao-Cunha A, Cunha AMG, et al
    Trends in the morbidity and mortality of coronavirus disease 2019 in different ethnic groups and gender in a large Brazilian city.
    J Med Virol. 2023;95:e28794.
    >> Share

    April 2023
  577. WU J, Liu W, Zhu L, Li N, et al
    Dysbiosis of oropharyngeal microbiome and antibiotic resistance in hospitalized COVID-19 patients.
    J Med Virol. 2023;95:e28727.
    >> Share

  578. BOUKHALFA Y, Stambouli N, Driss A, Daiki M, et al
    sCXCL16 as a prognostic biomarker for COVID-19 outcome.
    J Med Virol. 2023;95:e28728.
    >> Share

  579. ZHANG N, Qi X, Chang H, Li C, et al
    Combined effects of inflammation and coronavirus disease 2019 (COVID-19) on the risks of anxiety and depression: A cross-sectional study based on UK Biobank.
    J Med Virol. 2023;95:e28726.
    >> Share

  580. MENG M, Wu Y, Sha W, Zeng R, et al
    Associations of habitual glucosamine use with SARS-CoV-2 infection and hospital admission and death with COVID-19: Evidence from a large population based cohort study.
    J Med Virol. 2023;95:e28720.
    >> Share

  581. PATINO LH, Ballesteros N, Munoz M, Ramirez AL, et al
    Mu SARS-CoV-2 (B.1.621) variant: A genomic snapshot across the Colombian-Venezuelan border.
    J Med Virol. 2023;95:e28766.
    >> Share

  582. LI J, Bai H, Qiao H, Du C, et al
    Causal effects of COVID-19 on cancer risk: A Mendelian randomization study.
    J Med Virol. 2023;95:e28722.
    >> Share

  583. CENAT JM, Moshirian Farahi SMM, Bakombo SM, Dalexis RD, et al
    Vaccine mistrust among Black individuals in Canada: The major role of health literacy, conspiracy theories, and racial discrimination in the healthcare system.
    J Med Virol. 2023;95:e28738.
    >> Share

  584. CAMACHO J, Albert E, Alvarez-Rodriguez B, Rusu L, et al
    A machine learning model for predicting serum neutralizing activity against Omicron SARS-CoV-2 BA.2 and BA.4/5 sublineages in the general population.
    J Med Virol. 2023;95:e28739.
    >> Share

  585. SHANG W, Zhang S, Qian H, Pan X, et al
    Association of gut microbiota with COVID-19 susceptibility and severity: A two-sample Mendelian randomization study.
    J Med Virol. 2023;95:e28734.
    >> Share

  586. ZHAO Y, Zhao Y, Su X, Zhou Y, et al
    No association of vaccination with inactivated COVID-19 vaccines before conception with pregnancy complications and adverse birth outcomes: A cohort study of 5457 Chinese pregnant women.
    J Med Virol. 2023;95:e28735.
    >> Share

  587. VANLERBERGHE B, Vrij C, Bogaerts K, Vermeersch P, et al
    SARS-CoV-2 vaccine antibody response and breakthrough infections in transplant recipients.
    J Med Virol. 2023;95:e28736.
    >> Share

  588. LU T, Chen Z, Cao Y, Ao L, et al
    Dynamic immunogenicity after primary and booster inactivated SARS-CoV-2 vaccination in people living with HIV: A longitudinal observational study.
    J Med Virol. 2023;95:e28730.
    >> Share

  589. CHEN YC, Ho CH, Liu TH, Wu JY, et al
    Long-term risk of herpes zoster following COVID-19: A retrospective cohort study of 2 442 686 patients.
    J Med Virol. 2023;95:e28745.
    >> Share

  590. YE J, Shao X, Yang Y, Zhu F, et al
    Predicting the negative conversion time of nonsevere COVID-19 patients using machine learning methods.
    J Med Virol. 2023;95:e28747.
    >> Share

  591. ONG DSY, de Man P, Verhagen T, Doejaaren G, et al
    Airborne virus shedding of the alpha, delta, omicron SARS-CoV-2 variants and influenza virus in hospitalized patients.
    J Med Virol. 2023;95:e28748.
    >> Share

  592. SAENZ-ALDEA M, Salgado-Barreira A, Taracido-Trunk M, Pineiro-Lamas M, et al
    RE: Colchicine and risk of hospitalization due to COVID-19: A population-based study.
    J Med Virol. 2023;95:e28741.
    >> Share

  593. CHEN L, Shao Z, Liu H, Shi Q, et al
    Clinical observation of neutralizing antibody DXP-604 for treatment critical COVID-19 patients infected with SARS-CoV-2 Delta variant.
    J Med Virol. 2023;95:e28742.
    >> Share

  594. NING J, Wang Q, Chen Y, He T, et al
    Immunodominant SARS-CoV-2-specific CD4(+) and CD8(+) T-cell responses elicited by inactivated vaccines in healthy adults.
    J Med Virol. 2023;95:e28743.
    >> Share

  595. CHEEMA HA, Rehman AU, Elrashedy AA, Mohsin A, et al
    Antiandrogens for the treatment of COVID-19 patients: A meta-analysis of randomized controlled trials.
    J Med Virol. 2023;95:e28740.
    >> Share

  596. MAO S, Cai X, Niu S, Wei J, et al
    TRIM21 promotes ubiquitination of SARS-CoV-2 nucleocapsid protein to regulate innate immunity.
    J Med Virol. 2023;95:e28719.
    >> Share

  597. DENG G, Li D, Sun Y, Jin L, et al
    Real-world effectiveness of Azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19: A retrospective cohort study.
    J Med Virol. 2023;95:e28756.
    >> Share

  598. CHUANG MH, Wu JY, Liu TH, Hsu WH, et al
    Efficacy of nirmatrelvir and ritonavir for post-acute COVID-19 sequelae beyond 3 months of SARS-CoV-2 infection.
    J Med Virol. 2023;95:e28750.
    >> Share

  599. QUDUS MS, Tian M, Sirajuddin S, Liu S, et al
    The roles of critical pro-inflammatory cytokines in the drive of cytokine storm during SARS-CoV-2 infection.
    J Med Virol. 2023;95:e28751.
    >> Share

  600. TIAN F, Chen Z, Feng Q
    Nirmatrelvir-ritonavir compared with other antiviral drugs for the treatment of COVID-19 patients: A systematic review and meta-analysis.
    J Med Virol. 2023;95:e28732.
    >> Share

  601. SIMADIBRATA DM, Lesmana E, Pratama MIA, Annisa NG, et al
    Gastrointestinal Symptoms of Monkeypox Infection: A systematic review and meta-analysis.
    J Med Virol. 2023;95:e28709.
    >> Share

    March 2023
  602. SCARPA F, Giovanetti M, Azzena I, Locci C, et al
    Genome-based survey of the SARS-CoV-2 BF.7 variant from Asia.
    J Med Virol. 2023 Mar 31. doi: 10.1002/jmv.28714.
    >> Share

  603. LUO G
    Enhancement of SARS-CoV-2 infection and growth by an ACE2-specific monoclonal antibody.
    J Med Virol. 2023 Mar 28. doi: 10.1002/jmv.28711.
    >> Share

  604. ZHENG XQ, Xu QY, Xie L, He Y, et al
    Response and Duration of Serum Anti-SARS-CoV-2 Antibodies Induced by the Third Dose of an Inactivated Vaccine: A Prospective Longitudinal Cohort Study at 21 Serial Time Points over 641 Days.
    J Med Virol. 2023 Mar 25. doi: 10.1002/jmv.28703.
    >> Share

  605. ZHANG Z, Shao S, Liu X, Tong Z, et al
    Effect and safety of mesenchymal stem cells for patients with COVID-19: systematic review and meta-analysis with trial sequential analysis.
    J Med Virol. 2023 Mar 25. doi: 10.1002/jmv.28702.
    >> Share

  606. BARANOVA A, Cao H, Zhang F
    Causal associations and shared genetics between hypertension and COVID-19.
    J Med Virol. 2023 Mar 23. doi: 10.1002/jmv.28698.
    >> Share

  607. ADEN D, Zaheer S, Kumar R, Ranga S, et al
    Monkeypox (Mpox) outbreak during COVID-19 pandemic - Past and the future.
    J Med Virol. 2023 Mar 23. doi: 10.1002/jmv.28701.
    >> Share

  608. MANNAN A, Hoque MN, Noyon SH, Hamidullah Mehedi HM, et al
    SARS-CoV-2 infection alters the gut microbiome in diabetes patients: A cross-sectional study from Bangladesh.
    J Med Virol. 2023 Mar 22. doi: 10.1002/jmv.28691.
    >> Share

  609. CHANG HC, Gau SY
    Colchicine and risk of COVID-19-associated hospitalization.
    J Med Virol. 2023 Mar 22. doi: 10.1002/jmv.28690.
    >> Share

  610. CHEN Z, Huang T, He T, Zha G, et al
    Humoral responses after primary and booster SARS-CoV-2 inactivated vaccination in patients with chronic hepatitis B virus infection: a longitudinal observational study.
    J Med Virol. 2023 Mar 22. doi: 10.1002/jmv.28695.
    >> Share

  611. CHEUNG AKL, Lu Y, Zhu Y, Fung TY, et al
    Consistent neutralization of circulating omicron sub-variants by hybrid immunity up to 6 months after booster vaccination.
    J Med Virol. 2023 Mar 22. doi: 10.1002/jmv.28694.
    >> Share

  612. MAI W, Ren Y, Tian X, Al-Mahdi AY, et al
    Comparison of Common Human Respiratory Pathogens Among Hospitalized Children aged
    J Med Virol. 2023 Mar 22. doi: 10.1002/jmv.28692.
    >> Share

  613. DA SILVA AS, Campos GM, Giovanetti M, Zucherato VS, et al
    VIRAL METAGENOMICS UNVEILS MW (MALAWI) POLYOMAVIRUS INFECTION IN BRAZILIAN PEDIATRIC PATIENTS WITH ACUTE RESPIRATORY DISEASE.
    J Med Virol. 2023 Mar 22. doi: 10.1002/jmv.28688.
    >> Share

  614. MAHROUM N, Elsalti A, Shoenfeld Y
    Commentary: Herpes simplex virus and SLE: though uncommon yet with significant implications.
    J Med Virol. 2023 Mar 22. doi: 10.1002/jmv.28689.
    >> Share

  615. ZHANG Y, Lu M, Thongpan I, Xu J, et al
    Recombinant measles virus expressing prefusion spike protein stabilized by six rather than two prolines is more efficacious against SARS-CoV-2 infection.
    J Med Virol. 2023 Mar 20. doi: 10.1002/jmv.28687.
    >> Share

  616. BOJKOVA D, Bechtel M, Rothenburger T, Kandler JD, et al
    Omicron-induced interferon signalling prevents influenza A H1N1 and H5N1 virus infection.
    J Med Virol. 2023 Mar 20. doi: 10.1002/jmv.28686.
    >> Share

  617. BIANCONI V, Mannarino MR, Cosentini E, Figorilli F, et al
    The impact of statin therapy on in-hospital prognosis and endothelial function of patients at high-to-very high cardiovascular risk admitted for COVID-19: Statins, endothelial function, and COVID-19 outcomes.
    J Med Virol. 2023 Mar 17. doi: 10.1002/jmv.28678.
    >> Share

  618. GARCIA-PEREZ J, Bermejo M, Ramirez-Garcia A, Torre Tarazona HE, et al
    Longer intervals between SARS-CoV-2 infection and mRNA-1273 doses improve the neutralization of different variants of concern.
    J Med Virol. 2023 Mar 17. doi: 10.1002/jmv.28679.
    >> Share

  619. DENG J, Zheng SN, Xiao Y, Nan ML, et al
    SARS-CoV-2 NSP8 suppresses type I and III IFN responses by modulating the RIG-I/MDA5, TRIF, and STING signaling pathways.
    J Med Virol. 2023 Mar 17. doi: 10.1002/jmv.28680.
    >> Share

  620. KWON HJ, Zhang J, Kosikova M, Tang W, et al
    Distinct In Vitro and In Vivo Neutralization Profiles of Monoclonal Antibodies Elicited by the Receptor Binding Domain of the Ancestral SARS-CoV-2.
    J Med Virol. 2023 Mar 14. doi: 10.1002/jmv.28673.
    >> Share

  621. YU D, Zhao ZY, Yang YL, Qin Y, et al
    The origin and evolution of emerged swine acute diarrhea syndrome coronavirus with zoonotic potential.
    J Med Virol. 2023 Mar 14. doi: 10.1002/jmv.28672.
    >> Share

  622. FAN Z, Ruan Z, Liuzhi, Guo B, et al
    Causal association of the brain structure with the susceptibility, hospitalisation, and severity of COVID-19: A large-scale genetic correlation study.
    J Med Virol. 2023 Mar 13. doi: 10.1002/jmv.28651.
    >> Share

  623. KAN Q, Lin X, Li T, Ke X, et al
    A novel mAb broadly neutralizes SARS-CoV-2 VOCs in vitro and in vivo, including the Omicron variants.
    J Med Virol. 2023 Mar 13. doi: 10.1002/jmv.28657.
    >> Share

  624. UYGUR A, Sayili U
    Letter to the Editor: The efficacy of BNT162b2 (Pfizer-BioNTech) and CoronaVac vaccines in patients with cancer.
    J Med Virol. 2023 Mar 11. doi: 10.1002/jmv.28664.
    >> Share

  625. MAZZITELLI M, Trunfio M, Sasset L, Scaglione V, et al
    Risk of hospitalization and sequelae in patients with COVID-19 treated with 3-day early remdesivir vs. controls in the vaccine and Omicron era: a real-life cohort study.
    J Med Virol. 2023 Mar 11. doi: 10.1002/jmv.28660.
    >> Share

  626. GAO L, Gao Y, Han K, Wang Z, et al
    FBXO11 amplifies type I interferon signaling to exert antiviral effects by facilitating the assemble of TRAF3-TBK1-IRF3 complex.
    J Med Virol. 2023 Mar 10. doi: 10.1002/jmv.28655.
    >> Share

  627. JIA T, Wu Y, Liao G, Lei Y, et al
    Stable and durable antibody responses in SARS-recovered donors vaccinated with inactivated SARS-CoV-2 vaccine.
    J Med Virol. 2023 Mar 10. doi: 10.1002/jmv.28662.
    >> Share

  628. KELLER K, Sagoschen I, Konstantinides S, Gori T, et al
    Incidence and risk factors of myocarditis in hospitalized patients with COVID-19.
    J Med Virol. 2023 Mar 9. doi: 10.1002/jmv.28646.
    >> Share

  629. GUO Z, Zhao S, Mok CKP, So RTY, et al
    Comparing the incubation period, serial interval, and infectiousness profile between SARS-CoV-2 Omicron and Delta variants.
    J Med Virol. 2023 Mar 9. doi: 10.1002/jmv.28648.
    >> Share

  630. XIA S, Jiao F, Wang L, Yu X, et al
    SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors.
    J Med Virol. 2023 Mar 8. doi: 10.1002/jmv.28641.
    >> Share

  631. YI X, Wang Y, Li Q, Li X, et al
    Pre-existing immunity to SARS-CoV-2 associates with strong T cell responses induced by inactivated COVID-19 vaccines.
    J Med Virol. 2023 Mar 8. doi: 10.1002/jmv.28642.
    >> Share

  632. CORMA-GOMEZ A, Fernandez-Fuertes M, Vinuela L, Dominguez C, et al
    Reduced neutralizing antibody response to SARS-CoV-2 vaccine booster dose in people living with HIV with severe immunosuppression.
    J Med Virol. 2023 Mar 6. doi: 10.1002/jmv.28602.
    >> Share

  633. LY H
    SARS-CoV-2 infection of kidney tissues in some severe and fatal cases of COVID-19.
    J Med Virol. 2023 Mar 6. doi: 10.1002/jmv.28636.
    >> Share

  634. KUITUNEN I
    No signs of "tripledemic" in Finnish children.
    J Med Virol. 2023 Mar 2. doi: 10.1002/jmv.28631.
    >> Share

  635. WANG W, Qu Y, Wang X, Xiao MZX, et al
    Genetic variety of ORF3a shapes SARS-CoV-2 fitness through modulation of lipid droplet.
    J Med Virol. 2023 Mar 2. doi: 10.1002/jmv.28630.
    >> Share

  636. KIM D, Kim J, An S, Kim M, et al
    In vitro and in vivo suppression of SARS-CoV-2 replication by a modified, short, cell-penetrating peptide targeting the C-terminal domain of the viral spike protein.
    J Med Virol. 2023 Mar 1. doi: 10.1002/jmv.28626.
    >> Share

  637. SAHIN A, Karadag-Oncel E, Buyuksen O, Ekemen-Keles Y, et al
    The diversity in the clinical features of children hospitalized with COVID-19 during the nonvariant, Alpha (B.1.1.7), Delta (B.1.617.2), and Omicron (B.1.1.529) variant periods of SARS CoV-2: Caution for neurological symptoms in Omicron variant.
    J Med Virol. 2023 Mar 1. doi: 10.1002/jmv.28628.
    >> Share

    February 2023
  638. SCARPA F, Sanna D, Azzena I, Casu M, et al
    Genome-based comparison between the recombinant SARS-CoV-2 XBB and its parental lineages.
    J Med Virol. 2023 Feb 28. doi: 10.1002/jmv.28625.
    >> Share

  639. ZHANG J, Yang W, Huang F, Zhang K, et al
    Effectiveness of mRNA and viral-vector vaccines in epidemic period led by different SARS-CoV-2 variants: a systematic review and meta-analysis.
    J Med Virol. 2023 Feb 28. doi: 10.1002/jmv.28623.
    >> Share

  640. HUANG PY, Liu TH, Wu JY, Tsai YW, et al
    Clinical efficacy and safety of molnupiravir for nonhospitalized and hospitalized patients with COVID-19: A systematic review and meta-analysis of randomized control trials.
    J Med Virol. 2023 Feb 27. doi: 10.1002/jmv.28621.
    >> Share

  641. LEE AR, Kweon YC, Lee SM, Park CY, et al
    Human coronavirus 3CL proteases cleave Septins and disrupt Hedgehog signaling, causing ciliary dysfunction.
    J Med Virol. 2023 Feb 24. doi: 10.1002/jmv.28618.
    >> Share

  642. CHEN JM, Gong HY, Chen RX, Liu ST, et al
    Features and significance of the recent enormous COVID-19 epidemic in China.
    J Med Virol. 2023 Feb 24. doi: 10.1002/jmv.28616.
    >> Share

  643. FENG Z, Huo D, Cui S, Lvy B, et al
    Epidemiological features, genomic characteristics, and origin tracing of the COVID-19 outbreaks in Beijing from January to September 2022.
    J Med Virol. 2023 Feb 24. doi: 10.1002/jmv.28613.
    >> Share

  644. CHEN Z, Du R, Cooper L, Achi JG, et al
    Sulforaphane is a reversible covalent inhibitor of 3-chymotrypsin-like protease of SARS-CoV-2.
    J Med Virol. 2023 Feb 24. doi: 10.1002/jmv.28609.
    >> Share

  645. TAKAHASHI K, Saito M, Sekizuka T, Itokawa K, et al
    Emergence of BS.1 and BS.1.1, highly mutated new SARS-CoV-2 Omicron variants.
    J Med Virol. 2023 Feb 24. doi: 10.1002/jmv.28615.
    >> Share

  646. ZHANG S, Ju J, Yang F, Zheng C, et al
    Ocular Tropism of SARS-CoV-2 Infection.
    J Med Virol. 2023 Feb 23. doi: 10.1002/jmv.28594.
    >> Share

  647. JAMAATI H, Karimi S, Ghorbani F, Panahi Y, et al
    Effectiveness of Different Vaccine Platforms in Reducing Mortality and Length of ICU Stay in Severe and Critical Cases of COVID-19 in the Omicron Variant Era: A National Cohort Study in Iran.
    J Med Virol. 2023 Feb 23. doi: 10.1002/jmv.28607.
    >> Share

  648. WANG Y, Shi L, Liu D, Mao Y, et al
    Changes in Epstein-Barr virus infections in the children before and after the COVID-19 pandemic in Zhengzhou, China.
    J Med Virol. 2023 Feb 23. doi: 10.1002/jmv.28597.
    >> Share

  649. BRANDA F, Scarpa F, Ciccozzi M, Maruotti A, et al
    Is a new COVID-19 wave coming from China due to an unknown variant of concern? Keep calm and look at the data.
    J Med Virol. 2023 Feb 23. doi: 10.1002/jmv.28601.
    >> Share

  650. CHEN Y, Xue Y, Yang J
    Gilteritinib: Repurposing of AXL-targeting kinase inhibitors against COVID-19.
    J Med Virol. 2023 Feb 21. doi: 10.1002/jmv.28592.
    >> Share

  651. RECTOR A, Bloemen M, Thijssen M, Delang L, et al
    Monitoring of SARS-CoV-2 concentration and circulation of variants of concern in wastewater of Leuven, Belgium.
    J Med Virol. 2023 Feb 17. doi: 10.1002/jmv.28587.
    >> Share

  652. ZHU Z, Chen X, Wang C, Zhang S, et al
    An integrated strategy to identify COVID-19 causal genes and characteristics represented by LRRC37A2.
    J Med Virol. 2023 Feb 16. doi: 10.1002/jmv.28585.
    >> Share

  653. GERMANO MJ, Giai C, Cargnelutti DE, Colombo MI, et al
    Receptor-binding domain-based SARS-CoV-2 vaccine adjuvanted with cyclic di-adenosine monophosphate enhances humoral and cellular immunity in mice.
    J Med Virol. 2023 Feb 16. doi: 10.1002/jmv.28584.
    >> Share

  654. STICH M, Benning L, Speer C, Garbade SF, et al
    Live-virus neutralization of the omicron variant in children and adults 14 months after SARS-CoV-2 wild-type infection.
    J Med Virol. 2023 Feb 16. doi: 10.1002/jmv.28582.
    >> Share

  655. LIN Z, Sun L, Li L, Jiang S, et al
    Nasal mucosa is much more susceptible than oral mucosa to infection of SARS-CoV-2 Omicron subvariants: wearing nasal masks where facial masks cannot be used.
    J Med Virol. 2023 Feb 13. doi: 10.1002/jmv.28577.
    >> Share

  656. RZYMSKI P, Szuster-Ciesielska A, Dzieciatkowski T, Gwenzi W, et al
    mRNA vaccines: The future of prevention of viral infections?
    J Med Virol. 2023 Feb 10. doi: 10.1002/jmv.28572.
    >> Share

  657. YAO M, Huang X, Guo Y, Zhao JV, et al
    Disentangling the common genetic architecture and causality of rheumatoid arthritis and systemic lupus erythematosus with COVID-19 outcomes: genome-wide cross trait analysis and bi-directional Mendelian randomization study.
    J Med Virol. 2023 Feb 10. doi: 10.1002/jmv.28570.
    >> Share

  658. RADOVIC S, Meng W, Chen L, Paniz Mondolfi AE, et al
    SARS-CoV-2 infection of kidney tissues from severe COVID-19 patients.
    J Med Virol. 2023 Feb 9. doi: 10.1002/jmv.28566.
    >> Share

  659. NICOT F, Tremeaux P, Latour J, Carcenac R, et al
    WHOLE-GENOME SINGLE MOLECULE REAL-TIME SEQUENCING OF SARS-CoV-2 OMICRON.
    J Med Virol. 2023 Feb 9. doi: 10.1002/jmv.28564.
    >> Share

  660. WANG X, Yang Y, Song Z, Wang Y, et al
    Concerns on Bebtelovimab (LY-CoV1404) used to neutralize Omicron subvariants.
    J Med Virol. 2023 Feb 9. doi: 10.1002/jmv.28565.
    >> Share

  661. CRADDOCK V, Mahajan A, Spikes L, Krishnamachary B, et al
    Persistent Circulation of Soluble and Extracellular vesicle-linked Spike Protein in Individuals with Post-Acute Sequelae of COVID-19.
    J Med Virol. 2023 Feb 9. doi: 10.1002/jmv.28568.
    >> Share

  662. ZHANG T, Wang Z, Yang J, Xu X, et al
    Immunogenicity of novel DNA vaccines encoding receptor-binding domain (RBD) dimer-Fc fusing antigens derived from different SARS-CoV-2 variants of concern.
    J Med Virol. 2023 Feb 8. doi: 10.1002/jmv.28563.
    >> Share

  663. DUTTA D, Ghosh A, Dutta C, Sukla S, et al
    Cross reactivity of SARS-CoV-2 with other pathogens, especially dengue virus: A historical perspective.
    J Med Virol. 2023 Feb 8. doi: 10.1002/jmv.28557.
    >> Share

  664. KANG CK, Kim MG, Park SW, Kim YW, et al
    Comparable humoral and cellular immunity against Omicron variant BA.4/5 of once-boosted BA.1/2 convalescents and twice-boosted COVID-19-naive individuals.
    J Med Virol. 2023 Feb 8. doi: 10.1002/jmv.28558.
    >> Share

  665. DENG J, Zheng Y, Zheng SN, Nan ML, et al
    SARS-CoV-2 NSP7 inhibits type I and III IFN production by targeting the RIG-I/MDA5, TRIF, and STING signaling pathways.
    J Med Virol. 2023 Feb 8. doi: 10.1002/jmv.28561.
    >> Share

  666. CHEN J, Cheng X, Xu Y, Shi T, et al
    Analysis on the Physiological Changes of Residents Before and During the COVID-19 Pandemic: A Cross-Sectional Study.
    J Med Virol. 2023 Feb 8. doi: 10.1002/jmv.28562.
    >> Share

  667. TONYALI A, Karacetin G, Yesilkaya C, Arik FNT, et al
    Appearance of extrapyramidal symptoms in adolescent psychiatry patients during Covid-19 infection.
    J Med Virol. 2023 Feb 4. doi: 10.1002/jmv.28556.
    >> Share

  668. GUO Y, Guo Y, Zhang Y, Li F, et al
    Factors Affecting Prolonged SARS-CoV-2 Infection and Development and Validation of Predictive Nomograms.
    J Med Virol. 2023 Feb 3. doi: 10.1002/jmv.28550.
    >> Share

  669. WEI B, Liu Y, Li H, Peng Y, et al
    Impact of alcohol consumption on COVID-19 severity: A systematic review and meta-analysis.
    J Med Virol. 2023 Feb 3. doi: 10.1002/jmv.28547.
    >> Share

  670. AKIF A, Bhuiyan MA, Islam MR
    SARS-COV-2 omicron subvariant BF.7 is again triggering the Covid fear: What we need to know and what we should do?
    J Med Virol. 2023 Feb 3. doi: 10.1002/jmv.28551.
    >> Share

  671. KHAN A, Imran K, Zhu G, Ji J, et al
    Discovery of Isojacareubin as a covalent inhibitor of SARS-CoV-2 main protease using structural and experimental approaches.
    J Med Virol. 2023 Feb 2. doi: 10.1002/jmv.28542.
    >> Share

  672. TORRE-TARAZONA E, Gonzalez-Robles A, Cascajero A, Jimenez P, et al
    Treatment with integrase inhibitors alters SARS-CoV-2 neutralization levels measured with HIV-based pseudotypes in people living with HIV.
    J Med Virol. 2023 Feb 2. doi: 10.1002/jmv.28543.
    >> Share

  673. BAIOCCHI GC, Vojdani A, Rosenberg AZ, Vojdani E, et al
    Cross-sectional analysis reveals autoantibody signatures associated with COVID-19 severity.
    J Med Virol. 2023 Feb 1. doi: 10.1002/jmv.28538.
    >> Share

  674. WANG X, He X, Jiang S, Fu Z, et al
    Limited enhancement of antibody and B-cell responses to prototype booster vaccination following SARS-CoV-2 Delta breakthrough infection.
    J Med Virol. 2023 Feb 1. doi: 10.1002/jmv.28540.
    >> Share

  675. KORSUN N, Trifonova I, Dobrinov V, Madzharova I, et al
    Low prevalence of influenza viruses and predominance of A(H3N2) virus with respect to SARS-CoV-2 during the 2021-2022 season in Bulgaria.
    J Med Virol. 2023;95:e28489.
    >> Share

  676. SKINNER JP, Moran LV
    Persistent effects of COVID-19 in patients hospitalized during the first wave of the pandemic: The impact of persistent fatigue on quality of life in a cross-sectional study.
    J Med Virol. 2023;95:e28491.
    >> Share

  677. KUMARI D, Singh Y, Singh S, Dogra V, et al
    "Mitochondrial pathogenic mutations and metabolic alterations associated with COVID-19 disease severity".
    J Med Virol. 2023;95:e28553.
    >> Share

    January 2023
  678. CHEN Z, Li J, Zheng J, Jin Y, et al
    Emerging Omicron subvariants evade neutralizing immunity elicited by vaccine or BA.1/BA.2 infection.
    J Med Virol. 2023 Jan 31. doi: 10.1002/jmv.28539.
    >> Share

  679. HEYDECKE A, Gullsby K
    Evaluation of the performance of a rapid antigen test (Roche) for COVID-19 diagnosis in an emergency setting in Sweden.
    J Med Virol. 2023 Jan 30. doi: 10.1002/jmv.28537.
    >> Share

  680. QUAN NK, Thien DH, Huy NT
    Detect and suppress future zoonotic-derived outbreaks: A lesson from last two decades.
    J Med Virol. 2023 Jan 30. doi: 10.1002/jmv.28530.
    >> Share

  681. SUN C, Yau V, Uy JPN, Lowe S, et al
    Does viral inoculum play a role in disease severity in COVID-19?
    J Med Virol. 2023 Jan 27. doi: 10.1002/jmv.28532.
    >> Share

  682. WANG J, Yin X, Yu L, Cheng W, et al
    Delayed cutaneous hypersensitivity reactions following the use of infliximab or adalimumab in patients with coronavirus disease 2019.
    J Med Virol. 2023 Jan 26. doi: 10.1002/jmv.28518.
    >> Share

  683. BONGIOVANNI M, Barilaro G, Bini F
    Twelve-month clinical, functional and radiological outcomes in patients hospitalized for SARS-CoV-2 pneumonia.
    J Med Virol. 2023 Jan 25. doi: 10.1002/jmv.28524.
    >> Share

  684. SHIRAZ R, Tripathi S
    Enhanced recombination among omicron subvariants of SARS-CoV-2 contributes to viral immune escape.
    J Med Virol. 2023 Jan 24. doi: 10.1002/jmv.28519.
    >> Share

  685. KIM K, Cho K, Song J, Rahmati M, et al
    The case fatality rate of COVID-19 during the Delta and the Omicron epidemic phase: A meta-analysis.
    J Med Virol. 2023 Jan 24. doi: 10.1002/jmv.28522.
    >> Share

  686. SHEN F, Yang CX, Lu Y, Zhang M, et al
    Significant neutralizing escapes of Omicron and its sub-lineages in SARS-CoV-2-infected individuals vaccinated with inactivated vaccines.
    J Med Virol. 2023 Jan 21. doi: 10.1002/jmv.28516.
    >> Share

  687. ROBERTO P, Cinti L, Napoli A, Paesani D, et al
    Torque teno virus (TTV): a gentle spy virus of immune status, predictive marker of seroconversion to COVID-19 vaccine in kidney and lung transplant recipients.
    J Med Virol. 2023 Jan 20. doi: 10.1002/jmv.28512.
    >> Share

  688. LIAN XY, Xi L, Zhang ZS, Yang LL, et al
    Impact of air pollutants on influenza-like illness outpatient visits under COVID-19 pandemic in the sub-center of Beijing, China.
    J Med Virol. 2023 Jan 20. doi: 10.1002/jmv.28514.
    >> Share

  689. ZHAO Y, Du J, Li Z, Wu Y, et al
    It Is Time to Improve the Acceptance of COVID-19 Vaccines Among People with Chronic Diseases: A Systematic Review and Meta-analysis.
    J Med Virol. 2023 Jan 19. doi: 10.1002/jmv.28509.
    >> Share

  690. HASSEBROEK AM, Sooryanarain H, Lynn Heffron C, Hawks SA, et al
    A hepatitis B virus core antigen-based virus-like particle vaccine expressing SARS-CoV-2 B and T cell epitopes induces epitope-specific humoral and cell-mediated immune responses but confers limited protection against SARS-CoV-2 infection.
    J Med Virol. 2023 Jan 19. doi: 10.1002/jmv.28503.
    >> Share

  691. HARADA KH, Phosri A
    A protocol of trial of ivermectin in COVID-19 treatment critically changed after its completion.
    J Med Virol. 2023 Jan 19. doi: 10.1002/jmv.28505.
    >> Share

  692. MATIC S, Milovanovic D, Mijailovic Z, Djurdjevic P, et al
    IFNL3/4 polymorphisms as a two-edged sword: an association with COVID-19 outcome.
    J Med Virol. 2023 Jan 19. doi: 10.1002/jmv.28506.
    >> Share

  693. ABD-ELSALAM S, Medhat MA, Ramadan HK, Soliman S, et al
    Reply to letter to the editor.
    J Med Virol. 2023 Jan 19. doi: 10.1002/jmv.28502.
    >> Share

  694. PAN J, Yang S, Chen X, Che X, et al
    Two-year impact of COVID-19 pandemic on hospitalized patients with skin diseases in China.
    J Med Virol. 2023 Jan 19. doi: 10.1002/jmv.28511.
    >> Share

  695. ERDIK B
    Covid Associated Immune Dysfunction (CAID) Leading to Increased Pediatric Hospitalizations.
    J Med Virol. 2023 Jan 19. doi: 10.1002/jmv.28508.
    >> Share

  696. QI T, Jin Y, Wang H, Liao Y, et al
    Nirmatrelvir-ritonavir Therapy and COVID-19 Vaccination Improve Clinical Outcomes of SARS-CoV-2 Omicron Variant Infection.
    J Med Virol. 2023 Jan 18. doi: 10.1002/jmv.28497.
    >> Share

  697. MORALES-ORTEGA A, Farfan-Sedano AI, Martin-Lopez JVS, Escriba-Barcena A, et al
    Baricitinib or imatinib in hospitalized COVID-19 patients: results from COVINIB, an exploratory randomized clinical trial.
    J Med Virol. 2023 Jan 13. doi: 10.1002/jmv.28495.
    >> Share

  698. ALDEA MS, Salgado-Barreira A, Trunk MT, Lamas MP, et al
    Colchicine and risk of hospitalisation due to COVID-19: a population-based study.
    J Med Virol. 2023 Jan 13. doi: 10.1002/jmv.28496.
    >> Share

  699. BERBER NK, Geckil AA, Altan NO, Kiran TR, et al
    Efficacy of Serum Apelin and Galectin-3 as Potential Predictors of Mortality in Severe COVID-19 Patients.
    J Med Virol. 2023 Jan 12. doi: 10.1002/jmv.28494.
    >> Share

  700. KIM SH, Baek JY, Han M, Lee M, et al
    A decrease in the incidence of encephalitis in South Korea during the COVID-19 pandemic: A nationwide study between 2010 and 2021.
    J Med Virol. 2023 Jan 11. doi: 10.1002/jmv.28490.
    >> Share

  701. XIONG N, Sun Q
    How does SARS-CoV-2 Infection impact on immunity, procession and treatment of Pan Cancers.
    J Med Virol. 2023 Jan 10. doi: 10.1002/jmv.28487.
    >> Share

  702. YADAV PD, Kumar S, Agarwal K, Jain M, et al
    Needle-free injection system delivery of ZyCoV-D DNA vaccine demonstrated improved immunogenicity and protective efficacy in Rhesus macaques against SARS-CoV-2.
    J Med Virol. 2023 Jan 10. doi: 10.1002/jmv.28484.
    >> Share

  703. WANG M, Huang L
    Letter to the Editor Regarding "Effects of inactivated SARS-CoV-2 vaccination on male fertility: a retrospective cohort study".
    J Med Virol. 2023 Jan 10. doi: 10.1002/jmv.28486.
    >> Share

  704. KRISHNAMOORTHY P, Raj AS, Kumar H
    Machine learning-driven blood transcriptome-based discovery of SARS-CoV-2 specific severity biomarkers.
    J Med Virol. 2023 Jan 10. doi: 10.1002/jmv.28488.
    >> Share

  705. HUANG HC, Wang SH, Fang GC, Chou WC, et al
    Upregulation of PD-L1 by SARS-CoV-2 promotes immune evasion.
    J Med Virol. 2023 Jan 7. doi: 10.1002/jmv.28478.
    >> Share

  706. TENG L, Song X, Zhang M, Han Y, et al
    The pattern of cytokines expression and dynamic changes of renal function at 6 months in patients with Omicron COVID-19.
    J Med Virol. 2023 Jan 7. doi: 10.1002/jmv.28477.
    >> Share

  707. FARIAS JP, Pinheiro JR, Andreata-Santos R, Fogaca MMC, et al
    The third vaccine dose significantly reduces susceptibility to the B.1.1.529 (Omicron) SARS-CoV-2 variant.
    J Med Virol. 2023 Jan 7. doi: 10.1002/jmv.28481.
    >> Share

  708. CHEEMA HA, Jafar U, Sohail A, Shahid A, et al
    Nirmatrelvir-ritonavir for the treatment of COVID-19 patients: a systematic review and meta-analysis.
    J Med Virol. 2023 Jan 6. doi: 10.1002/jmv.28471.
    >> Share

  709. LEI Z, Zhu L, Pan P, Ruan Z, et al
    A vaccine delivery system promotes strong immune responses against SARS-CoV-2 variants.
    J Med Virol. 2023 Jan 6. doi: 10.1002/jmv.28475.
    >> Share

  710. LI X, Yin W, Li A, Li D, et al
    ACE2 PET to Reveal the Dynamic Patterns of ACE2 Recovery in an Infection Model with Pseudo Corona Virus.
    J Med Virol. 2023 Jan 6. doi: 10.1002/jmv.28470.
    >> Share

  711. CHUNG H, Ko H, Lee H, Yon DK, et al
    Development and validation of a deep learning model to diagnose COVID-19 using time-series heart rate values before the onset of symptoms.
    J Med Virol. 2023 Jan 5. doi: 10.1002/jmv.28462.
    >> Share

  712. KWON R, Koo MJ, Lee SW, Choi YS, et al
    National trends in physical activity among adolescents in South Korea before and during the COVID-19 pandemic, 2009-2021.
    J Med Virol. 2023 Jan 5. doi: 10.1002/jmv.28456.
    >> Share

  713. MERZA MA, Almufty HB, Younis HA, Rasool SO, et al
    Memory impairment among recovered COVID-19 patients: the prevalence and risk factors, a retrospective cohort study.
    J Med Virol. 2023 Jan 5. doi: 10.1002/jmv.28459.
    >> Share

  714. VAEZI M, Ravanshad S, Rad MA, Zarrinfar H, et al
    The effect of synbiotic adjunct therapy on clinical and paraclinical outcomes in hospitalized COVID-19 patients: A randomized placebo-controlled trial.
    J Med Virol. 2023 Jan 5. doi: 10.1002/jmv.28463.
    >> Share

  715. KOH LP, Chua SL, Vasoo S, Toh MPHS, et al
    Real-World Effectiveness of Sotrovimab and Remdesivir for Early Treatment of High-Risk Hospitalized COVID-19 Patients - a Propensity Score Adjusted Retrospective Cohort Study.
    J Med Virol. 2023 Jan 5. doi: 10.1002/jmv.28460.
    >> Share

  716. TOWNSEND JP, Hassler HB, Dornburg A
    Infection by SARS-CoV-2 with alternate frequencies of mRNA vaccine boosting.
    J Med Virol. 2023 Jan 5. doi: 10.1002/jmv.28461.
    >> Share

  717. PRADO CAS, Fonseca DLM, Singh Y, Filgueiras IS, et al
    Title: Integrative systems immunology uncovers molecular networks of the cell cycle that stratify COVID-19 severity.
    J Med Virol. 2023 Jan 4. doi: 10.1002/jmv.28450.
    >> Share

  718. LIU X, Du Z, Wang J, Wang Q, et al
    Association between trans fatty acids and COVID-19: a multivariate Mendelian randomization study.
    J Med Virol. 2023 Jan 4. doi: 10.1002/jmv.28455.
    >> Share

  719. KIRAZ A, Sezer O, Alemdar A, Canbek S, et al
    Contribution of genotypes in Prothrombin and Factor V Leiden to COVID-19 and disease severity in patients at high risk for hereditary thrombophilia.
    J Med Virol. 2023 Jan 4. doi: 10.1002/jmv.28457.
    >> Share

  720. BELTRAN DM, Villamil Osorio M, Fonseca SLG, Restrepo S, et al
    PREDICTORS OF SEVERITY IN SEVERE RESPIRATORY INFECTION IN CHILDREN WITH COVID-19 RESPIRATORY INFECTION IN A DEVELOPING COUNTRY.
    J Med Virol. 2023 Jan 3. doi: 10.1002/jmv.28453.
    >> Share

  721. FOCOSI D, Maggi F, Shoham S, Casadevall A, et al
    Discriminating endogenous vaccine-elicited anti-Spike antibody responses from exogenous anti-Spike monoclonal antibodies: The case of Evusheld.
    J Med Virol. 2023;95:e28277.
    >> Share

  722. LAI CJ, Kim D, Kang S, Li K, et al
    Viral codon optimization on SARS-CoV-2 Spike boosts immunity in the development of COVID-19 mRNA vaccines.
    J Med Virol. 2023;95:e29183.
    >> Share

    December 2022
  723. KIM JG, Zhang A, Rauseo AM, Goss CW, et al
    The salivary and nasopharyngeal microbiomes are associated with SARS-CoV-2 infection and disease severity.
    J Med Virol. 2022 Dec 30. doi: 10.1002/jmv.28445.
    >> Share

  724. LUO J, Zhang J, Tang HT, Wong HK, et al
    Weekly Symptom Profiles of Non-hospitalized Individuals Infected with SARS-CoV-2 During the Omicron Outbreak in Hong Kong: A Retrospective Observational Study from a Telemedicine Centre.
    J Med Virol. 2022 Dec 30. doi: 10.1002/jmv.28447.
    >> Share

  725. WANG Y, Zhao D, Liu X, Chen X, et al
    Early administration of Paxlovid reduces the viral elimination time in patients infected with SARS-CoV-2 omicron variants.
    J Med Virol. 2022 Dec 29. doi: 10.1002/jmv.28443.
    >> Share

  726. ACOSTA N, Bautista MA, Waddell BJ, Du K, et al
    Surveillance for SARS-CoV-2 and its variants in wastewater of tertiary care hospitals correlates with increasing case burden and outbreaks.
    J Med Virol. 2022 Dec 29. doi: 10.1002/jmv.28442.
    >> Share

  727. HOFFMANN AT, da Silva MS, Gularte JS, Pasqualotto AC, et al
    Dynamics of nosocomial SARS-CoV-2 transmissions: facing the challenge of variants of concern in a Brazilian reference hospital.
    J Med Virol. 2022 Dec 29. doi: 10.1002/jmv.28446.
    >> Share

  728. HUANG J, Yang X, Ren L, Jiang W, et al
    A novel, ultrafast, ultrasensitive diagnosis platform for the detection of SARS-COV-2 using restriction endonuclease-mediated reverse transcription multiple cross displacement amplification.
    J Med Virol. 2022 Dec 29. doi: 10.1002/jmv.28444.
    >> Share

  729. AMANI B, Amani B
    Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID-19 : a rapid review and meta-analysis.
    J Med Virol. 2022 Dec 28. doi: 10.1002/jmv.28441.
    >> Share

  730. LI S, Wu J, Jiang W, He H, et al
    Characterization of cross-reactive monoclonal antibodies against SARS-CoV-1 and SARS-CoV-2: implication for rational design and development of pan-sarbecovirus vaccines and neutralizing antibodies.
    J Med Virol. 2022 Dec 27. doi: 10.1002/jmv.28440.
    >> Share

  731. ZHANG GF, Meng W, Chen L, Ding L, et al
    Infectivity of pseudotyped SARS-CoV-2 variants of concern in different human cell types and inhibitory effects of recombinant spike protein and entry-related cellular factors.
    J Med Virol. 2022 Dec 27. doi: 10.1002/jmv.28437.
    >> Share

  732. LI T, Li X, Chen N, Yang J, et al
    Influence of the COVID-19 Pandemic on the Vitamin D Status of Children: A Cross-Sectional Study.
    J Med Virol. 2022 Dec 27. doi: 10.1002/jmv.28438.
    >> Share

  733. ZARUR-TORRALVO S, Stand-Nino I, Florez-Garcia V, Mendoza H, et al
    Viruses Responsible for Acute Respiratory Infections Before (2016-2019) and During (2021) Circulation of the SARS-CoV-2 virus in Pediatric Patients in a Reference Center at Barranquilla Colombia: A Pattern Analysis.
    J Med Virol. 2022 Dec 27. doi: 10.1002/jmv.28439.
    >> Share

  734. MACHADO TL, Santos AC, Azamor T, Vieira da Silva AM, et al
    CLEC5A expression can be triggered by spike glycoprotein and may be a potential target for COVID-19 therapy.
    J Med Virol. 2022 Dec 26. doi: 10.1002/jmv.28427.
    >> Share

  735. LAI CC, Hsueh PR
    Coronavirus disease 2019 rebounds following nirmatrelvir/ritonavir treatment.
    J Med Virol. 2022 Dec 26. doi: 10.1002/jmv.28430.
    >> Share

  736. BARANOVA A, Cao H, Teng S, Su KP, et al
    Shared genetics and causal associations between COVID-19 and multiple sclerosis.
    J Med Virol. 2022 Dec 26. doi: 10.1002/jmv.28431.
    >> Share

  737. ZHAN H, Gao H, Liu Y, Zhang X, et al
    Booster shot of inactivated SARS-CoV-2 vaccine induces potent immune responses in people living with HIV.
    J Med Virol. 2022 Dec 26. doi: 10.1002/jmv.28428.
    >> Share

  738. LI H, Cai D, Jiang D, Li X, et al
    Risk of waning humoral responses after inactivated or subunit recombinant SARS-CoV-2 vaccination in patients with chronic diseases: Findings from a prospective observational study in China.
    J Med Virol. 2022 Dec 26. doi: 10.1002/jmv.28434.
    >> Share

  739. ZHAO Y, Zhao Y, Ai A, Jin L, et al
    Association of inactivated COVID-19 vaccination with in vitro fertilization and early pregnancy outcomes.
    J Med Virol. 2022 Dec 26. doi: 10.1002/jmv.28432.
    >> Share

  740. LAI CC, Hsu CK, Hsueh SC, Yen MY, et al
    Multisystem inflammatory syndrome in adults: Characteristics, treatment, and outcomes.
    J Med Virol. 2022 Dec 26. doi: 10.1002/jmv.28426.
    >> Share

  741. RUSSELL SL, Klaver BRA, Harrigan SP, Kamelian K, et al
    Clinical severity of Omicron sub-variants BA.1, BA.2 and BA.5 in a population-based cohort study in British Columbia, Canada.
    J Med Virol. 2022 Dec 22. doi: 10.1002/jmv.28423.
    >> Share

  742. MAHALINGAM G, Periyasami Y, Arjunan P, Subaschandrabose RK, et al
    Omicron infection increases IgG binding to spike protein of predecessor variants.
    J Med Virol. 2022 Dec 22. doi: 10.1002/jmv.28419.
    >> Share

  743. WANG Y, Chen X, Liu X, Zhao D, et al
    Nirmatrelvir-ritonavir might only be effective in elderly patients.
    J Med Virol. 2022 Dec 21. doi: 10.1002/jmv.28418.
    >> Share

  744. BANERJEE A, Mazumder A, Roy J, Das J, et al
    Emergence of a unique SARS-CoV-2 Delta sub-cluster harboring a constellation of co-appearing non-Spike mutations.
    J Med Virol. 2022 Dec 21. doi: 10.1002/jmv.28413.
    >> Share

  745. FOURIE E, Sijm YE, Badoux P, Merelle ME, et al
    High Detection Rate of Viral Pathogens in Nasal Discharge in Children Aged 0 till 5 Years.
    J Med Virol. 2022 Dec 21. doi: 10.1002/jmv.28415.
    >> Share

  746. PRAKASHAN D, Shrikrishna NS, Byakodi M, Nagamani K, et al
    Gold nanoparticle conjugate-based lateral flow immunoassay (LFIA) for rapid detection of RBD antigen of SARS CoV-2 in clinical samples using smartphone-based application.
    J Med Virol. 2022 Dec 21. doi: 10.1002/jmv.28416.
    >> Share

  747. ALZAHRANI MM, Bamashmous S, Alkharobi H, Alghamdi A, et al
    Mouth Rinses Efficacy on Salivary SARS-CoV-2 Viral Load: A Randomized Clinical Trial.
    J Med Virol. 2022 Dec 17. doi: 10.1002/jmv.28412.
    >> Share

  748. JIANG ML, Xu YP, Wu H, Zhu RN, et al
    Changes in endemic patterns of respiratory syncytial virus infection in pediatric patients under the pressure of nonpharmaceutical interventions for COVID-19 in Beijing, China.
    J Med Virol. 2022 Dec 16. doi: 10.1002/jmv.28411.
    >> Share

  749. WANG Q, Ye SB, Zhou ZJ, Song AL, et al
    Key mutations in the spike protein of SARS-CoV-2 affecting neutralization resistance and viral internalization.
    J Med Virol. 2022 Dec 15. doi: 10.1002/jmv.28407.
    >> Share

  750. ZHOU C, Wu A, Ye S, Zhou Z, et al
    Possible transmission of COVID-19 epidemic by a dog as a passive mechanical carrier of SARS-CoV-2, Chongqing, China, 2022.
    J Med Virol. 2022 Dec 15. doi: 10.1002/jmv.28408.
    >> Share

  751. LI X, Li T, Chen N, Wang X, et al
    Influence of COVID-19 pandemic on inhaled allergens in children with allergic diseases, Henan, China.
    J Med Virol. 2022 Dec 15. doi: 10.1002/jmv.28409.
    >> Share

  752. ABEYWARDHANA S, Bandaranayake U, Perera DB, Premathilaka M, et al
    In silico study of SARS-CoV-2 Spike protein RBD and human ACE-2 affinity dynamics across variants and Omicron sub-variants.
    J Med Virol. 2022 Dec 15. doi: 10.1002/jmv.28406.
    >> Share

  753. VIETZEN H, Furlano PL, Traugott M, Totschnig D, et al
    The Natural Killer cell-associated rs9916629-C allele is a novel genetic risk factor for fatal COVID-19.
    J Med Virol. 2022 Dec 14. doi: 10.1002/jmv.28404.
    >> Share

  754. AKRAMI S, Montazeri EA, Saki M, Neisi N, et al
    Bacterial profiles and their antibiotic resistance background in superinfections caused by multidrug-resistant bacteria among COVID-19 ICU patients from southwest Iran.
    J Med Virol. 2022 Dec 14. doi: 10.1002/jmv.28403.
    >> Share

  755. HAYES LJ, Uri H, Bojkova D, Cinatl J Jr, et al
    Impact of the COVID-19 pandemic on the circulation of other pathogens in England.
    J Med Virol. 2022 Dec 13. doi: 10.1002/jmv.28401.
    >> Share

  756. CAMACHO J, Albert E, Zulaica J, Alvarez-Rodriguez B, et al
    A Performance Comparison of two (Electro) chemiluminescence Immunoassays for Detection and Quantitation of Serum Anti-Spike Antibodies According to SARS-CoV-2 Vaccination and Infections Status.
    J Med Virol. 2022 Dec 12. doi: 10.1002/jmv.28397.
    >> Share

  757. PANAHI Y, Ghanei M, Rahimi M, Samim A, et al
    Evaluation the efficacy and safety of N-acetylcysteine inhalation spray in controlling the symptoms of patients with COVID-19: An open-label randomized controlled clinical trial.
    J Med Virol. 2022 Dec 10. doi: 10.1002/jmv.28393.
    >> Share

  758. GOEL A, Ray A, Chavan A, Sahni S, et al
    A study on the morbid Histopathological changes in COVID-19 patients with or without comorbidities using minimally invasive tissue sampling.
    J Med Virol. 2022 Dec 8. doi: 10.1002/jmv.28384.
    >> Share

  759. YANG Q, Tang J, Cao J, Liu F, et al
    SARS-CoV-2 infection activates CREB/CBP in cellular cyclic AMP-dependent pathways.
    J Med Virol. 2022 Dec 8. doi: 10.1002/jmv.28383.
    >> Share

  760. YAN Q, Zheng W, Jiang Y, Zhou P, et al
    Transcriptomic reveals the ferroptosis features of host response in a mouse model of Zika virus infection.
    J Med Virol. 2022 Dec 8. doi: 10.1002/jmv.28386.
    >> Share

  761. RIZZO A, Foschi A, Bracchitta F, Faggion I, et al
    Persistent detection and sequencing of SARS-CoV-2 in the bloodstream of an immunocompromised patient.
    J Med Virol. 2022 Dec 7. doi: 10.1002/jmv.28381.
    >> Share

  762. LI M, Hao J, Jiang T, Deng W, et al
    Maternal and neonatal safety of COVID-19 vaccination during peri-pregnancy period: a prospective study.
    J Med Virol. 2022 Dec 7. doi: 10.1002/jmv.28378.
    >> Share

  763. WANG H, Gan M, Wu B, Zeng R, et al
    Humoral and cellular immunity of two-dose inactivated COVID-19 vaccination in Chinese children: a prospective cohort study.
    J Med Virol. 2022 Dec 7. doi: 10.1002/jmv.28380.
    >> Share

  764. LIN-WANG HT, Damiani LP, Farias EDS, Bajgelman MC, et al
    Longitudinal study comparing IgG antibodies induced by heterologous prime-boost COVID-19 vaccine.
    J Med Virol. 2022 Dec 7. doi: 10.1002/jmv.28379.
    >> Share

  765. ZHENG Z, Lu Y, Wang M, Luo Y, et al
    Low COVID-19 Vaccine Coverage and Guardian Acceptance Among Pediatric Transplant Recipients.
    J Med Virol. 2022 Dec 7. doi: 10.1002/jmv.28377.
    >> Share

  766. SCHULTHEISS C, Willscher E, Paschold L, Gottschick C, et al
    Liquid biomarkers of macrophage dysregulation and circulating spike protein illustrate the biological heterogeneity in patients with post-acute sequelae of COVID-19.
    J Med Virol. 2022 Dec 2. doi: 10.1002/jmv.28364.
    >> Share

  767. KANG SW, Kim JY, Park H, Lim SY, et al
    Comparison of Secondary Attack Rate and Viable Virus Shedding between Patients with SARS-CoV-2 Delta and Omicron Variants: A Prospective Cohort Study.
    J Med Virol. 2022 Dec 2. doi: 10.1002/jmv.28369.
    >> Share

  768. SHEN KY, Yang CH, Chen CT, Ho HM, et al
    Omicron-specific mRNA vaccine induced cross-protective immunity against ancestral SARS-CoV-2 infection with low neutralizing antibodies.
    J Med Virol. 2022 Dec 2. doi: 10.1002/jmv.28370.
    >> Share

  769. VIRSEDA-BERDICES A, Concostrina-Martinez L, Martinez-Gonzalez O, Blancas R, et al
    RELATIVE TELOMERE LENGTH IMPACT ON MORTALITY OF COVID-19: SEX DIFFERENCES.
    J Med Virol. 2022 Dec 2. doi: 10.1002/jmv.28368.
    >> Share

  770. WOLF JM, Wolf LM, Bello GL, Maccari JG, et al
    Molecular evolution of SARS-CoV-2 from December 2019 to August 2022.
    J Med Virol. 2022 Dec 2. doi: 10.1002/jmv.28366.
    >> Share

  771. LI J, Zheng J, Chen P, Wang B, et al
    Higher SARS-CoV-2 shedding in exhaled aerosol probably contributed to the enhanced transmissibility of Omicron BA.5 subvariant.
    J Med Virol. 2022 Dec 2. doi: 10.1002/jmv.28365.
    >> Share

  772. PARKER M, Sawant HB, Flannery T, Tarrant R, et al
    Effect of using a structured pacing protocol on post-exertional symptom exacerbation and health status in a longitudinal cohort with the post-COVID-19 syndrome.
    J Med Virol. 2022 Dec 2. doi: 10.1002/jmv.28373.
    >> Share

  773. MOKHTARI MB, Samaniego V, Mokhtari MB, Ishak A, et al
    Relationship of Prior COVID-19 infection and Side Effects of Pfizer-BioNTech Vaccine: Results from a Community Hospital.
    J Med Virol. 2022 Dec 2. doi: 10.1002/jmv.28374.
    >> Share

    November 2022
  774. FATMA B, Yohan N, Domitille C, Anne-Laure L, et al
    Early Plasma Interferon-beta Levels as a Predictive Marker of COVID-19 Severe Clinical Events in Adult Patients.
    J Med Virol. 2022 Nov 30. doi: 10.1002/jmv.28361.
    >> Share

  775. LUO D, Li T, Yang X, Ning N, et al
    The immunodominance of RBD antigen of delta variant as vaccine candidate against SARS-CoV-2 infection.
    J Med Virol. 2022 Nov 29. doi: 10.1002/jmv.28359.
    >> Share

  776. MIHAYLOVA A, Lesichkova S, Baleva M, Nikolova-Vlahova M, et al
    DURABILITY OF HUMORAL AND CELL-MEDIATED IMMUNE RESPONSE AFTER SARS-CoV-2 mRNA VACCINE ADMINISTRATION.
    J Med Virol. 2022 Nov 29. doi: 10.1002/jmv.28360.
    >> Share

  777. PARK SH, Hong SH, Kim K, Lee SW, et al
    Non-Pharmaceutical Interventions Reduce the Incidence, and Mortality of COVID-19: A Study based on the Survey from the International COVID-19 Research Network (ICRN).
    J Med Virol. 2022 Nov 29. doi: 10.1002/jmv.28354.
    >> Share

  778. PAN Y, Wang S, Liu G, Wang L, et al
    The third inactivated vaccine booster dramatically enhanced SARS-CoV-2 antibody responses and did not influence the profile of prothrombotic antibody.
    J Med Virol. 2022 Nov 28. doi: 10.1002/jmv.28356.
    >> Share

  779. GHOLAMI M, Zoughi M, Hasanzad M, Larijani B, et al
    Haplotypic variants of COVID-19 related genes are associated with blood pressure and metabolites levels.
    J Med Virol. 2022 Nov 28. doi: 10.1002/jmv.28355.
    >> Share

  780. DU M, Wang R, Yuan J, Lv X, et al
    Trends and disparities in 44 national notifiable infectious diseases in China: an analysis of national surveillance data from 2010 to 2019.
    J Med Virol. 2022 Nov 28. doi: 10.1002/jmv.28353.
    >> Share

  781. YAN H, Zhang R, Yan G, Liu Z, et al
    Production of a versatile SARS-CoV-2 main protease biosensor based on a dimerization-dependent red fluorescent protein.
    J Med Virol. 2022 Nov 24. doi: 10.1002/jmv.28342.
    >> Share

  782. LI K, Shi J, Liu X, Ward MP, et al
    Early warning signals for Omicron outbreaks in China: a retrospective study.
    J Med Virol. 2022 Nov 24. doi: 10.1002/jmv.28341.
    >> Share

  783. JIA C, Zhou Z, Pan W, Zhang P, et al
    Immune Repertoire Sequencing Reveals an Abnormal Adaptive Immune System in COVID-19 Survivors.
    J Med Virol. 2022 Nov 24. doi: 10.1002/jmv.28340.
    >> Share

  784. LIN YF, Wu X, Li Y, Bian J, et al
    Impact of combination preventative interventions on hospitalization and death under the pandemic of SARS-CoV-2 Omicron variant in China.
    J Med Virol. 2022 Nov 23. doi: 10.1002/jmv.28335.
    >> Share

  785. DONG Y, Li X, Li Z, Zhu Y, et al
    Effects of inactivated SARS-CoV-2 vaccination on male fertility: a retrospective cohort study.
    J Med Virol. 2022 Nov 22. doi: 10.1002/jmv.28329.
    >> Share

  786. TAKAKURA K, Suka M, Kajihara M, Koido S, et al
    Clinical features, therapeutic outcomes and recovery period of long COVID.
    J Med Virol. 2022 Nov 22. doi: 10.1002/jmv.28316.
    >> Share

  787. ONG CP, Ye ZW, Tang K, Liang R, et al
    Comparative analysis of SARS-CoV-2 Omicron BA.2.12.1 and BA.5.2 variants.
    J Med Virol. 2022 Nov 21. doi: 10.1002/jmv.28326.
    >> Share

  788. RAHMATI M, Koyanagi A, Banitalebi E, Yon DK, et al
    The effect of SARS-CoV-2 infection on cardiac function in post-COVID-19 survivors: A systematic review and meta-analysis.
    J Med Virol. 2022 Nov 18. doi: 10.1002/jmv.28325.
    >> Share

  789. GAO W, Li Z, Guan Q, Cui W, et al
    Characterisation and analysis of linear epitopes corresponding to SARS-CoV-2 outbreak in Jilin Province, China.
    J Med Virol. 2022 Nov 18. doi: 10.1002/jmv.28323.
    >> Share

  790. DOBROVOLNA M, Brazda V, Warner EF, Bidula S, et al
    Inverted repeats in the monkeypox virus genome are hot spots for mutation.
    J Med Virol. 2022 Nov 18:e28322. doi: 10.1002/jmv.28322.
    >> Share

  791. CHAN CC, Liaw YP
    Letter to the Editor Regarding "The clinical and bioinformatics analysis for the role of antihypertension drugs on mortality among patients with hypertension hospitalized with COVID-19".
    J Med Virol. 2022 Nov 17. doi: 10.1002/jmv.28319.
    >> Share

  792. SMITH H, Mahon A, Moss A, Rao S, et al
    SARS-CoV-2 Infection in Children Evaluated in an Ambulatory Setting During Delta and Omicron Time Periods.
    J Med Virol. 2022 Nov 17. doi: 10.1002/jmv.28318.
    >> Share

  793. ALI AM, Tofiq AM, Rostam HM, Ali KM, et al
    Reply to Letter to the Editor on disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers.
    J Med Virol. 2022 Nov 15. doi: 10.1002/jmv.28313.
    >> Share

  794. SCHLESINGER M, McDonald C, Ahuja A, Canete CA, et al
    GLUCOSE AND MANNOSE ANALOGS INHIBIT KSHV REPLICATION BY BLOCKING N-GLYCOSYLATION AND INDUCING THE UNFOLDED PROTEIN RESPONSE.
    J Med Virol. 2022 Nov 15. doi: 10.1002/jmv.28314.
    >> Share

  795. LIN L, Deng J, Li J, Zheng L, et al
    Pathogenesis and histological changes of nephropathy associated with COVID-19.
    J Med Virol. 2022 Nov 15. doi: 10.1002/jmv.28311.
    >> Share

  796. LOU M, Huang D, Zhou Z, Shi X, et al
    DNA virus oncoprotein HPV18 E7 selectively antagonizes cGAS-STING-triggered innate immune activation.
    J Med Virol. 2022 Nov 15. doi: 10.1002/jmv.28310.
    >> Share

  797. ERGOREN MC, Akan G, Volkan E, Kandemis E, et al
    The "vaccine" hubbub: Viral load comparisons of SARS-CoV-2 Delta and Omicron variants against different vaccine-booster vaccine combinations.
    J Med Virol. 2022 Nov 14. doi: 10.1002/jmv.28309.
    >> Share

  798. ABORODE AT, Huang H, Awuah WA, Mehta A, et al
    Approaching COVID-19 with epidemiological genomic surveillance and the sustainability of biodiversity informatics in Africa.
    J Med Virol. 2022 Nov 13. doi: 10.1002/jmv.28308.
    >> Share

  799. CHEN J, Li F, Tian J, Xie X, et al
    Varicella Zoster Virus Reactivation Following COVID-19 Vaccination in patients with autoimmune inflammatory rheumatic diseases: A cross-sectional Chinese study of 318 cases.
    J Med Virol. 2022 Nov 13. doi: 10.1002/jmv.28307.
    >> Share

  800. REUSCH J, Wagenhauser I, Gabel A, Eggestein A, et al
    Influencing factors of anti-SARS-CoV-2-spike-IgG antibody titers in healthcare workers: A cross-section study.
    J Med Virol. 2022 Nov 11:e28300. doi: 10.1002/jmv.28300.
    >> Share

  801. CHIRUMBOLO S
    The widest use of paracetamol in home therapy might have actually increased the occurrence of severe forms of COVID-19 in Italy, affecting hospitalization and death rates.
    J Med Virol. 2022 Nov 11:e28301. doi: 10.1002/jmv.28301.
    >> Share

  802. YANG Y, Xing H, Zhao Y
    Transplacental transmission of SARS-CoV-2 immunoglobulin G antibody to infants from maternal COVID-19 vaccine immunization before pregnancy.
    J Med Virol. 2022 Nov 11:e28296. doi: 10.1002/jmv.28296.
    >> Share

  803. RAHMATI M, Fatemi R, Yon DK, Lee SW, et al
    The effect of adherence to high-quality dietary pattern on COVID-19 outcomes: A systematic review and meta-analysis.
    J Med Virol. 2022 Nov 11:e28298. doi: 10.1002/jmv.28298.
    >> Share

  804. YE Q, Liu H, Mao J, Shu Q, et al
    Nonpharmaceutical interventions for COVID-19 disrupt the dynamic balance between influenza A virus and human immunity.
    J Med Virol. 2022 Nov 11. doi: 10.1002/jmv.28292.
    >> Share

  805. MOYO E, Moyo P, Mashe T, Dzobo M, et al
    Implementation of Public Health Genomics in Africa: Lessons from the COVID-19 pandemic, challenges, and recommendations.
    J Med Virol. 2022 Nov 11:e28295. doi: 10.1002/jmv.28295.
    >> Share

  806. HAN K, Wang J, Zou Y, Zhang Y, et al
    Association between emphysema and other pulmonary computed tomography patterns in COVID-19 pneumonia.
    J Med Virol. 2022 Nov 10:e28293. doi: 10.1002/jmv.28293.
    >> Share

  807. CHEE YJ, Fan BE, Young BE, Dalan R, et al
    Clinical trials on the pharmacological treatment of long COVID: a systematic review.
    J Med Virol. 2022 Nov 8. doi: 10.1002/jmv.28289.
    >> Share

  808. QIU S, Xu D, Dai J, Zhang L, et al
    Improving the efficiency and biosafety of respiratory syncytial virus identification using a nucleic acid extraction-free reagent.
    J Med Virol. 2022 Nov 7. doi: 10.1002/jmv.28287.
    >> Share

  809. BLANCO S, Aguilar JJ, Spinsanti L, Diaz A, et al
    Neutralization of B.1.617.2 variant through antibodies elicited by ChAdOx1-S, BBIBP-CorV and Gam-COVID-Vac in an Argentinean cohort.
    J Med Virol. 2022 Nov 7. doi: 10.1002/jmv.28286.
    >> Share


  810. Zhu, C, He, G, Yin, Q, et al. Molecular biology of the SARs-CoV-2 spike protein: A review of current knowledge. J Med Virol. 2021;93: 5729- 5741.
    J Med Virol. 2022 Nov 4. doi: 10.1002/jmv.28282.
    >> Share

  811. CAMACHO J, Gimenez E, Albert E, Zulaica J, et al
    Cumulative incidence of SARS-CoV-2 infection in the general population of the Valencian Community (Spain) after the surge of the Omicron BA.1 variant.
    J Med Virol. 2022 Nov 4:e28284. doi: 10.1002/jmv.28284.
    >> Share

  812. ZHAO L, Li Y, Yi W, Yan K, et al
    Reply to Chan, et al.
    J Med Virol. 2022 Nov 4. doi: 10.1002/jmv.28283.
    >> Share

  813. LIU C, Zhang J, Zeng Y, Huang C, et al
    Effectiveness of SARS-CoV-2 inactivated vaccine and the correlation to neutralizing antibodies: a test-negative case-control study.
    J Med Virol. 2022 Nov 3. doi: 10.1002/jmv.28280.
    >> Share

  814. LI X, Yin Y, Cui Q, Huang W, et al
    Long-term variations and potency of neutralizing antibodies against Omicron subvariants after CoronaVac inactivated booster: a 7-month follow-up study.
    J Med Virol. 2022 Nov 3. doi: 10.1002/jmv.28279.
    >> Share

  815. HE ST, Qin H, Guan L, Liu K, et al
    Bovine lactoferrin inhibits SARS-CoV-2 and SARS-CoV-1 by targeting the RdRp complex and alleviates viral infection in the hamster model.
    J Med Virol. 2022 Nov 3. doi: 10.1002/jmv.28281.
    >> Share

  816. FURUSE Y
    Cartography of SARS-CoV-2 variants based on the susceptibility to therapeutic monoclonal antibodies.
    J Med Virol. 2022 Nov 3. doi: 10.1002/jmv.28275.
    >> Share

  817. SHMUELIAN Z, Warszawer Y, Or O, Arbel-Alon S, et al
    Post-exposure-vaccine-prophylaxis against COVID-19.
    J Med Virol. 2022 Nov 2. doi: 10.1002/jmv.28274.
    >> Share

  818. HALLMANN E, Sikora D, Poniedzialek B, Szymanski K, et al
    IgG autoantibodies against ACE2 in SARS-CoV-2 infected patients.
    J Med Virol. 2022 Nov 2. doi: 10.1002/jmv.28273.
    >> Share

  819. ROSENBAUER J, Stahl-Pehe A, Schlesinger S, Kuss O, et al
    Comments on Rahmati et al., The global impact of COVID-19 pandemic on the incidence of pediatric new-onset type 1 diabetes and ketoacidosis: A systematic review and meta-analysis. J Med Virol. 2022; 1-16 (doi: 10.1002/jmv.27996).
    J Med Virol. 2022 Nov 2. doi: 10.1002/jmv.28272.
    >> Share

  820. LUCZKOWIAK J, Rivas G, Labiod N, Lasala F, et al
    Cross Neutralization of SARS-CoV-2 Omicron Subvariants after repeated doses of COVID-19 mRNA vaccines.
    J Med Virol. 2022 Nov 1. doi: 10.1002/jmv.28268.
    >> Share

  821. WEI Z, Jiang Y, Zhao G, Li C, et al
    Irradiation accelerates SARS-CoV-2 infection by enhancing sphingolipid metabolism.
    J Med Virol. 2022 Nov 1. doi: 10.1002/jmv.28266.
    >> Share

    October 2022
  822. BARANOVA A, Cao H, Teng S, Zhang F, et al
    A phenome-wide investigation of risk factors for severe COVID-19.
    J Med Virol. 2022 Oct 31. doi: 10.1002/jmv.28264.
    >> Share

  823. HUANG J, Fang Z, Huang L, Fan L, et al
    Effect of COVID-19 vaccination on semen parameters: a systematic review and meta-analysis.
    J Med Virol. 2022 Oct 30. doi: 10.1002/jmv.28263.
    >> Share


  824. Corrigendum.
    J Med Virol. 2022 Oct 29. doi: 10.1002/jmv.28261.
    >> Share

  825. ZHOU Y, Li GX, Zhao TS, Du J, et al
    Parents' willingness to vaccinate themselves and their children with the booster vaccine against SARS-CoV-2: a cross-sectional study in Puyang city, China.
    J Med Virol. 2022 Oct 28. doi: 10.1002/jmv.28256.
    >> Share

  826. ROUERS A, Wong N, Goh YS, Torres-Ruesta A, et al
    Efficient recall of SARS-CoV-2 variant-reactive B cells and T responses in the elderly upon heterologous mRNA vaccines as boosters.
    J Med Virol. 2022 Oct 27. doi: 10.1002/jmv.28258.
    >> Share

  827. MENG W, Guo S, Cao S, Shuda M, et al
    Development and Characterization of a New Monoclonal Antibody against SARS-CoV-2 NSP12.
    J Med Virol. 2022 Oct 21. doi: 10.1002/jmv.28246.
    >> Share

  828. GUO Z, Zhao S, Sun S, He D, et al
    Estimation of the serial interval of monkeypox during the early outbreak in 2022.
    J Med Virol. 2022 Oct 21. doi: 10.1002/jmv.28248.
    >> Share

  829. SHARMA D, Notarte KI, Fernandez RA, Lippi G, et al
    In silico evaluation of the impact of Omicron variant of concern sublineage BA.4 and BA.5 on the sensitivity of RT-qPCR assays for SARS-CoV-2 detection using whole genome sequencing.
    J Med Virol. 2022 Oct 19. doi: 10.1002/jmv.28241.
    >> Share

  830. ZHAO Y, Zhao Y, Zhang Y, Li M, et al
    Association of COVID-19 vaccination before conception with maternal thyroid function during early pregnancy: a single-center study in China.
    J Med Virol. 2022 Oct 19. doi: 10.1002/jmv.28245.
    >> Share

  831. BE S, Celikbilek A, Y K, B I, et al
    Neurological symptoms and neuronal damage markers in acute COVID 19: is there a correlation? A pilot study.
    J Med Virol. 2022 Oct 19. doi: 10.1002/jmv.28240.
    >> Share

  832. HE L, Zhong J, Li G, Lin Z, et al
    Development of SARS-CoV-2 animal vaccines using a stable and efficient NDV expression system.
    J Med Virol. 2022 Oct 18. doi: 10.1002/jmv.28237.
    >> Share

  833. AL-EMRAN HM, Shaminur Rahman M, Hasan MS, Alam ASMRU, et al
    Microbiome analysis revealing microbial interactions and secondary bacterial infections in COVID-19 patients co-morbidly affected by type 2 diabetes.
    J Med Virol. 2022 Oct 18. doi: 10.1002/jmv.28234.
    >> Share

  834. RAMIREZ-VELEZ R, Olabarrieta-Landa L, Rivera D, Izquierdo M, et al
    Factor Structure of the 10-item CES-D Scale Among Patients with Persistent COVID-19.
    J Med Virol. 2022 Oct 18. doi: 10.1002/jmv.28236.
    >> Share

  835. GELENER P, Demirtas E
    Autoimmune seronegative limbic encephalitis following ChAdOx1-S/nCoV-19 vaccination in a patient with ankylosing spondylitis.
    J Med Virol. 2022 Oct 18. doi: 10.1002/jmv.28235.
    >> Share

  836. ERDIK B
    Antiviral Treatment of COVID-19 is associated with lack of immune response.
    J Med Virol. 2022 Oct 18. doi: 10.1002/jmv.28233.
    >> Share

  837. HORITA N, Fukumoto T
    Global case fatality rate from COVID-19 has decreased by 96.8% during 2.5 years of the pandemic.
    J Med Virol. 2022 Oct 17. doi: 10.1002/jmv.28231.
    >> Share

  838. FISH CS, Owiti P, Begnel ER, Itell HL, et al
    Comparison of nucleocapsid and spike antibody ELISAs for determining SARS-CoV-2 seropositivity in Kenyan women and infants.
    J Med Virol. 2022 Oct 17. doi: 10.1002/jmv.28221.
    >> Share

  839. WU F, Yuan Y, Li Y, Yin D, et al
    The acceptance of SARS-CoV-2 rapid antigen self-testing: a cross-sectional study in China.
    J Med Virol. 2022 Oct 14. doi: 10.1002/jmv.28227.
    >> Share

  840. ZHOU L, Mo C, Yang Y, Zhou Z, et al
    Characterization and application of a series of monoclonal antibodies against SARS-CoV-2 nucleocapsid protein.
    J Med Virol. 2022 Oct 13. doi: 10.1002/jmv.28225.
    >> Share

  841. WANG M, Liu Z, Wang Z, Li K, et al
    Clinical characteristics of 1139 mild cases of the SARS-CoV-2 Omicron variant infected patients in Shanghai.
    J Med Virol. 2022 Oct 13. doi: 10.1002/jmv.28224.
    >> Share

  842. SHEN S, Rui Y, Wang Y, Su J, et al
    SARS-CoV-2, HIV, HPV: convergent evolution of selective regulation of cGAS-STING signaling.
    J Med Virol. 2022 Oct 13. doi: 10.1002/jmv.28220.
    >> Share

  843. LI L, Cui J, Tang J, Shi J, et al
    High titers of neutralizing antibodies in the blood fail to eliminate SARS-CoV-2 viral RNA in the upper respiratory tract.
    J Med Virol. 2022 Oct 13. doi: 10.1002/jmv.28219.
    >> Share

  844. PISAREVA E, Badiou S, Mihalovicova L, Mirandola A, et al
    Persistence of Neutrophil extracellular traps and anti-cardiolipin auto-antibodies in post-acute phase COVID-19 patients.
    J Med Virol. 2022 Oct 13. doi: 10.1002/jmv.28209.
    >> Share

  845. C AM, Singh AK, Roy P, Ravichandran M, et al
    Long COVID following Omicron wave in Eastern India - A retrospective cohort study.
    J Med Virol. 2022 Oct 12. doi: 10.1002/jmv.28214.
    >> Share

  846. NIRANJI SS, Amin Al-Jaf SM
    In response to: Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers.
    J Med Virol. 2022 Oct 12. doi: 10.1002/jmv.28213.
    >> Share

  847. LI X, Yuan H, Li X, Wang H, et al
    Spike protein mediated membrane fusion during SARS-CoV-2 infection.
    J Med Virol. 2022 Oct 12. doi: 10.1002/jmv.28212.
    >> Share

  848. GAHUKAR AM, Khairnar K
    Omicron variant of SARS-CoV-2: A pandemic of global concern warrants a cautious approach.
    J Med Virol. 2022 Oct 12. doi: 10.1002/jmv.28211.
    >> Share

  849. ZHANG Y, Ndzouboukou JB, Lin X, Hou H, et al
    SARS-CoV-2 evolves to reduce but not abolish neutralizing action.
    J Med Virol. 2022 Oct 11. doi: 10.1002/jmv.28207.
    >> Share

  850. MUKHERJEE AG, Wanjari UR, Kannampuzha S, Das S, et al
    The pathophysiological and immunological background of the monkeypox virus infection: An update.
    J Med Virol. 2022 Oct 11. doi: 10.1002/jmv.28206.
    >> Share

  851. YEUNG SLA, Wong THT, He B, Luo S, et al
    Does ACE2 mediate the detrimental effect of exposures related to COVID-19 risk: A Mendelian randomization investigation.
    J Med Virol. 2022 Oct 10. doi: 10.1002/jmv.28205.
    >> Share

  852. WANG P, Xu Y, Zhe SU, Xie C, et al
    Impact of COVID-19 Pandemic on Influenza virus Prevalence in Children in Sichuan, China.
    J Med Virol. 2022 Oct 10. doi: 10.1002/jmv.28204.
    >> Share

  853. RENGASAMY KR
    Will Monkeypox Outbreak mirror COVID-19 or AIDs?
    J Med Virol. 2022 Oct 10. doi: 10.1002/jmv.28202.
    >> Share

  854. CAMP JV, Redlberger-Fritz M
    Increased cases of Influenza C virus in children and adults in Austria, 2022.
    J Med Virol. 2022 Oct 9. doi: 10.1002/jmv.28201.
    >> Share

  855. MIGUERES M, Chapuy-Regaud S, Miedouge M, Jamme T, et al
    Current immunoassays and detection of antibodies elicited by Omicron SARS-CoV-2 infection.
    J Med Virol. 2022 Oct 7. doi: 10.1002/jmv.28200.
    >> Share

  856. BARANOVA A, Xu Y, Cao H, Zhang F, et al
    Associations between pulse rate and COVID-19.
    J Med Virol. 2022 Oct 6. doi: 10.1002/jmv.28194.
    >> Share

  857. MIRSHARIF ES, Chenary MR, Bozorgmehr M, Mohammadi S, et al
    Immunophenotyping Characteristics of COVID-19 Patients: Peripheral Blood CD8+ HLA-DR+ T Cells as a Biomarker for Mortality Outcome.
    J Med Virol. 2022 Oct 3. doi: 10.1002/jmv.28192.
    >> Share

  858. VALENTINA M, Alessandro CL, Francesca C, Silvia R, et al
    Viral load decrease in SARS-CoV-2 BA.1 and BA.2 Omicron sublineages infection after treatment with monoclonal antibodies and direct antiviral agents.
    J Med Virol. 2022 Oct 2. doi: 10.1002/jmv.28186.
    >> Share

    September 2022
  859. GUNELL M, Rantasarkka K, Arjonen R, Sanden A, et al
    Clinical evaluation of an automated, rapid mariPOC(R) antigen test in screening of symptomatics and asymptomatics for SARS-CoV-2 infection.
    J Med Virol. 2022 Sep 30. doi: 10.1002/jmv.28189.
    >> Share

  860. XU W, Song D, Liu J, Han X, et al
    Development of chemiluminescent lab-on-fiber immunosensor for rapid point-of-care testing of anti-SARS-CoV-2 antibodies and evaluation of longitudinal immune response kinetics following three-dose inactivation virus vaccination.
    J Med Virol. 2022 Sep 30. doi: 10.1002/jmv.28190.
    >> Share

  861. YEO YH, Wang M, He X, Lv F, et al
    Excess risk for acute myocardial infarction mortality during the COVID-19 pandemic.
    J Med Virol. 2022 Sep 29. doi: 10.1002/jmv.28187.
    >> Share

  862. SRIRAMAN K, Shaikh A, Vaswani S, Mestry T, et al
    Impact of COVID-19 vaccination on transmission risk of breakthrough infections: Lessons from Adapted N95 Mask Sampling for Emerging Variants and Interventions.
    J Med Virol. 2022 Sep 29. doi: 10.1002/jmv.28188.
    >> Share

  863. NAGASAWA M, Kato T, Yamaguchi Y, Sugita Y, et al
    Rapid decrease of nasopharyngeal SARS-Co-V2 antigen in an outbreak of the Omicron strain.
    J Med Virol. 2022 Sep 29. doi: 10.1002/jmv.28179.
    >> Share

  864. YANG J, Song H, Hao X
    Whole-transcriptome sequencing data reveals a disparate cognitive and immune signature in COVID-19 patients with and without dementia.
    J Med Virol. 2022 Sep 27. doi: 10.1002/jmv.28177.
    >> Share

  865. SU J, Shen S, Hu Y, Chen S, et al
    SARS-CoV-2 ORF3a inhibits cGAS-STING-mediated autophagy flux and antiviral function.
    J Med Virol. 2022 Sep 26. doi: 10.1002/jmv.28175.
    >> Share

  866. ZHOU J, Liu Z, Zhang G, Xu W, et al
    Development of variant-proof SARS-CoV-2, pan-sarbecovirus and pan-beta-coronavirus vaccines.
    J Med Virol. 2022 Sep 25. doi: 10.1002/jmv.28172.
    >> Share

  867. HANAFUSA M, Nawa N, Goto Y, Kawahara T, et al
    Effectiveness of remdesivir with corticosteroids for COVID-19 patients in intensive care unit: a hospital-based observational study.
    J Med Virol. 2022 Sep 23. doi: 10.1002/jmv.28168.
    >> Share

  868. MESSALI S, Bugatti A, Filippini F, Caruso A, et al
    Emergence of S gene-based quasispecies explains an optimal adaptation of Omicron BA.5 subvariant in the immunocompetent vaccinated human host.
    J Med Virol. 2022 Sep 22. doi: 10.1002/jmv.28167.
    >> Share

  869. SILVA MFS, Pinto ACMD, Oliveira FCE, Caetano LF, et al
    Antibody response six months after the booster dose of Pfizer in previous recipients of CoronaVac.
    J Med Virol. 2022 Sep 22. doi: 10.1002/jmv.28169.
    >> Share

  870. FAVRESSE J, Gillot C, Bayart JL, David C, et al
    Vaccine-induced binding and neutralizing antibodies against Omicron 6 months after a homologous BNT162b2 booster.
    J Med Virol. 2022 Sep 21. doi: 10.1002/jmv.28164.
    >> Share

  871. DURAND GA, Amroun A, Grard G, Badaut C, et al
    Positive SARS-CoV-2 RT-qPCR of a nasal swab spot after 30 days of conservation on filter paper at room temperature.
    J Med Virol. 2022 Sep 21. doi: 10.1002/jmv.28165.
    >> Share

  872. VEGA-RODRIGUEZ W, Ly H
    GETTING AHEAD OF MONKEYPOX: Learning from the COVID-19 pandemic experience to prevent the potentially new monkeypox pandemic.
    J Med Virol. 2022 Sep 21. doi: 10.1002/jmv.28146.
    >> Share

  873. KONG W, Zhong Q, Chen M, Yu P, et al
    Ad5-nCoV booster and Omicron variant breakthrough infection following two doses of inactivated vaccine elicit comparable antibody levels against Omicron variants.
    J Med Virol. 2022 Sep 20. doi: 10.1002/jmv.28163.
    >> Share

  874. KRISHNAMOORTHY S, Li GH, Cheung CL
    Transcriptome-wide Summary Data based Mendelian Randomization analysis reveals 38 novel genes associating with Severe COVID-19.
    J Med Virol. 2022 Sep 20. doi: 10.1002/jmv.28162.
    >> Share

  875. TAN Y, Lu S, Wang B, Duan X, et al
    Single-cell transcriptome atlas reveals protective characteristics of COVID-19 mRNA vaccine.
    J Med Virol. 2022 Sep 19. doi: 10.1002/jmv.28161.
    >> Share

  876. QIU X, Liu Y, Sha A
    SARS-CoV-2 and Natural Infection in Animals.
    J Med Virol. 2022 Sep 19. doi: 10.1002/jmv.28147.
    >> Share

  877. BOYTZ R, Slabicki M, Ramaswamy S, Patten JJ, et al
    Anti-SARS-CoV-2 Activity of Targeted Kinase Inhibitors: Repurposing Clinically Available Drugs for COVID-19 Therapy.
    J Med Virol. 2022 Sep 18. doi: 10.1002/jmv.28157.
    >> Share

  878. CECCARELLI G, d'Ettorre G, Russo A, Fabris S, et al
    SARS-CoV-2 pandemic, influenza, and influenza-like illness epidemics: Allies or enemies?
    J Med Virol. 2022 Sep 17. doi: 10.1002/jmv.28148.
    >> Share

  879. DESINGU PA, Nagarajan K
    Unveiling HERV-K113-ENV as SARS-CoV-2 severity admissible biomarker by mining transcriptome data.
    J Med Virol. 2022 Sep 16. doi: 10.1002/jmv.28149.
    >> Share

  880. LI Z, Yong H, Wang W, Gao Y, et al
    GSK3326595 is a promising drug to prevent SARS-CoV-2 Omicron and other variants infection by inhibiting ACE2-R671 di-methylation.
    J Med Virol. 2022 Sep 16. doi: 10.1002/jmv.28158.
    >> Share

  881. CENAT JM, Noorishad PG, Moshirian Farahi SMM, Darius WP, et al
    COVID-19 Vaccine Hesitancy and Related Factors in Canada: A Systematic Review and Meta-analysis.
    J Med Virol. 2022 Sep 16. doi: 10.1002/jmv.28156.
    >> Share

  882. LI XK, Tu B, Zhang XA, Xu W, et al
    Dysregulation of glutamine/glutamate metabolism in COVID-19 patients: a metabolism study in African population and mini meta-analysis.
    J Med Virol. 2022 Sep 16. doi: 10.1002/jmv.28150.
    >> Share

  883. KLOPFENSTEIN T, Gendrin V, Zayet S
    "Olfactory dysfunction in COVID-19, new insights from a cohort of 353 patients: The ANOSVID study": Author's reply.
    J Med Virol. 2022 Sep 15. doi: 10.1002/jmv.28151.
    >> Share

  884. LAN Q, Wang L, Jiao F, Lu L, et al
    Pan-coronavirus fusion inhibitors to combat COVID-19 and other emerging coronavirus infectious diseases.
    J Med Virol. 2022 Sep 13. doi: 10.1002/jmv.28143.
    >> Share

  885. CALABRETTO M, D'Alisa R, Faraone S, Mazzuti L, et al
    DETECTION OF SARS-COV-2 RNA AND ANTIBODIES IN BREAST MILK OF INFECTED MOTHERS.
    J Med Virol. 2022 Sep 13. doi: 10.1002/jmv.28142.
    >> Share

  886. FRYE CJ, Shine M, Makowski JA, Kensinger AH, et al
    Bioinformatics Analysis of the s2m Mutations within the SARS-CoV-2 Omicron Lineages.
    J Med Virol. 2022 Sep 13. doi: 10.1002/jmv.28141.
    >> Share

  887. ZHOU Y, Zhi H, Teng Y
    The outbreak of SARS-CoV-2 Omicron lineages, immune escape and vaccine effectivity.
    J Med Virol. 2022 Sep 12. doi: 10.1002/jmv.28138.
    >> Share

  888. LIANG LG, Zhu MJ, He R, Shi DR, et al
    Development of a multi-recombinase polymerase amplification assay for rapid identification of COVID-19, Influenza A and B.
    J Med Virol. 2022 Sep 11. doi: 10.1002/jmv.28139.
    >> Share

  889. QUEROMES G, Frobert E, Bouscambert-Duchamp M, Oblette A, et al
    Rapid and reliable inactivation protocols for the diagnostics of emerging viruses: the example of SARS-CoV-2 and monkeypox virus.
    J Med Virol. 2022 Sep 11. doi: 10.1002/jmv.28126.
    >> Share

  890. JIANG W, Johnson D, Adekunle R, Heather H, et al
    COVID-19 is associated with bystander polyclonal autoreactive B cell activation as reflected by a broad autoantibody production, but none is linked to disease severity.
    J Med Virol. 2022 Sep 10. doi: 10.1002/jmv.28134.
    >> Share

  891. LI Y, Yang J, Shen S, Wang W, et al
    SARS-CoV-2-encoded Inhibitors of Human LINE-1 Retrotransposition.
    J Med Virol. 2022 Sep 9. doi: 10.1002/jmv.28135.
    >> Share

  892. MARCHI L, Vidiri A, Fera EA, Pallottini M, et al
    SARS-CoV-2 IgG "heritage" in newborn: a credit of maternal natural infection.
    J Med Virol. 2022 Sep 7. doi: 10.1002/jmv.28133.
    >> Share

  893. CELIK E, Ozcan G, Vatansever C, Paerhati E, et al
    Alterations in Vaginal Microbiota among Pregnant Women with COVID-19.
    J Med Virol. 2022 Sep 6. doi: 10.1002/jmv.28132.
    >> Share

  894. RZYMSKI P, Kasianchuk N, Sikora D, Poniedzialek B, et al
    COVID-19 Vaccinations and Rates of Infections, Hospitalizations, ICU Admissions, and Deaths in Europe during SARS-CoV-2 Omicron wave in the first quarter of 2022.
    J Med Virol. 2022 Sep 6. doi: 10.1002/jmv.28131.
    >> Share

  895. FAIZO AA, Qashqari FS, El-Kafrawy SA, Barasheed O, et al
    A Potential Association between Obesity and Reduced Effectiveness of COVID-19 Vaccine-Induced Neutralizing Humoral Immunity.
    J Med Virol. 2022 Sep 6. doi: 10.1002/jmv.28130.
    >> Share

  896. ABDALLA M, El-Arabey AA, Gai Z
    Hypertension is still a moving target in the context of COVID-19 and post-acute COVID-19 syndrome.
    J Med Virol. 2022 Sep 6. doi: 10.1002/jmv.28128.
    >> Share

  897. AKASH S, Rahman MM, Islam MR, Sharma R, et al
    Emerging global concern of Langya Henipavirus: Pathogenicity, Virulence, Genomic features, and Future perspectives.
    J Med Virol. 2022 Sep 6. doi: 10.1002/jmv.28127.
    >> Share

  898. SCARPA F, Sanna D, Azzena I, Giovanetti M, et al
    On the SARS-CoV-2 BA.2.75 variant: a genetic and structural point of view.
    J Med Virol. 2022 Sep 4. doi: 10.1002/jmv.28119.
    >> Share

  899. NICOT F, Tremeaux P, Latour J, Nicolas J, et al
    WHOLE GENOME SEQUENCING OF SARS-CoV-2: COMPARISON OF TARGET CAPTURE AND AMPLICON SINGLE MOLECULAR REAL TIME SEQUENCING PROTOCOLS.
    J Med Virol. 2022 Sep 3. doi: 10.1002/jmv.28123.
    >> Share

  900. ARISH M, Qian W, Narasimhan H, Sun J, et al
    COVID-19 immunopathology: From acute diseases to chronic sequelae.
    J Med Virol. 2022 Sep 3. doi: 10.1002/jmv.28122.
    >> Share

  901. WETTSTEIN L, Immenschuh P, Weil T, Conzelmann C, et al
    Native and activated antithrombin inhibits TMPRSS2 activity and SARS-CoV-2 infection.
    J Med Virol. 2022 Sep 3. doi: 10.1002/jmv.28124.
    >> Share

  902. YU T, Liu F, Yi N, Yin H, et al
    Evaluating agreement in different diagnosis methods is necessary.
    J Med Virol. 2022 Sep 2. doi: 10.1002/jmv.28117.
    >> Share

  903. WANG C, Liu B, Zhang S, Huang N, et al
    Differences in incidence and fatality of COVID-19 by SARS-CoV-2 Omicron variant versus Delta variant in relation to vaccine coverage: a world-wide review.
    J Med Virol. 2022 Sep 2. doi: 10.1002/jmv.28118.
    >> Share

  904. WANG Q, Ye SB, Zhou ZJ, Li JY, et al
    Key mutations on spike protein altering ACE2 receptor utilization and potentially expanding host range of emerging SARS-CoV-2 variants.
    J Med Virol. 2022 Sep 2. doi: 10.1002/jmv.28116.
    >> Share

    August 2022
  905. KAYA Y, Gulcu O, Aksakal E, Kalkan K, et al
    A Significant Predictor of In-Hospital and Long-term Mortality and Progression In COVID-19 Patients: The End-Stage Liver Disease (MELD) Score Model.
    J Med Virol. 2022 Aug 31. doi: 10.1002/jmv.28109.
    >> Share

  906. BARANOVA A, Cao H, Zhang F
    Causal Effect of COVID-19 on Alzheimer's Disease: A Mendelian Randomization Study.
    J Med Virol. 2022 Aug 30. doi: 10.1002/jmv.28107.
    >> Share

  907. GENG Y, Wang Y
    Stability and transmissibility of SARS-CoV-2 in the environment.
    J Med Virol. 2022 Aug 30. doi: 10.1002/jmv.28103.
    >> Share

  908. YAO Y, Song H, Zhang F, Liu J, et al
    Genetic predisposition to blood cell indices in relation to severe COVID-19.
    J Med Virol. 2022 Aug 29. doi: 10.1002/jmv.28104.
    >> Share

  909. COLSON P, Gautret P, Delerce J, Chaudet H, et al
    The emergence, spread and vanishing of a French SARS-CoV-2 variant exemplifies the fate of RNA virus epidemics and obeys the Mistigri rule.
    J Med Virol. 2022 Aug 28. doi: 10.1002/jmv.28102.
    >> Share

  910. LIU S, Cai J, Li Y, Ying L, et al
    Outbreak of acute respiratory disease caused by human adenovirus type 7 and Human Coronavirus-229E in Zhejiang Province, China.
    J Med Virol. 2022 Aug 28. doi: 10.1002/jmv.28101.
    >> Share

  911. XIE J, Klemsz MJ, Kacena MA, Sandusky G, et al
    Inhibition of MEK signaling prevents SARS-CoV2-induced lung damage and improves the survival of infected mice.
    J Med Virol. 2022 Aug 28. doi: 10.1002/jmv.28094.
    >> Share

  912. GHANG B, Kim S, Kim J
    Autoimmune rheumatic disease after SARS-CoV-2 vaccination.
    J Med Virol. 2022 Aug 27. doi: 10.1002/jmv.28092.
    >> Share

  913. CAO H, Baranova A, Wei X, Wang C, et al
    Bidirectional causal associations between type 2 diabetes and COVID-19.
    J Med Virol. 2022 Aug 27. doi: 10.1002/jmv.28100.
    >> Share

  914. SALIMIAN J, Ahmadi A, Amani J, Olad G, et al
    Safety and Immunogenicity of a Recombinant Receptor Binding Domain-Based Protein Subunit Vaccine (Noora Vaccine) Against COVID-19 in Adults: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Trial.
    J Med Virol. 2022 Aug 27. doi: 10.1002/jmv.28097.
    >> Share

  915. ALI AM, Tofiq AM, Rostam HM, Ali KM, et al
    Disease Severity and Efficacy of Homologous Vaccination Among Patients Infected with SARS-CoV-2 Delta or Omicron VOCs, Compared to Unvaccinated using Main Biomarkers.
    J Med Virol. 2022 Aug 27. doi: 10.1002/jmv.28098.
    >> Share

  916. LIU H, Chang S, Chen S, Du Y, et al
    Highly sensitive and rapid detection of SARS-CoV-2 via a portable CRISPR-Cas13a-based lateral flow assay.
    J Med Virol. 2022 Aug 27. doi: 10.1002/jmv.28096.
    >> Share

  917. PATERSON C, Davis D, Roche M, Bissett B, et al
    What are the long-term holistic health consequences of COVID-19 among survivors? An umbrella systematic review.
    J Med Virol. 2022 Aug 24. doi: 10.1002/jmv.28086.
    >> Share

  918. MENG Y, Zeng F, Sun H, Li Y, et al
    Clinical characteristics and outcomes of patients with COVID-19 and psoriasis.
    J Med Virol. 2022 Aug 24. doi: 10.1002/jmv.28085.
    >> Share

  919. DING C, Ni S, Zhang X, Xie J, et al
    Evaluation of humoral immune responses induced by different SARS-CoV-2 spike trimers from wild-type and emerging variants with individual, sequential, and combinational delivered strategies.
    J Med Virol. 2022 Aug 19. doi: 10.1002/jmv.28081.
    >> Share

  920. DE MICHELENA P, Olea B, Torres I, Gonzalez-Candelas F, et al
    SARS-CoV-2 RNA load in nasopharyngeal specimens from outpatients with breakthrough COVID-19 due to Omicron BA.1 and BA.2.
    J Med Virol. 2022 Aug 19. doi: 10.1002/jmv.28079.
    >> Share

  921. MA Z, Mao Y, Wang Y, Duan Z, et al
    Suicidal ideation and attempted suicide among cancer patients during the COVID-19 pandemic.
    J Med Virol. 2022 Aug 18. doi: 10.1002/jmv.28076.
    >> Share

  922. ALI MA, Zhang GF, Hu C, Yuan B, et al
    Ultra-Rapid and Ultra-Sensitive Detection of SARS-CoV-2 Antibodies in COVID-19 Patients via A 3D-Printed Nanomaterial-Based Biosensing Platform.
    J Med Virol. 2022 Aug 18. doi: 10.1002/jmv.28075.
    >> Share

  923. LIU H, Li Q, Xiang Y, Li H, et al
    An Outbreak of Acute Respiratory Disease Caused by HAdV-55 in Beijing, China, 2020.
    J Med Virol. 2022 Aug 18. doi: 10.1002/jmv.28074.
    >> Share

  924. CUI A, Xie Z, Xu J, Hu K, et al
    Comparative analysis of the clinical and epidemiological characteristics of human influenza virus vs. human respiratory syncytial virus vs. human metapneumovirus infection in nine provinces of China during 2009-2021.
    J Med Virol. 2022 Aug 18. doi: 10.1002/jmv.28073.
    >> Share

  925. TAO SS, Wang XY, Yang XK, Liu YC, et al
    COVID-19 and inflammatory bowel disease crosstalk: from emerging association to clinical proposal.
    J Med Virol. 2022 Aug 16. doi: 10.1002/jmv.28067.
    >> Share

  926. MOHEBI L, Karami H, Mirsalehi N, Ardestani NH, et al
    A delayed resurgence of respiratory syncytial virus (RSV) during the COVID-19 pandemic: An unpredictable outbreak in a small proportion of children in the Southwest of Iran, April 2022.
    J Med Virol. 2022 Aug 12. doi: 10.1002/jmv.28065.
    >> Share

  927. YU W, Guo Y, Zhang S, Kong Y, et al
    Proportion of asymptomatic infection and non-severe disease caused by SARS-CoV-2 Omicron variant: a systematic review.
    J Med Virol. 2022 Aug 12. doi: 10.1002/jmv.28066.
    >> Share

  928. GEISEN UM, Rose R, Neumann F, Ciripoi M, et al
    The long term vaccine-induced anti-SARS-CoV-2 immune response is impaired in quantity and quality under TNFalpha blockade.
    J Med Virol. 2022 Aug 9. doi: 10.1002/jmv.28063.
    >> Share

  929. THAKUR N, Das S, Kumar S, Maurya VK, et al
    Tracing the origin of Severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2): A systematic review and narrative synthesis.
    J Med Virol. 2022 Aug 9. doi: 10.1002/jmv.28060.
    >> Share

  930. JIA M, Wang X, Gong W, Zhong J, et al
    Humoral responses after inactivated COVID-19 vaccination in individuals with and without prior SARS-CoV-2 infection: A prospective cohort study.
    J Med Virol. 2022 Aug 8. doi: 10.1002/jmv.28055.
    >> Share

  931. CHEUNG PH, Ye ZW, Lui WY, Ong CP, et al
    Production of single-cycle infectious SARS-CoV-2 through a trans-complemented replicon.
    J Med Virol. 2022 Aug 8. doi: 10.1002/jmv.28057.
    >> Share

  932. INFANTINO M, Manfredi M, Alessio MG, Previtali G, et al
    CLINICAL UTILITY OF CIRCULATING CALPROTECTIN TO ASSIST PREDICTION AND MONITORING OF COVID-19 SEVERITY: AN ITALIAN STUDY.
    J Med Virol. 2022 Aug 8. doi: 10.1002/jmv.28056.
    >> Share

  933. KUMBHAKAR R, Neradilek M, Barnabas RV, Stewart J, et al
    Using Time Weighted Average Change from Baseline of SARS-CoV-2 Viral Load to Assess Impact of Hydroxychloroquine (HCQ) as Post-exposure Prophylaxis and Early Treatment for COVID-19.
    J Med Virol. 2022 Aug 8. doi: 10.1002/jmv.28054.
    >> Share

  934. WANG H, Guo S, Yang H
    Rapid quantitative monitoring of SARS-CoV-2 spike protein mediated syncytia formation using split NanoLuc.
    J Med Virol. 2022 Aug 8. doi: 10.1002/jmv.28053.
    >> Share

  935. ELBAYIYEV S, Simsek GK, Ceran B, Akin MS, et al
    Could red cell distribution width be used for predicting cardiac injury in neonates with COVID-19?
    J Med Virol. 2022 Aug 8. doi: 10.1002/jmv.28050.
    >> Share

  936. ZOU L, Zhang H, Zheng Z, Jiang Y, et al
    Serosurvey in SARS-CoV-2 inactivated vaccine-elicited neutralizing antibodies against authentic SARS-CoV-2 and its viral variants.
    J Med Virol. 2022 Aug 5. doi: 10.1002/jmv.28049.
    >> Share

  937. ZHANG H, Ding Q, Yuan J, Han F, et al
    Susceptibility to mice and potential evolutionary characteristics of porcine deltacoronavirus.
    J Med Virol. 2022 Aug 4. doi: 10.1002/jmv.28048.
    >> Share


  938. Corrigendum.
    J Med Virol. 2022 Aug 4. doi: 10.1002/jmv.28046.
    >> Share

  939. SUNTRONWONG N, Kanokudom S, Auphimai C, Assawakosri S, et al
    Effects of boosted mRNA and adenoviral-vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccination.
    J Med Virol. 2022 Aug 4. doi: 10.1002/jmv.28044.
    >> Share


  940. Corrigendum.
    J Med Virol. 2022 Aug 2. doi: 10.1002/jmv.28043.
    >> Share

  941. LIM CC, Leeu JJ, Mok IY, Tan HZ, et al
    Influenza Vaccine Awareness and Acceptance in Kidney Disease during the Corononavirus Disease 2019 pandemic.
    J Med Virol. 2022 Aug 2. doi: 10.1002/jmv.28039.
    >> Share

  942. KOJIMA Y, Nakakubo S, Kamada K, Yamashita Y, et al
    Combination therapy with remdesivir and immunomodulators improves respiratory status in COVID-19: A retrospective study.
    J Med Virol. 2022 Aug 2. doi: 10.1002/jmv.28037.
    >> Share

  943. LIANG W, Wang S, Wang H, Li X, et al
    When 3D genome technology meets viral infection, including SARS-CoV-2.
    J Med Virol. 2022 Aug 2. doi: 10.1002/jmv.28040.
    >> Share

    July 2022
  944. PENG P, Deng H, Li Z, Chen Y, et al
    Distinct immune responses in the early phase to natural SARS-CoV-2 infection or vaccination.
    J Med Virol. 2022 Jul 29. doi: 10.1002/jmv.28034.
    >> Share

  945. MURPHY H, Ly H
    What are the levels of risk of humans contracting SARS-CoV-2 from pets and vice versa?
    J Med Virol. 2022 Jul 29. doi: 10.1002/jmv.28035.
    >> Share

  946. ALEXIEV I, Giovanetti M, Cella E, Ivanov I, et al
    Initial Introduction and Spread of the SARS-CoV-2 AY.4.2.1 Delta Variant in Bulgaria, a Genomic Insight.
    J Med Virol. 2022 Jul 28. doi: 10.1002/jmv.28033.
    >> Share

  947. ZHANG GF, Meng W, Chen L, Ding L, et al
    Neutralizing Antibodies to SARS-CoV-2 Variants of Concern Including Delta and Omicron in Subjects Receiving mRNA-1273, BNT162b2 and Ad26.COV2.S Vaccines.
    J Med Virol. 2022 Jul 28. doi: 10.1002/jmv.28032.
    >> Share

  948. KOJIMA N, Desai V, Klausner JD
    Distributing Effective SARS-CoV-2 Medicines in a Timely Manner.
    J Med Virol. 2022 Jul 26. doi: 10.1002/jmv.28030.
    >> Share

  949. POURAKBARI B, Mirbeyk M, Mahmoudi S, Sadeghi RH, et al
    Evaluation of response to different COVID-19 vaccines in vaccinated healthcare workers in a single center in Iran.
    J Med Virol. 2022 Jul 26. doi: 10.1002/jmv.28029.
    >> Share

  950. JANG EJ, Choe YJ, Yun GW, Wang S, et al
    Reinfection with SARS-CoV-2 in general population, South Korea; nationwide retrospective cohort study.
    J Med Virol. 2022 Jul 25. doi: 10.1002/jmv.28026.
    >> Share

  951. DU Y, Li W, Guo Y, Li L, et al
    Epidemiology and genetic characterization of human metapneumovirus in pediatric patients from Hangzhou China.
    J Med Virol. 2022 Jul 24. doi: 10.1002/jmv.28024.
    >> Share

  952. LIU R, Lin X, Chen B, Hou Z, et al
    The mutation features and geographical distributions of the surface glycoprotein (S gene) in SARS-CoV-2 strains: a comparative analysis of the early and current strains.
    J Med Virol. 2022 Jul 24. doi: 10.1002/jmv.28023.
    >> Share

  953. PENG H, Zheng B, Yang S, Du J, et al
    A soluble DR5-Fc chimeric protein (sDR5-Fc) attenuates inflammatory responses induced by coronavirus MHV-A59 and SARS-CoV-2.
    J Med Virol. 2022 Jul 22. doi: 10.1002/jmv.28021.
    >> Share

  954. WANG X, Zhao X, Cui Y, Qiao R, et al
    Neutralization of Distinct Omicron Sublineages by Longitudinal Vaccination Sera.
    J Med Virol. 2022 Jul 22. doi: 10.1002/jmv.28017.
    >> Share

  955. OSTERDAHL MF, Christakou E, Hart D, Harris F, et al
    Concordance of B and T cell responses to SARS-CoV-2 infection, irrespective of symptoms suggestive of COVID-19.
    J Med Virol. 2022 Jul 21. doi: 10.1002/jmv.28016.
    >> Share

  956. LIANG Y, Gong Z, Guo J, Cheng Q, et al
    Spatiotemporal analysis of the morbidity of global Omicron from November 2021 to February 2022.
    J Med Virol. 2022 Jul 21. doi: 10.1002/jmv.28013.
    >> Share

  957. WANG Y, Wang X, Luu LDW, Li J, et al
    Single-cell transcriptomic atlas reveals distinct immunological responses between COVID-19 vaccine and natural SARS-CoV-2 infection.
    J Med Virol. 2022 Jul 20. doi: 10.1002/jmv.28012.
    >> Share

  958. YANG Y, Zhao R, Wang Y, Song D, et al
    Rapid and universal detection of SARS-CoV-2 and influenza A virus using a reusable dual-channel optic fiber immunosensor.
    J Med Virol. 2022 Jul 20. doi: 10.1002/jmv.28015.
    >> Share

  959. CHEEMA HA, Shahid A, Aziz H
    Severe acute pediatric hepatitis: the undue emphasis on adenovirus needs to be reassessed.
    J Med Virol. 2022 Jul 20. doi: 10.1002/jmv.28014.
    >> Share

  960. DE VITO A, Colpani A, Bitti A, Zauli B, et al
    Safety and efficacy of molnupiravir in SARS-CoV-2 infected patients: a real-life experience.
    J Med Virol. 2022 Jul 20. doi: 10.1002/jmv.28011.
    >> Share

  961. HUANG D, Lin S, He J, Wang Q, et al
    Association between COVID-19 and telomere length: a bidirectional Mendelian randomization study.
    J Med Virol. 2022 Jul 19. doi: 10.1002/jmv.28008.
    >> Share

  962. MONARI C, Pisaturo M, Maggi P, Macera M, et al
    EARLY PREDICTORS OF CLINICAL DETERIORATION IN A COHORT OF OUTPATIENTS WITH COVID-19 IN SOUTHERN ITALY: A MULTICENTER OBSERVATIONAL STUDY.
    J Med Virol. 2022 Jul 19. doi: 10.1002/jmv.28007.
    >> Share

  963. HUANG N, Wang C, Han B, Zhao T, et al
    Change in willingness to COVID-19 vaccination in China: two online surveys during the pandemic.
    J Med Virol. 2022 Jul 18. doi: 10.1002/jmv.28004.
    >> Share

  964. BAUER G, Struck F, Staschik E, Maile J, et al
    Differential avidity determination of IgG directed towards the receptor-binding domain (RBD) of SARS-CoV-2 wild-type and its variants in one assay: Rational tool for the assessment of protective immunity.
    J Med Virol. 2022 Jul 18. doi: 10.1002/jmv.28006.
    >> Share

  965. CHEN J, Liu X, Liu W, Yang C, et al
    Comparison of the respiratory tract microbiome in hospitalized COVID-19 patients with different disease severity.
    J Med Virol. 2022 Jul 15. doi: 10.1002/jmv.28002.
    >> Share

  966. JASIM SA, Mahdi RS, Bokov DO, Najm MAA, et al
    The deciphering of the immune cells and marker signature in COVID-19 pathogenesis: An update.
    J Med Virol. 2022 Jul 14. doi: 10.1002/jmv.28000.
    >> Share

  967. VAIRA LA, De Riu G, Boscolo-Rizzo P, Hopkins C, et al
    In response to: Olfactory dysfunction in COVID-19, new insights from a cohort of 353 patients: The ANOSVID study.
    J Med Virol. 2022 Jul 13. doi: 10.1002/jmv.27999.
    >> Share

  968. FERRAVANTE C, Arslan-Gatz BS, Dell'Annunziata F, Palumbo D, et al
    Dynamics of nasopharyngeal tract phageome and association with disease severity and age of patients during three waves of COVID-19.
    J Med Virol. 2022 Jul 13. doi: 10.1002/jmv.27998.
    >> Share

  969. FILHO FFD, Chaves EBM, D'Avila KG, Neyeloff JL, et al
    Clinical characteristics and outcomes of healthcare workers with COVID-19 pre- and postvaccination.
    J Med Virol. 2022 Jul 13. doi: 10.1002/jmv.27997.
    >> Share

  970. RAHMATI M, Keshvari M, Mirnasuri S, Yon DK, et al
    The global impact of COVID-19 pandemic on the incidence of pediatric new-onset type 1 diabetes and ketoacidosis: A systematic review and meta-analysis.
    J Med Virol. 2022 Jul 13. doi: 10.1002/jmv.27996.
    >> Share

  971. CHEN J, Song J, Dai L, Post SR, et al
    SARS-CoV-2 Infection and Lytic Reactivation of Herpesviruses: a Potential Threat at Post-pandemic Era?
    J Med Virol. 2022 Jul 12. doi: 10.1002/jmv.27994.
    >> Share

  972. FARHEEN S, Araf Y, Tang YD, Zheng C, et al
    The Deltacron conundrum: its origin and potential health risks.
    J Med Virol. 2022 Jul 11. doi: 10.1002/jmv.27990.
    >> Share

  973. RANKIN DA, Yanis A, Talj R, Howe HL, et al
    Clinical Presentations of Adult and Pediatric SARS-CoV-2-Positive Cases in a Community Cohort, Nashville, Tennessee.
    J Med Virol. 2022 Jul 11. doi: 10.1002/jmv.27988.
    >> Share

  974. DUMAN N, Tuncel G, Bisgin A, Bozdogan ST, et al
    "Analysis of ACE2 and TMPRSS2 coding variants as a risk factor for SARS-CoV-2 from 946 whole exome sequencing data in the Turkish Population.
    J Med Virol. 2022 Jul 10. doi: 10.1002/jmv.27976.
    >> Share

  975. ALMUFTY HB, Mamani MMA, Ali AH, Merza MA, et al
    COVID-19 vaccine breakthrough infection among fully vaccinated healthcare workers in Duhok governorate, Iraqi Kurdistan; a retrospective cohort study.
    J Med Virol. 2022 Jul 10. doi: 10.1002/jmv.27985.
    >> Share

  976. TEO KW, Patel D, Sisodia S, Roland D, et al
    Rhinovirus persistence during the COVID-19 pandemic - impact on paediatric acute wheezing admissions.
    J Med Virol. 2022 Jul 10. doi: 10.1002/jmv.27986.
    >> Share

  977. QI X, Wang J, Zhang Q, Ai J, et al
    Safety and Immunogenicity of COVID-19 Vaccination in Patients with Hepatocellular Carcinoma (CHESS-NMCID 2101): A Multicenter Prospective Study.
    J Med Virol. 2022 Jul 10. doi: 10.1002/jmv.27992.
    >> Share

  978. CARDENOSO DOMINGO L, Roy Vallejo E, Zurita Cruz ND, Chicot Llano M, et al
    Relevant SARS-CoV-2 viremia is associated with COVID-19 severity: prospective cohort study and validation cohort.
    J Med Virol. 2022 Jul 10. doi: 10.1002/jmv.27989.
    >> Share

  979. CHENG ZJ, Huang H, Liu Q, Zhong R, et al
    Immunoassay and mass cytometry revealed immunological profiles induced by inactivated BBIBP COVID-19 vaccine.
    J Med Virol. 2022 Jul 8. doi: 10.1002/jmv.27983.
    >> Share

  980. PETRIE JG, Eisenberg MC, Lauring AS, Gilbert J, et al
    Variant-specific burden of SARS-CoV-2 in Michigan: March 2020 through November 2021.
    J Med Virol. 2022 Jul 7. doi: 10.1002/jmv.27982.
    >> Share

  981. CHIRUMBOLO S
    Myopericarditis in young subjects after vaccination, clearing the clouds of misunderstanding.
    J Med Virol. 2022 Jul 7. doi: 10.1002/jmv.27981.
    >> Share

  982. ZENG G, Wang X
    Ending the COVID-19 pandemic: We still have a long way to go.
    J Med Virol. 2022 Jul 7. doi: 10.1002/jmv.27980.
    >> Share

  983. VELAZQUEZ-SALINAS L
    The complex evolutionary dynamics of SARS-CoV-2, a big challenge to control the pandemic of COVID-19.
    J Med Virol. 2022 Jul 7. doi: 10.1002/jmv.27979.
    >> Share

  984. YUASA S, Nakajima J, Takatsuki Y, Takahashi Y, et al
    Viral load of SARS-CoV-2 Omicron is not high despite its high infectivity.
    J Med Virol. 2022 Jul 5. doi: 10.1002/jmv.27974.
    >> Share

  985. AKSAK T, Satar DA, Ridvan B, Gultekin EO, et al
    INVESTIGATION OF THE EFFECT OF COVID-19 ON SPERM COUNT, MOTILITY AND MORPHOLOGY.
    J Med Virol. 2022 Jul 1. doi: 10.1002/jmv.27971.
    >> Share

    June 2022
  986. DESINGU PA, Nagarajan K
    The emergence of Omicron lineages BA.4 and BA.5, and the global spreading trend.
    J Med Virol. 2022 Jun 30. doi: 10.1002/jmv.27967.
    >> Share

  987. HAN L, Zheng Y, Deng J, Nan ML, et al
    SARS-CoV-2 ORF10 antagonizes STING-dependent interferon activation and autophagy.
    J Med Virol. 2022 Jun 28. doi: 10.1002/jmv.27965.
    >> Share

  988. CRUZ CA, Medina PM
    Temporal Changes in the Accessory Protein Mutations of SARS-CoV-2 Variants and Their Predicted Structural and Functional Effects.
    J Med Virol. 2022 Jun 28. doi: 10.1002/jmv.27964.
    >> Share

  989. AKCAY N, Bektas G, Menentoglu ME, Sevketoglu E, et al
    Response to Finsterer on the letter to the editor ''Diagnose SARS-CoV-2 associated Guillain-Barre syndrome upon appropriate criteria and after exclusion of differentials''.
    J Med Virol. 2022 Jun 27. doi: 10.1002/jmv.27960.
    >> Share

  990. TAVAKOLI N, Nafissi N, Shokri S, Fallahpour M, et al
    Pediatric and Adolescent COVID-19 Vaccination Side Effects: A Retrospective Cohort Study of Iranian Teenage group in 2021.
    J Med Virol. 2022 Jun 27. doi: 10.1002/jmv.27962.
    >> Share

  991. CIMOLAI N
    Disinfection and Decontamination in the Context of SARS-CoV-2 Specific Data.
    J Med Virol. 2022 Jun 27. doi: 10.1002/jmv.27959.
    >> Share

  992. LI D, Xiong L, Pan G, Wang T, et al
    Molecular Imaging on ACE2-dependent Transocular Infection of Coronavirus.
    J Med Virol. 2022 Jun 26. doi: 10.1002/jmv.27958.
    >> Share

  993. UMAIR M, Ikram A, Rehman Z, Haider SA, et al
    Genomic diversity of SARS-CoV-2 in Pakistan during the fourth wave of pandemic.
    J Med Virol. 2022 Jun 26. doi: 10.1002/jmv.27957.
    >> Share

  994. TANG K, Wei Z, Wu X
    Impaired serological response to COVID-19 vaccination following anti-cancer therapy: a systematic review and meta-analysis.
    J Med Virol. 2022 Jun 24. doi: 10.1002/jmv.27956.
    >> Share

  995. KONTOPOULOU K, Nakas CT, Belai C, Papazisis G, et al
    Antibody Titers After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in immunocompromised adults in Greece: is a fourth dose necessary?
    J Med Virol. 2022 Jun 23. doi: 10.1002/jmv.27954.
    >> Share

  996. MIAO G, Peng H, Tang H, Liu Y, et al
    Antiviral efficacy of selective estrogen receptor modulators against SARS-CoV-2 infection in vitro and in vivo reveals bazedoxifene acetate as an entry inhibitor.
    J Med Virol. 2022 Jun 22. doi: 10.1002/jmv.27951.
    >> Share

  997. TASEEN S, Nasir F, Abbas M, Altaf M, et al
    Post-pandemic World at the Mercy of Monkeypox Virus Outbreak: Time to worry or not?
    J Med Virol. 2022 Jun 22. doi: 10.1002/jmv.27948.
    >> Share

  998. CHEN JM, Li GH, Ji YF, Sun MH, et al
    A highly powerful non-specific strategy to reduce COVID-19 deaths.
    J Med Virol. 2022 Jun 21. doi: 10.1002/jmv.27949.
    >> Share

  999. PHAN T, Boes S, McCullough M, Gribschaw J, et al
    Emergence of SARS-CoV-2 Omicron BA.5 variant of concern in Western Pennsylvania, United States.
    J Med Virol. 2022 Jun 17. doi: 10.1002/jmv.27945.
    >> Share

  1000. STAERK-OSTERGAARD J, Kirkeby C, Christiansen LE, Andersen MA, et al
    Evaluation of diagnostic test procedures for SARS-CoV-2 using latent class models.
    J Med Virol. 2022 Jun 17. doi: 10.1002/jmv.27943.
    >> Share

  1001. WOLF JM, Petek H, Maccari JG, Nasi LA, et al
    COVID-19 pandemic in Southern Brazil: Hospitalizations, intensive care unit admissions, lethality rates, and length of stay between March 2020 and April 2022.
    J Med Virol. 2022 Jun 16. doi: 10.1002/jmv.27942.
    >> Share

  1002. CEYLAN MR, Kankilic N, Oz O
    Are H1 and H3 haplotypes of endothelial protein C receptor (PROCR) an important factor in contracting COVID-19?
    J Med Virol. 2022 Jun 16. doi: 10.1002/jmv.27938.
    >> Share

  1003. TIAN F, Yang R
    Safety and Efficacy of COVID-19 Vaccines in Children and Adolescents: a Systematic Review of Randomized Controlled Trials.
    J Med Virol. 2022 Jun 15. doi: 10.1002/jmv.27940.
    >> Share

  1004. WANG L, Zhou HY, Li JY, Cheng YX, et al
    Potential Inter-variant and Intra-variant Recombination of Delta and Omicron Variants.
    J Med Virol. 2022 Jun 15. doi: 10.1002/jmv.27939.
    >> Share

  1005. WELLS DA, Cantoni D, Mayora-Neto M, Di Genova C, et al
    Human seasonal coronavirus neutralisation and COVID-19 severity.
    J Med Virol. 2022 Jun 15. doi: 10.1002/jmv.27937.
    >> Share

  1006. AKASH K, Sharma A, Kumar D, Singh SK, et al
    MOLECULAR ASPECTS OF OMICRON, VACCINE DEVELOPMENT AND RECOMBINANT STRAIN XE: A REVIEW.
    J Med Virol. 2022 Jun 15. doi: 10.1002/jmv.27936.
    >> Share

  1007. LYTRAS T, Kontopidou F, Lambrou A, Tsiodras S, et al
    Comparative effectiveness and durability of COVID-19 vaccination against death and severe disease in an ongoing nationwide mass vaccination campaign.
    J Med Virol. 2022 Jun 14. doi: 10.1002/jmv.27934.
    >> Share

  1008. ATLURI VL, Stalter RM, McGuffin SA, Johnson L, et al
    Patient Characteristics Associated with Conversion from Negative to Positive SARS-CoV2 PCR Test Results: Implications for Clinical False-Negativity from a Single-Center: A Case-Control Study.
    J Med Virol. 2022 Jun 14. doi: 10.1002/jmv.27932.
    >> Share

  1009. RUDIANSYAH M, Jasim SA, Mohammad Pour ZG, Athar SS, et al
    Coronavirus disease 2019 (COVID-19) update: From metabolic reprogramming to immunometabolism.
    J Med Virol. 2022 Jun 10. doi: 10.1002/jmv.27929.
    >> Share

  1010. KUMAR S, Karuppanan K, Subramaniam G
    Omicron (BA.1) and sub-variants (BA.1.1, BA.2, and BA.3) of SARS-CoV-2 spike infectivity and pathogenicity: A comparative sequence and structural-based computational assessment.
    J Med Virol. 2022 Jun 9. doi: 10.1002/jmv.27927.
    >> Share

  1011. GIRAY BG, Acik GG
    SARS-CoV-2and Mutation RT-qPCR Test Positivity Correlation with ABO and Rh Blood Types.
    J Med Virol. 2022 Jun 8. doi: 10.1002/jmv.27923.
    >> Share

  1012. CHEN YQ, Ji YF, Chen JM
    Dual impacts of the COVID-19 non-pharmaceutical interventions on other infectious diseases.
    J Med Virol. 2022 Jun 8. doi: 10.1002/jmv.27922.
    >> Share

  1013. LI H, Chen Z, Liu X, Hu P, et al
    T cell epitopes are largely conserved in the SARS-CoV-2 Omicron subvariant (BA.1, BA.2, BA.3 and GKA).
    J Med Virol. 2022 Jun 8. doi: 10.1002/jmv.27925.
    >> Share

  1014. CHEUNG CL, Ho SC, Krishnamoorthy S, Li GH, et al
    COVID-19 and Platelet Traits: A Bi-directional Mendelian Randomization Study.
    J Med Virol. 2022 Jun 8. doi: 10.1002/jmv.27920.
    >> Share

  1015. MERCIER J, Osman M, Bouiller K, Tipirdamaz C, et al
    Olfactory dysfunction in COVID-19, new insights from a cohort of 353 patients: the ANOSVID study.
    J Med Virol. 2022 Jun 7. doi: 10.1002/jmv.27918.
    >> Share

  1016. IDIZ UO, Yurttas TT, Degirmencioglu S, Orhan B, et al
    Immunophenotyping of lymphocytes and monocytes and the status of cytokines in the clinical course of Covid-19 patients.
    J Med Virol. 2022 Jun 6. doi: 10.1002/jmv.27917.
    >> Share

  1017. TSAGKARIS C, Eleftheriades A, Laubscher L, Vladyckuk V, et al
    Viruses monkeying around with surgical safety: Monkeypox preparedness in surgical settings.
    J Med Virol. 2022 Jun 3. doi: 10.1002/jmv.27915.
    >> Share

  1018. BREHM TT, Pfefferle S, von Possel R, Karolyi M, et al
    Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for SARS-CoV-2 delta and omicron variants.
    J Med Virol. 2022 Jun 3. doi: 10.1002/jmv.27916.
    >> Share

  1019. ZHAO L, Li Y, Yi W, Yan K, et al
    The clinical and bioinformatics analysis for the role of anti-hypertension drugs on mortality among patients with hypertension hospitalized with COVID-19.
    J Med Virol. 2022 Jun 3. doi: 10.1002/jmv.27914.
    >> Share

  1020. AU TY, Assavarittirong C
    The potential rationale of COVID-19 vaccine-induced myopericarditis.
    J Med Virol. 2022 Jun 2. doi: 10.1002/jmv.27910.
    >> Share

  1021. SAIED AA, Nascimento MSL, Rangel AHDN, Skowron K, et al
    Transchromosomic bovines (TcB)-derived broadly neutralizing antibodies as potent biotherapeutics to counter important emerging viral pathogens with a special focus on SARS-CoV-2, MERS-CoV, Ebola, Zika, HIV-1 and Influenza A virus.
    J Med Virol. 2022 Jun 2. doi: 10.1002/jmv.27907.
    >> Share

  1022. MAK GCK, Lau SSY, Wong KKY, Lau CS, et al
    Analytical sensitivity of the Rapid Antigen Test kits for detection of SARS-CoV-2 Omicron variant BA.2 sublineage.
    J Med Virol. 2022 Jun 2. doi: 10.1002/jmv.27908.
    >> Share

  1023. NAH EH, Cho S, Park H, Kim S, et al
    Antibody response after two doses of homologous or heterologous SARS-CoV-2 vaccines in healthcare workers at health promotion centers: a prospective observational study.
    J Med Virol. 2022 Jun 2. doi: 10.1002/jmv.27911.
    >> Share

  1024. OKTAY GULTEKIN E, Gultekin O, Coskun A, Aksak T, et al
    Antibody response three months after SARS-CoV-2 infection.
    J Med Virol. 2022 Jun 2. doi: 10.1002/jmv.27909.
    >> Share

  1025. URSIC T, Kogoj R, Sikonja J, Roskaric D, et al
    Performance of nasopharyngeal swab and saliva in detecting Delta and Omicron SARS-CoV-2 variants.
    J Med Virol. 2022 Jun 1. doi: 10.1002/jmv.27898.
    >> Share

    May 2022
  1026. LIU P, Xu M, Lu L, Ma A, et al
    The changing pattern of common respiratory and enteric viruses among outpatient children in Shanghai, China: Two years of the COVID-19 pandemic.
    J Med Virol. 2022 May 31. doi: 10.1002/jmv.27896.
    >> Share

  1027. KOZAWA K, Miura H, Kawamura Y, Higashimoto Y, et al
    Unremarkable antibody responses against various infectious agents after inoculation with the BNT162b2 COVID-19 vaccine.
    J Med Virol. 2022 May 31. doi: 10.1002/jmv.27895.
    >> Share

  1028. MESTANZA O, Lizarraga W, Padilla-Rojas C, Jimenez-Vasquez V, et al
    GENOMIC SURVEILLANCE OF LAMBDA SARS-COV-2 VARIANT IN A GLOBAL PHYLOGENETIC CONTEXT.
    J Med Virol. 2022 May 29. doi: 10.1002/jmv.27889.
    >> Share

  1029. KHORATTANAKULCHAI N, Manopwisedjaroen S, Rattanapisit K, Panapitakkul C, et al
    Receptor Binding Domain Proteins of SARS-CoV-2 Variants Produced in Nicotiana benthamiana Elicit Neutralizing Antibodies Against Variants of Concern.
    J Med Virol. 2022 May 26. doi: 10.1002/jmv.27881.
    >> Share

  1030. FLEISCHER B, Olum R, Nakwagala FN, Nassozi DR, et al
    Higher intensive care unit consultations for COVID-19 patients living with HIV compared to those without HIV coinfection in Uganda.
    J Med Virol. 2022 May 26. doi: 10.1002/jmv.27887.
    >> Share

  1031. GAO X, Hao J, Yu L, Cao Y, et al
    Evaluation of enterovirus nucleic acids detection method based on ultra-fast real-time fluorescence RT-PCR technology - A pilot study.
    J Med Virol. 2022 May 26. doi: 10.1002/jmv.27886.
    >> Share

  1032. NGUYEN-KIM H, Beckmann C, Redondo M, Ziliox J, et al
    COVID Salivary diagnostics: a comparative technical study.
    J Med Virol. 2022 May 25. doi: 10.1002/jmv.27883.
    >> Share

  1033. DU P, Li N, Xiong X, Tang S, et al
    A bivalent vaccine containing D614G and BA.1 spike trimer proteins or a BA.1 spike trimer protein booster shows broad neutralizing immunity.
    J Med Virol. 2022 May 25. doi: 10.1002/jmv.27885.
    >> Share

  1034. JIANG Y, Zhang H, Yu J, Huang D, et al
    Humoral immune response to authentic circulating SARS-CoV-2 variants elicited by booster vaccination with distinct RBD subunits in mice.
    J Med Virol. 2022 May 25. doi: 10.1002/jmv.27882.
    >> Share

  1035. SIVAN M, Preston N, Parkin A, Makower S, et al
    The modified COVID-19 Yorkshire Rehabilitation Scale (C19-YRSm) patient-reported outcome measure for Long Covid or Post-COVID-19 syndrome.
    J Med Virol. 2022 May 23. doi: 10.1002/jmv.27878.
    >> Share

  1036. LIU S, Li W, Jiang S
    Disease of influenza virus and SARS-CoV-2 coinfection: Flurona or Flucovid?
    J Med Virol. 2022 May 19. doi: 10.1002/jmv.27874.
    >> Share

  1037. LEE CJ, Woo W, Kim AY, Yon DK, et al
    Clinical Manifestations of COVID-19 Breakthrough Infections: A Systematic Review and Meta-Analysis.
    J Med Virol. 2022 May 19. doi: 10.1002/jmv.27871.
    >> Share

  1038. TORRES I, Gimenez E, Albert E, Zulaica J, et al
    SARS-CoV-2 Omicron BA.1 variant breakthrough infections in nursing home residents after an homologous third dose of the Comirnaty(R) COVID-19 vaccine: Looking for correlates of protection.
    J Med Virol. 2022 May 18. doi: 10.1002/jmv.27867.
    >> Share

  1039. VILLACRES B, Paz E, Burbano MJ, Villacres-Granda I, et al
    Neutralizing activity to SARS-CoV-2 in 1.2 to 10.0 month convalescent plasma samples of COVID-19: a transversal surrogate in vitro study performed in Quito-Ecuador.
    J Med Virol. 2022 May 18. doi: 10.1002/jmv.27866.
    >> Share

  1040. CAI S, Liao G, Yu T, Gao Q, et al
    Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine in people living with HIV: A cross-sectional study.
    J Med Virol. 2022 May 18. doi: 10.1002/jmv.27872.
    >> Share

  1041. CHIRUMBOLO S
    May the concurrent use of indomethacin and an anti-oxidant in the SARS-CoV2 infection treatment induce an exacerbation of COVID-19?
    J Med Virol. 2022 May 18. doi: 10.1002/jmv.27868.
    >> Share

  1042. YE Y, Ye Z, Yang L, Xiang B, et al
    Unignorable public health risk of avian influenza virus during COVID-19 pandemic.
    J Med Virol. 2022 May 17. doi: 10.1002/jmv.27864.
    >> Share

  1043. NILGIRIWALA K, Kadam P, Patel G, Shaikh A, et al
    Genomics of Post-Vaccination SARS-CoV-2 Infections During the Delta Dominated Second Wave of COVID-19 Pandemic, from Mumbai Metropolitan Region (MMR), India.
    J Med Virol. 2022 May 16. doi: 10.1002/jmv.27861.
    >> Share

  1044. KUITUNEN I, Artama M, Haapanen M, Renko M, et al
    Respiratory virus circulation in children after relaxation of COVID-19 restrictions in fall 2021 - a nationwide register study in Finland.
    J Med Virol. 2022 May 16. doi: 10.1002/jmv.27857.
    >> Share

  1045. BEAUDOIN CA, Pandurangan AP, Kim SY, Hamaia SW, et al
    In silico analysis of mutations near S1/S2 cleavage site in SARS-CoV-2 spike protein reveals increased propensity of glycosylation in Omicron strain.
    J Med Virol. 2022 May 16. doi: 10.1002/jmv.27845.
    >> Share

  1046. YU T, Ling Q, Xu M, Wang N, et al
    ORF8 protein of SARS-CoV-2 reduces male fertility in mice.
    J Med Virol. 2022 May 15. doi: 10.1002/jmv.27855.
    >> Share

  1047. CHO K, Park S, Kim EY, Koyanagi A, et al
    Immunogenicity of COVID-19 Vaccines in Patients with Diverse Health Conditions: a Comprehensive Systematic Review.
    J Med Virol. 2022 May 13. doi: 10.1002/jmv.27828.
    >> Share

  1048. VAKIL MK, Mansoori Y, Al-Awsi GRL, Hosseinipour A, et al
    Individual Genetic Variability Mainly of Proinflammatory Cytokines, Cytokine Receptors and Toll-like receptors Dictates Pathophysiology of COVID-19 Disease.
    J Med Virol. 2022 May 10. doi: 10.1002/jmv.27849.
    >> Share

  1049. CLEMENTINO M, Cavalcante KF, Viana VAF, Silva DO, et al
    Detection of SARS-CoV-2 in Different Human Biofluids Using the Loop-Mediated Isothermal Amplification Assay: A Prospective Diagnostic Study in Fortaleza, Brazil.
    J Med Virol. 2022 May 10. doi: 10.1002/jmv.27842.
    >> Share

  1050. LEVESQUE S, Beauchemin S, Vallee M, Longtin J, et al
    Evaluation of water gargle samples for SARS-CoV-2 detection using Abbott ID NOW COVID-19 assay.
    J Med Virol. 2022 May 9. doi: 10.1002/jmv.27847.
    >> Share

  1051. PHAN T, Boes S, McCullough M, Gribschaw J, et al
    First detection of SARS-CoV-2 Omicron BA.4 variant in Western Pennsylvania, United States.
    J Med Virol. 2022 May 9. doi: 10.1002/jmv.27846.
    >> Share

  1052. ZERBINATI RM, Palmieri M, Schwab G, Felix AC, et al
    Use of Saliva and RT-PCR Screening for SARS-CoV-2 Variants of Concern: Surveillance and Monitoring.
    J Med Virol. 2022 May 6. doi: 10.1002/jmv.27839.
    >> Share

  1053. WENG Y, Yi GY
    Estimation of the COVID-19 Mean Incubation Time: Systematic Review, Meta-analysis, and Sensitivity Analysis.
    J Med Virol. 2022 May 6. doi: 10.1002/jmv.27841.
    >> Share

  1054. LIN Z, Cheng M, Zhu F, Yang X, et al
    Immunogenicity and safety of different platforms of COVID-19 vaccines given as a 3rd (booster) dose in healthy adults.
    J Med Virol. 2022 May 6. doi: 10.1002/jmv.27836.
    >> Share

  1055. DAI Y, Zhong J, Lan Y
    Virus-virus interactions of febrile respiratory syndrome among patients in China based on surveillance data from February 2011 to December 2020.
    J Med Virol. 2022 May 5. doi: 10.1002/jmv.27833.
    >> Share

  1056. SIMSEK M, Yasin AI, Besiroglu M, Topcu A, et al
    The Efficacy of BNT162b2 (Pfizer-BioNTech) and CoronaVac Vaccines in Patients with Cancer.
    J Med Virol. 2022 May 5. doi: 10.1002/jmv.27835.
    >> Share

  1057. KIM KW, Wang X, Adhikari A, Yeang M, et al
    Persistent high-level shedding of cultivable SARS-CoV-2 Delta virus 33 days after onset of COVID-19 in a hospitalized patient with pneumonia.
    J Med Virol. 2022 May 4. doi: 10.1002/jmv.27832.
    >> Share

  1058. KEIJSERS CJPW, Broeders MEAC, Baptista Lopes V, Klinkert AF, et al
    Memory impairment and concentration problems in COVID-19 survivors eight weeks after non-ICU hospitalization: a retrospective cohort study.
    J Med Virol. 2022 May 4. doi: 10.1002/jmv.27831.
    >> Share

  1059. ISLAM F, Dhawan M, Mitra S, Bin Emran T, et al
    Assessing the risks associated with the emergence of Florona and possible preventive measures.
    J Med Virol. 2022 May 4. doi: 10.1002/jmv.27830.
    >> Share

  1060. PEIXOTO SG, Wolf JM, Glaeser AB, Maccari JG, et al
    Longer length of stay, days between discharge/first readmission, and pulmonary involvement >/=50% increase prevalence of admissions in ICU in unplanned readmissions after COVID-19 hospitalizations.
    J Med Virol. 2022 May 4. doi: 10.1002/jmv.27792.
    >> Share

  1061. WU F, Yuan Y, Deng Z, Yin D, et al
    Acceptance of COVID-19 Booster Vaccination Based on the Protection Motivation Theory (PMT): A Cross-Sectional Study in China.
    J Med Virol. 2022 May 4. doi: 10.1002/jmv.27825.
    >> Share

  1062. FONSECA MHG, Silva MFS, Pinto ACMD, Melo ACL, et al
    Persistently positive SARS-CoV-2 specific IgM during one-year follow-up.
    J Med Virol. 2022 May 3. doi: 10.1002/jmv.27822.
    >> Share

  1063. SHAFIEE A, Aghajanian S, Athar MMT, Gargari OK, et al
    Epstein-Barr virus and COVID-19.
    J Med Virol. 2022 May 3. doi: 10.1002/jmv.27823.
    >> Share

  1064. KHOKHER W, Beran A, Iftikhar S, Malhas SE, et al
    Pulse versus Non-pulse Steroid Regimens in Patients with Coronavirus Disease 2019: A Systematic Review and Meta-Analysis.
    J Med Virol. 2022 May 3. doi: 10.1002/jmv.27824.
    >> Share

  1065. SEDIGHI M, Amanollahi A, Moghaddam OM, Ghafouri HB, et al
    Linear mixed model analysis to evaluate correlations between remdesivir adverse effects with age and gender of patients with mild Covid-19 pneumonia.
    J Med Virol. 2022 May 2. doi: 10.1002/jmv.27800.
    >> Share

  1066. MAJUMDAR S, Sarkar R
    Mutational and phylogenetic analyses of the two lineages of the Omicron variant.
    J Med Virol. 2022;94:1777-1779.
    >> Share

    April 2022
  1067. BANERJEE S, Wang X, Du S, Zhu C, et al
    Comprehensive Role of SARS-CoV-2 Spike Glycoprotein in Regulating Host Signaling Pathway.
    J Med Virol. 2022 Apr 29. doi: 10.1002/jmv.27820.
    >> Share

  1068. KHAN YH, Mallhi TH, Alanazi AS, Butt MH, et al
    Outbreak of Acute Hepatitis of Unknown etiology in Children; The Critical Role of Healthcare Professionals in Neutralizing Misleading Narratives during the COVID-19 Pandemic.
    J Med Virol. 2022 Apr 29. doi: 10.1002/jmv.27819.
    >> Share

  1069. TASAR S, Karadag-Oncel E, Yilmaz-Ciftdogan D, Kara-Aksay A, et al
    Influenza is More Severe than Our Newest Enemy (COVID-19) in Hospitalized Children: Experience from a Tertiary Center.
    J Med Virol. 2022 Apr 27. doi: 10.1002/jmv.27817.
    >> Share

  1070. QAMAR N, Rukh G, Khan SN
    Vaccines for Covid-19: An Insight on Their Effectiveness and Adverse Effects.
    J Med Virol. 2022 Apr 26. doi: 10.1002/jmv.27810.
    >> Share

  1071. LI Y, Wang X, Jin J, Ma Z, et al
    T cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine.
    J Med Virol. 2022 Apr 26. doi: 10.1002/jmv.27814.
    >> Share

  1072. SUN ZP, Yang SY, Cai X, Han WD, et al
    Survival of SARS-CoV-2 in artificial seawater and on the surface of inanimate materials.
    J Med Virol. 2022 Apr 26. doi: 10.1002/jmv.27807.
    >> Share

  1073. GUPTA N, Wilson W, Ravindra P, Raghu R, et al
    Coinfection of leptospirosis and Coronavirus disease 2019: a retrospective case series from a coastal region in South India.
    J Med Virol. 2022 Apr 26. doi: 10.1002/jmv.27816.
    >> Share

  1074. PRAZUCK T, Gravier A, Pires-Roteira D, Theillay A, et al
    Evaluation of A NEW "All in One" SARS-CoV-2 antigen-detecting rapid diagnostic test AND self-test: diagnostic performance and usability in child and adult populationS.
    J Med Virol. 2022 Apr 26. doi: 10.1002/jmv.27812.
    >> Share

  1075. ZHOU B, Song S, Guo H, Zhou X, et al
    A fourth dose of Omicron RBD vaccine enhances broad neutralization against SARS-CoV-2 variants including BA.1 and BA.2 in vaccinated mice.
    J Med Virol. 2022 Apr 26. doi: 10.1002/jmv.27811.
    >> Share

  1076. RAMIREZ AL, Luna N, Patino LH, Castaneda S, et al
    Impact of SARS-CoV-2 Mu variant on vaccine effectiveness: a comparative genomics study at the peak of the third wave in Bogota, Colombia.
    J Med Virol. 2022 Apr 26. doi: 10.1002/jmv.27808.
    >> Share

  1077. ZHANG J, Cao J, Ye Q
    Nonpharmaceutical interventions against the COVID-19 pandemic significantly decreased the spread of enterovirus in children.
    J Med Virol. 2022 Apr 26. doi: 10.1002/jmv.27806.
    >> Share

  1078. JAIN S, Meena R, Kumar V, Kaur R, et al
    Comparison of haematologic abnormalities between hospitalized Coronavirus disease 2019 (COVID-19) positive and negative patients with correlation to disease severity and outcome.
    J Med Virol. 2022 Apr 25. doi: 10.1002/jmv.27793.
    >> Share

  1079. COLSON P, Fournier PE, Delerce J, Million M, et al
    Culture and identification of a "Deltamicron" SARS-CoV-2 in a three cases cluster in southern France.
    J Med Virol. 2022 Apr 25. doi: 10.1002/jmv.27789.
    >> Share

  1080. LANZAFAME M, Gibbin E, Lattuada E, Vento S, et al
    Is monoclonal antibody administration necessary in all vaccinated patients with breakthrough COVID-19 infections?
    J Med Virol. 2022 Apr 22. doi: 10.1002/jmv.27802.
    >> Share

  1081. PHAN T, Cravener Z, McCullough M, Mays A, et al
    Clinical evaluation of the Cue's COVID-19 diagnostic test to detect.
    J Med Virol. 2022 Apr 22. doi: 10.1002/jmv.27805.
    >> Share

  1082. GUO J, Zhang J, Du P, Lu J, et al
    Generation and Characterization of Humanized Synergistic Neutralizing Antibodies against SARS-CoV-2.
    J Med Virol. 2022 Apr 21. doi: 10.1002/jmv.27801.
    >> Share

  1083. WANG C, Yang YN, Xi L, Yang LL, et al
    Dynamics of influenza-like illness under urbanization procedure and COVID-19 pandemic in the sub-center of Beijing during 2013-2021.
    J Med Virol. 2022 Apr 21. doi: 10.1002/jmv.27803.
    >> Share

  1084. TORRES I, Bellido-Blasco JB, Gimeno C, Burgos JS, et al
    SARS-CoV-2 Delta-variant breakthrough infections in nursing home residents at mid-term after Comirnaty(R) COVID-19 vaccination.
    J Med Virol. 2022 Apr 20. doi: 10.1002/jmv.27799.
    >> Share

  1085. YE Q, Shao W, Meng H
    Performance and Application Evaluation of SARS-CoV-2 Antigen Assay.
    J Med Virol. 2022 Apr 20. doi: 10.1002/jmv.27798.
    >> Share


  1086. Corrigendum.
    J Med Virol. 2022 Apr 20. doi: 10.1002/jmv.27776.
    >> Share

  1087. SUBRAMONEY K, Mtileni N, Bharuthram A, Davis A, et al
    Identification of SARS-CoV-2 Omicron variant using spike gene target failure and genotyping assays, Gauteng, South Africa, 2021.
    J Med Virol. 2022 Apr 20. doi: 10.1002/jmv.27797.
    >> Share

  1088. KUMAR N, Misra BR, Reddy MM, Deval H, et al
    COVID-19 transmission among vaccinated laboratory workers during the second wave in eastern Uttar Pradesh, India.
    J Med Virol. 2022 Apr 17. doi: 10.1002/jmv.27788.
    >> Share

  1089. YAVUZ E, Gunal O, Basbulut E, Sen A, et al
    SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine.
    J Med Virol. 2022 Apr 17. doi: 10.1002/jmv.27794.
    >> Share

  1090. LIN-WANG HT, Lemes RC, Farias EDS, Bajgelman MC, et al
    Sequential IgG antibody monitoring for virus-inactivated and adenovirus-vectored COVID-19 vaccine in Brazilian healthcare workers.
    J Med Virol. 2022 Apr 14. doi: 10.1002/jmv.27782.
    >> Share

  1091. STEPANEK L, Janosikova M, Stepanek L, Nakladalova M, et al
    The kinetics and predictors of anti-SARS-CoV-2 antibodies up to eight months after symptomatic COVID-19: a Czech cross-sectional study.
    J Med Virol. 2022 Apr 14. doi: 10.1002/jmv.27784.
    >> Share

  1092. LUCIJANIC M, Soric E, Lacko MS, Sabljic A, et al
    Gradual increase in RDW is similarly prognostic for in-hospital mortality in both anemic and non-anemic COVID-19 patients.
    J Med Virol. 2022 Apr 14. doi: 10.1002/jmv.27785.
    >> Share

  1093. LIN YF, Li Y, Duan Q, Lei H, et al
    Vaccination strategy for preventing the spread of SARS-CoV-2 in the limited supply condition: a mathematical modelling study.
    J Med Virol. 2022 Apr 14. doi: 10.1002/jmv.27783.
    >> Share

  1094. OZUDOGRU O, Acer O, Genc Bahce Y
    Risks of catching COVID-19 according to vaccination status of healthcare workers during the SARS COV-2 Delta variant dominant period and their clinical characteristics.
    J Med Virol. 2022 Apr 13. doi: 10.1002/jmv.27778.
    >> Share

  1095. IN E, Altintop Geckil A, Kavuran G, Sahin M, et al
    Using Artificial Intelligence to Improve the Diagnostic Efficiency of Pulmonologists in Differentiating COVID-19 Pneumonia from Community-Acquired Pneumonia.
    J Med Virol. 2022 Apr 13. doi: 10.1002/jmv.27777.
    >> Share

  1096. MOHAPATRA RK, Kandi V, Tuli HS, Chakraborty C, et al
    The recombinant variants of SARS-CoV-2: concerns continues amid COVID-19 pandemic.
    J Med Virol. 2022 Apr 13. doi: 10.1002/jmv.27780.
    >> Share

  1097. ALLEN RA, Williams CL, Penrod Y, McCloskey C, et al
    A pyrosequencing protocol for rapid identification of SARS-CoV-2 variants.
    J Med Virol. 2022 Apr 13. doi: 10.1002/jmv.27770.
    >> Share

  1098. AHMED KAHM, Hasabo EA, Haroun MS, Eljack MMF, et al
    Clinical Characteristics, Complications and Predictors of Outcome of Hospitalized Adult Sudanese Patients with COVID-19 and Malaria Co-Infection in Sudan: A Multi-Center Retrospective Cross-sectional Study.
    J Med Virol. 2022 Apr 12. doi: 10.1002/jmv.27771.
    >> Share

  1099. ZHAI SL, Li CL, Sun MF, Zhang JF, et al
    Natural infections of SARS-CoV-2 increased in animals: How should humans get along with animals?
    J Med Virol. 2022 Apr 12. doi: 10.1002/jmv.27772.
    >> Share

  1100. LAPIC I, Antolic MR, Horvat I, Premuzic V, et al
    Association of polymorphisms in genes encoding prothrombotic and cardiovascular risk factors with disease severity in COVID-19 patients: a pilot study.
    J Med Virol. 2022 Apr 12. doi: 10.1002/jmv.27774.
    >> Share

  1101. BOGLIONE L, Dodaro V, Meli G, Rostagno R, et al
    Remdesivir treatment in hospitalized patients affected by COVID-19 pneumonia: a case-control study.
    J Med Virol. 2022 Apr 11. doi: 10.1002/jmv.27768.
    >> Share

  1102. MEHRAEEN E, SeyedAlinaghi S, Karimi A
    The Post-Omicron Situation: The End of the Pandemic or a Bigger Challenge?
    J Med Virol. 2022 Apr 6. doi: 10.1002/jmv.27765.
    >> Share

  1103. GAMA S
    RDW shows prognostic potential in hospitalised patients with COVID-19.
    J Med Virol. 2022 Apr 6. doi: 10.1002/jmv.27764.
    >> Share

  1104. AL-BASSAM WW, Al-Karaawi IA, Sharquie IK, Ad'hiah AH, et al
    Evaluation of interleukin-38 levels in serum of patients with coronavirus disease 2019.
    J Med Virol. 2022 Apr 6. doi: 10.1002/jmv.27762.
    >> Share

  1105. ABORODE AT, Awuah WA, Mehta A, Abdul-Rahman T, et al
    Concern over Nipah Virus Cases Amidst the COVID-19 Pandemic in India.
    J Med Virol. 2022 Apr 5. doi: 10.1002/jmv.27745.
    >> Share

  1106. ELIE B, Roquebert B, Sofonea MT, Trombert-Paolantoni S, et al
    Variant-specific SARS-CoV-2 within-host kinetics.
    J Med Virol. 2022 Apr 4. doi: 10.1002/jmv.27757.
    >> Share


  1107. Dominant clade-featured SARS-CoV-2 co-occurring mutations reveal plausible epistasis: An in silico based hypothetical model.
    J Med Virol. 2022 Apr 4. doi: 10.1002/jmv.27733.
    >> Share

  1108. YE C, Lv Y, Kuang W, Yang L, et al
    Inactivated vaccines prevent severe COVID-19 in patients infected with the Delta variant: a comparative study of the Delta and Alpha variants from China.
    J Med Virol. 2022 Apr 2. doi: 10.1002/jmv.27759.
    >> Share

  1109. BHATNAGAR S, Jones K, Montoya A
    COVID-19 Vaccine Side Effects among Nursing Home Residents and Staff.
    J Med Virol. 2022 Apr 1. doi: 10.1002/jmv.27756.
    >> Share

  1110. KWOK CS, Muntean EA, Mallen CD
    The impact of COVID-19 on the patient, clinician, healthcare services and society: A patient pathway review.
    J Med Virol. 2022 Apr 1. doi: 10.1002/jmv.27758.
    >> Share

  1111. KAYGUSUZ S, Korukluoglu G, Cosgun Y, Sahin O, et al
    INVESTIGATION AND LONG-TERM MONITORING OF THE PRESENCE OF NEUTRALIZING ANTIBODY IN PATIENTS WITH COVID-19 DISEASE OF DIFFERENT CLINICAL SEVERITY.
    J Med Virol. 2022 Apr 1. doi: 10.1002/jmv.27751.
    >> Share

  1112. GAUTRET P, Hoang VT, Jimeno MT, Lagier JC, et al
    Severity of the first 207 infections with the SARS-CoV-2 Omicron BA.2 variant, in Marseille, France, December, 2021-February, 2022.
    J Med Virol. 2022 Apr 1. doi: 10.1002/jmv.27760.
    >> Share

  1113. CHIRUMBOLO S
    Antioxidants associated with NSAIDs might even exacerbate the progress of SARS-CoV2 disease.
    J Med Virol. 2022;94:1264-1266.
    >> Share

    March 2022
  1114. CHAI C, Chen K, Li S, Cheng G, et al
    Effect of elevated fasting blood glucose level on the one-year mortality and sequelae in hospitalized COVID-19 patients: a bidirectional cohort study.
    J Med Virol. 2022 Mar 31. doi: 10.1002/jmv.27737.
    >> Share

  1115. PENNEY J, Jung A, Koethe B, Doron S, et al
    Cycle Threshold Values and SARS-CoV-2: Relationship to Demographic Characteristics and Disease Severity.
    J Med Virol. 2022 Mar 31. doi: 10.1002/jmv.27752.
    >> Share

  1116. TAMARIZ L, Bast E, Abad M, Klimas N, et al
    Letter to the editor: Post COVID-19 joint pain: Preliminary report of the relationship with antinuclear antibodies and inflammation.
    J Med Virol. 2022 Mar 31. doi: 10.1002/jmv.27753.
    >> Share

  1117. CHEN C, Feng Y, Chen Z, Xia Y, et al
    SARS-CoV-2 cold-chain transmission: Characteristics, risks and strategies.
    J Med Virol. 2022 Mar 31. doi: 10.1002/jmv.27750.
    >> Share

  1118. YANG S, Cao L, Xu W, Xu T, et al
    Comparison of model-specific histopathology in mouse models of COVID-19.
    J Med Virol. 2022 Mar 30. doi: 10.1002/jmv.27747.
    >> Share

  1119. COTO E, Albaiceta GM, Amado-Rodriguez L, Garcia-Clemente M, et al
    FURIN gene variants (rs6224/rs4702) as potential markers of deat hand cardiovascular traits in severe COVID-19.
    J Med Virol. 2022 Mar 30. doi: 10.1002/jmv.27748.
    >> Share

  1120. RAJPAL VR, Sharma S, Kumar A, Chand S, et al
    'Is Omicron mild'? Testing this narrative with the mutational landscape of its three lineages and response to existing vaccines and therapeutic antibodies.
    J Med Virol. 2022 Mar 30. doi: 10.1002/jmv.27749.
    >> Share

  1121. SINGH R, Kaur U, Singh A, Chakrabarti SS, et al
    Refractory hyper-eosinophilia associated with newly diagnosed rheumatoid arthritis following inactivated BBV152 COVID-19 vaccine.
    J Med Virol. 2022 Mar 29. doi: 10.1002/jmv.27742.
    >> Share

  1122. REITER RJ, Sharma R, Tan DX, Neel RL, et al
    Melatonin Use for SARS-CoV-2 Infection:Time to Diversify the Treatment Portfolio.
    J Med Virol. 2022 Mar 26. doi: 10.1002/jmv.27740.
    >> Share

  1123. WANG W, Peng X, Jin Y, Pan JA, et al
    Reverse genetics systems for SARS-CoV-2.
    J Med Virol. 2022 Mar 24. doi: 10.1002/jmv.27738.
    >> Share

  1124. CHEN Q, Huang XY, Liu Y, Sun MX, et al
    Comparative characterization of SARS-CoV-2 variants of concern and mouse-adapted strains in mice.
    J Med Virol. 2022 Mar 23. doi: 10.1002/jmv.27735.
    >> Share

  1125. ZHU G, Zhou S, Xu Y, Gao R, et al
    Mendelian randomization study on the causal effects of COVID-19 on childhood intelligence.
    J Med Virol. 2022 Mar 23. doi: 10.1002/jmv.27736.
    >> Share

  1126. YANG S, Zhou H, Liu M, Jaijyan D, et al
    SARS-CoV-2, SARS-CoV and MERS-CoV encode circular RNAs of spliceosome-independent origin.
    J Med Virol. 2022 Mar 22. doi: 10.1002/jmv.27734.
    >> Share

  1127. OZTAS M, Bektas M, Karacan I, Aliyeva N, et al
    Frequency and Severity of COVID-19 in Patients with Various Rheumatic Diseases Treated Regularly with Colchicine or Hydroxychloroquine.
    J Med Virol. 2022 Mar 21. doi: 10.1002/jmv.27731.
    >> Share

  1128. MASYENI S, Iqhrammullah M, Frediansyah A, Nainu F, et al
    Molnupiravir: a lethal mutagenic drug against rapidly mutating SARS-CoV-2 - A narrative review.
    J Med Virol. 2022 Mar 21. doi: 10.1002/jmv.27730.
    >> Share

  1129. FERNANDEZ-DE-LAS-PENAS C, Martin-Guerrero JD, Navarro-Pardo E, Torres-Macho J, et al
    Exploring the recovery curve for gastrointestinal symptoms from the acute COVID-19 phase to long-term post-COVID: The LONG-COVID-EXP-CM Multicenter Study.
    J Med Virol. 2022 Mar 21. doi: 10.1002/jmv.27727.
    >> Share

  1130. MAGALIS BR, Mavian C, Tagliamonte M, Rich SN, et al
    Low-frequency variants in mildly symptomatic vaccine breakthrough infections presents a doubled-edged sword.
    J Med Virol. 2022 Mar 20. doi: 10.1002/jmv.27726.
    >> Share

  1131. HASSANIAZAD M, Farshidi H, Gharibzadeh A, Bazram A, et al
    Efficacy and safety of favipiravir plus interferon-beta versus lopinavir/ritonavir plus interferon-beta in moderately ill patients with covid-19: a randomized clinical trial.
    J Med Virol. 2022 Mar 16. doi: 10.1002/jmv.27724.
    >> Share

  1132. TSAGKARIS C, Loudovikou A, Matiashova L, Papadakis M, et al
    Public health concerns over polio in war-torn Ukraine and nearby regions: Four lessons and a warning from the history of epidemics.
    J Med Virol. 2022 Mar 15. doi: 10.1002/jmv.27723.
    >> Share

  1133. MISHRA AR, Nayak D, Byrareddy SN
    Are we moving towards ending SARS-CoV-2?
    J Med Virol. 2022 Mar 14. doi: 10.1002/jmv.27722.
    >> Share

  1134. YAN Y, Tang YD, Zheng C
    When cyclin-dependent kinases meet viral infections, including SARS-CoV-2.
    J Med Virol. 2022 Mar 14. doi: 10.1002/jmv.27719.
    >> Share

  1135. QIN S, Li R, Zheng Z, Zeng X, et al
    Review of selected animal models for respiratory coronavirus infection and its application in drug research.
    J Med Virol. 2022 Mar 13. doi: 10.1002/jmv.27718.
    >> Share

  1136. DHEIR H, Tocoglu A, Toptan H, Pinar M, et al
    Short and mid-term SARS-CoV-2 antibody response after inactivated COVID-19 vaccine in hemodialysis and kidney transplant patients.
    J Med Virol. 2022 Mar 12. doi: 10.1002/jmv.27714.
    >> Share

  1137. SHEN L, Sun M, Song S, Hu Q, et al
    The impact of anti-COVID-19 non-pharmaceutical interventions on hand, foot, and mouth disease-a spatiotemporal perspective in Xi'an, northwestern China.
    J Med Virol. 2022 Mar 11. doi: 10.1002/jmv.27715.
    >> Share

  1138. CHAVDA VP, Patel AB, Vaghasiya DD
    SARS-CoV-2 variants and vulnerability at the global level.
    J Med Virol. 2022 Mar 11. doi: 10.1002/jmv.27717.
    >> Share

  1139. ARCANI R, Cauchois R, Suchon P, Jean R, et al
    Factors associated with dexamethasone efficacy in COVID-19. A retrospective investigative cohort study.
    J Med Virol. 2022 Mar 11. doi: 10.1002/jmv.27712.
    >> Share

  1140. YOSHIOKA N, Deguchi M, Hagiya H, Kagita M, et al
    Comparison of Extraction-based and Elution-based Polymerase Chain Reaction Testing, and Automated and Rapid Antigen Testing for the Diagnosis of Severe Acute Respiratory Syndrome Coronavirus 2.
    J Med Virol. 2022 Mar 10. doi: 10.1002/jmv.27709.
    >> Share

  1141. GHAFOURI M, Saadati H, Taghavi MR, Azimian A, et al
    Survival of the hospitalized patients with COVID-19 receiving Atorvastatin: a randomized clinical trial.
    J Med Virol. 2022 Mar 10. doi: 10.1002/jmv.27710.
    >> Share

  1142. XIAO F, Wan P, Wei Q, Wei G, et al
    Prolonged fecal shedding of SARS-CoV-2 in a young immunocompetent COVID-19 patient: a case report and literature overview.
    J Med Virol. 2022 Mar 10. doi: 10.1002/jmv.27694.
    >> Share

  1143. ARORA G, Taneja J, Bhardwaj P, Goyal S, et al
    Adverse events and Breakthrough infections associated with COVID-19 vaccination in the Indian population.
    J Med Virol. 2022 Mar 8. doi: 10.1002/jmv.27708.
    >> Share

  1144. DIRICAN E, Savrun ST, Aydin IE, Gulbay G, et al
    ANALYSIS OF MITOCHONDRIAL DNA CYTOCHROME-B (CYB) and ATPase-6 GENE MUTATIONS IN COVID-19 PATIENTS.
    J Med Virol. 2022 Mar 8. doi: 10.1002/jmv.27704.
    >> Share

  1145. CAI C, Tang YD, Zheng C
    When RING Finger Family Proteins meet SARS-CoV-2.
    J Med Virol. 2022 Mar 7. doi: 10.1002/jmv.27701.
    >> Share

  1146. LIU N, Long H, Sun J, Li H, et al
    New laboratory evidence for the association between endothelial dysfunction and COVID-19 disease progression.
    J Med Virol. 2022 Mar 5. doi: 10.1002/jmv.27693.
    >> Share

  1147. CHENCHULA S, Karunakaran P
    Current Evidence on Efficacy of COVID-19 Booster Dose Vaccination Against the Omicron Variant. A Systematic Review.
    J Med Virol. 2022 Mar 4. doi: 10.1002/jmv.27697.
    >> Share

  1148. RAMIREZ JD, Castaneda S, Ballesteros N, Munoz M, et al
    Hotspots for SARS-CoV-2 Omicron Variant Spread: Lessons from New York City.
    J Med Virol. 2022 Mar 3. doi: 10.1002/jmv.27691.
    >> Share

  1149. COLSON P, Delerce J, Beye M, Levasseur A, et al
    First cases of infection with the 21L/BA.2 Omicron variant in Marseille, France.
    J Med Virol. 2022 Mar 3. doi: 10.1002/jmv.27695.
    >> Share

  1150. TSUCHIDA T, Hirose M, Inoue Y, Kunishima H, et al
    Relationship between changes in symptoms and antibody titers after a single vaccination in patients with Long COVID.
    J Med Virol. 2022 Mar 2. doi: 10.1002/jmv.27689.
    >> Share

  1151. MARGIOTTI K, Fabiani M, Mesoraca A, Giorlandino C, et al
    Survey of fully vaccinated anti-COVID 19 people from June to November 2021: Single Italian centre study.
    J Med Virol. 2022 Mar 2. doi: 10.1002/jmv.27690.
    >> Share

  1152. OLIVEIRA GS, Silva-Flannery L, da Silva JF, Siza C, et al
    Active surveillance and early detection of community transmission of SARS-CoV-2 Mu variant (B.1.621) in the Brazilian Amazon.
    J Med Virol. 2022 Mar 2. doi: 10.1002/jmv.27686.
    >> Share

  1153. CICCARESE G, Drago F, Marinaro E, Parodi A, et al
    PITYRIASIS ROSEA DURING COVID-19: PATHOGENESIS, DIAGNOSIS AND TREATMENT.
    J Med Virol. 2022 Mar 1. doi: 10.1002/jmv.27672.
    >> Share

  1154. LIMA ARJ, Ribeiro G, Viala VL, Lima LPO, et al
    SARS-COV-2 GENOMIC MONITORING IN THE STATE OF SAO PAULO UNVEILS TWO EMERGING AY.43 SUBLINEAGES.
    J Med Virol. 2022 Mar 1. doi: 10.1002/jmv.27674.
    >> Share

    February 2022
  1155. GIANNOS P, Prokopidis K
    Gut Dysbiosis and Long COVID-19: Feeling Gutted.
    J Med Virol. 2022 Feb 28. doi: 10.1002/jmv.27684.
    >> Share

  1156. NOTARTE KI, Guerrero-Arguero I, Velasco JV, Ver AT, et al
    Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic review.
    J Med Virol. 2022 Feb 28. doi: 10.1002/jmv.27688.
    >> Share

  1157. LETAFATI A, Aghamirmohammadali FS, Rahimi-Foroushani A, Hasani SA, et al
    No Human Respiratory Syncytial Virus but SARS-CoV-2 in children under 5 years old referred to Children Medical Center in 2021, Tehran, Iran.
    J Med Virol. 2022 Feb 28. doi: 10.1002/jmv.27685.
    >> Share

  1158. CHIU W, Verschueren L, Eynde CVD, Buyck C, et al
    Development and optimisation of a high-throughput screening assay for in vitro anti-SARS-CoV-2 activity: evaluation of 5676 phase 1 passed structures.
    J Med Virol. 2022 Feb 28. doi: 10.1002/jmv.27683.
    >> Share

  1159. HAUSLER M, Kleines M
    The SARS-CoV-2 pandemic in Germany may represent the sum of a large number of local but independent epidemics each initiated by individuals aged 10 - 19 years, middle aged males, or elderly individuals.
    J Med Virol. 2022 Feb 28. doi: 10.1002/jmv.27682.
    >> Share

  1160. ZENG L, Zang F, Song N, Li Z, et al
    Analysis of influenza trend and impact of COVID-19 in Kezhou, Xinjiang for 8 consecutive years.
    J Med Virol. 2022 Feb 25. doi: 10.1002/jmv.27678.
    >> Share

  1161. LINSSEN J, Schapendonk C, Munster M, Daemen P, et al
    A method comparison study of the high throughput automated HISCL((R)) SARS-CoV-2 antigen assay using nasopharyngeal swab samples from symptomatic and asymptomatic subjects against conventional RT-PCR.
    J Med Virol. 2022 Feb 25. doi: 10.1002/jmv.27679.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016